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ABSTRACT 
 
Background 
Coronary artery disease (CAD) is a clinical condition characterised by an obstruction of the 
blood flow to the myocardium. Coronary angiography is the gold standard clinical procedure 
to assess the coronary stenosis based on the vessel anatomy. Fractional flow reserve (FFR) 
describes the physiological severity of the stenosis during maximum coronary flow, induced 
by adenosine infusion. 
Hypothesis  
Mathematical models can be used to represent the cardiovascular system and be employed as 
investigative and predictive tools to assess CAD in individual patients. 
Aims 
To support the computational estimation of coronary FFR (vFFR) by characterising and 
predicting the response to the administration of adenosine in terms of the myocardial resistance 
and by investigating correlations between patient parameters and myocardial resistance.    
Methods & Results 
1) A zero-dimensional (0D) cardiovascular model has been developed starting from published 
models to simulate adenosine-induced hyperaemia as a function and is shown to reproduce 
qualitatively the effects described in the literature using generic parameters. A sensitivity 
analysis was performed to introduce and test assumptions, including the decoupling of the 
systemic model from the local coronary compartment, which later facilitates the process of 
tuning model parameters to individual patient data. 
2) Clinical data from patients with CAD have been used to personalise the systemic 
cardiovascular system and subsequently, at a coronary level, to represent the individual-
specific response to adenosine. The 0D coronary model included representation of a vessel 
stenosis, characterised by a computational fluid dynamics analysis, and the myocardial 
impedance. The nature of the response of individual patients to the administration of adenosine 
was quantitatively characterised in terms of the underlying parameters described by the model. 
The myocardium adenosine concentration profile and resistance were used to identify 
correlation with patient parameters. No statistically significant associations were found 
between the type of response and observations in the clinical records.
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3) Considering the lack of consensus on the definition of FFR under hyperaemia, an algorithm 
has been developed to objectively identify stable and minimum FFR. 
Conclusions  
It is possible to use a 0D model to support the individual characterisation of the response to 
adenosine, and thus to provide insight into the nature of the physiological response to this drug. 
However, this approach does not support the reliable prediction of this response in individuals 
with CAD from baseline measurements that are made in the routine clinical pathway. Arising 
from this work, a robust algorithm has been developed to identify the stable and minimum 
FFR, which can be used to improve clinical decision making.  
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STATEMENT OF CONTRIBUTIONS 
 
This thesis investigates the combination of zero-dimensional modelling with sparse clinical 
data to predict individual patient response to the administration of adenosine. The main 
contributions of this thesis are: 
1) A 0-D model to represent adenosine response in a generic individual, simulating some of 
the physiological effects produced by adenosine, based on literature information; 
2) A sensitivity analysis of the relative influence of model parameters on the simulated 
adenosine response; 
3) An algorithm to identify the minimum and stable FFR during adenosine response, which 
can support the objectivity of the definition of the FFR on which the clinical decision is 
made; 
4) An optimisation method to personalise the parameters of the model to represent the patient-
specific coronary and systemic circulations  
5) A method to quantify the myocardial resistance during hyperaemic response to find 
correlations with patients‘ characteristics for predictive purposes; 
6) A method to define the myocardial blood volume during adenosine administration based 
on an optimisation process on the myocardial resistance and the coronary tree-structure 
model. 
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1 CHAPTER 1   
INTRODUCTION & BACKGROUND 
 
BACKGROUND 
This section presents an introduction to terms and concepts together with background review 
of the three essential components of this thesis. 
- The anatomy and physiology of the cardiovascular system is reviewed, including the 
regulatory control maintaining adequate blood pressure and flow in all the organs. 
- The use of mathematical models to study the cardiovascular system is widespread and the 
literature provides access to an enormous number of in silico studies on the cardiovascular 
system. Models, from 0 dimensional to 3 dimensional, are used separately or in 
combination, to represent a specific cardiovascular compartment or the overall 
cardiovascular system. In the current project, the 0-D model (lumped-parameter) model 
has been chosen to represent system physiology, using the electric-hydraulic analogy. 
- At the end of this chapter, the focus will move onto the clinical context of coronary artery 
disease. Diagnostic and therapeutic processes are discussed, including angiography and 
the use of the Fractional Flow Reserve index.
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OVERVIEW 
The cardiovascular system plays an essential role in transporting the blood and carrying 
metabolites, to and from all the tissues in a body. The coronary arteries are responsible for 
supplying blood to the heart muscle (the myocardium), enabling its pumping function [1, 2]. 
In common with many other arteries, coronary arteries can be affected by arterial disease with 
plaque deposition resulting in stenosis which may lead to a reduction of the blood flowing to 
the myocardium. Vessel narrowing can result in an inadequate blood supply (myocardial 
ischemia) and limit the quantity of metabolites which can be transported to and from the 
myocardial cells. In severe cases, this can lead to death [3, 4]. 
Quantification of the reduction in blood flow to the myocardium has been demonstrated to be 
a valuable diagnostic and prognostic tool in the evaluation of the impact of coronary disease. 
Moreover, the reduction in flow is linked to the physiological state of the patient (for example 
the reduction might be greater in an exercise state). A computational model can be a powerful 
aid in this context since it has the potential to be employed to quantify the effect of the stenosis 
under different physiological states. 
A major challenge in the development of a computational model for diagnostic purposes in an 
individual patient is the personalisation of the model, which consists of a selection of the 
parameters values to represent the individual cardiovascular model. The success of the process, 
and the degree to which a model can be personalised, is critically dependent on the availability, 
and quality, of measured data. Typically, a wealth of clinical information is accessible, 
including patient demographics, comorbidities, laboratory test results, and images. However, 
physiological information (such as pressure and flow data) that can be used directly to tune the 
model is often insufficient and, indeed, as will be demonstrated in this thesis, may often be 
contradictory. 
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It is evident that the chances of a computational work flow being adopted into the clinical 
process will be greater if the information already collected as part of the routine clinical 
protocol can be exploited to provide the inputs rather than requiring new measurements which 
will inevitably increase costs. Of course, this point of view may change as confidence in the 
process increases and as savings associated with better diagnosis and management are 
quantified but, for now at least, this remains the pragmatic starting point. 
The clinical community is increasingly aware of the importance of physiological assessment 
of the severity of the stenosis [5, 6] and technology provides an important aid to achieve this 
[7, 8]. Angiography has become the gold standard clinical procedure to visualise the lumen of 
the diseased coronary artery. This process requires catheterisation of the patient to provide 
access to inject a radio-opaque agent directly into the coronary artery of interest 
[http://www.nhs.uk/]. Images of the diseased artery are then evaluated by clinicians to 
determine the severity of the stenosis and hence the best treatment. This evaluation might be 
subjective, but more often it is based on a quantitative measurement derived from the image 
data (Quantitative Coronary Angiography, QCA). However, the assessment of the severity of 
the stenosis based on anatomy alone is a major limitation. For this reason, the concept of 
Fractional Flow Reserve index (FFR) has been introduced to support assessment of the 
physiological severity of the stenosis during angiography [5, 9, 10]. The FFR represents the 
stenosis severity as the ratio between the hyperaemic coronary flow in presence of the lesion 
and the hyperaemic coronary flow that would be expected in the absence of disease. In order 
to measure this, it is necessary to stimulate hyperaemia, under the assumption that when the 
coronary flow is maximum the impact of the lesion is more evident.   
Although the clinical merit of FFR is recognised across the world, it is still conducted in only 
a small percentage of patients primarily due to the necessity of skills and the increase of 
procedure’s costs and time [11]. Furthermore, the lack of a standardised protocol leads to inter-
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operator variability [12]. These concerns have motivated the development of the concept of a 
virtual FFR (vFFR) [13], which could be introduced as an addition to the angiography and 
bring more objectivity in the lesion severity assessment. 
The clinical process of FFR measurement produces exactly the type of physiological 
information that can be used to personalise (tune) a computational model. The pressure data is 
collected over the transition from resting to hyperaemic state resulting from the administration 
of a hyperaemic drug (adenosine). An immediate benefit of the personalisation of a 
mathematical model of coronary flow to reproduce the patient measurements is that it might 
be possible to derive relationships between the model parameters and the broader patient 
characteristics. These relationships could then be used predictively in a vFFR model for those 
cases when FFR has not been measured clinically, making assessment less invasive. 
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AIMS AND OBJECTIVES 
The challenges of vFFR computation are described by Morris et al. [13]. The local 
pressure/flow characteristics of the lesion itself can be computed from its anatomy, using 
Computational Fluid Dynamics, but it remains a major challenge to estimate the patient- and 
vessel-specific distal resistance associated with the smaller vessels in the myocardium. 
The primary aims of the project described in this thesis are: 
1. to characterise the time-course response of coronary pressure and flow under a change 
of physiological state, and specifically during the administration of adenosine in the 
clinical protocol for induction of coronary hyperaemia; 
2. to investigate correlations between patient parameters and myocardial resistance, and 
with changes of myocardial resistance in the transition from a baseline to a hyperaemic 
state.    
To support the characterisation of response, and the understanding and interpretation of these 
characteristics, the secondary aims of the project are: 
i. to develop a model to represent the clinical process, including significant compartments 
and regulatory mechanisms; 
ii. to personalise the parameters in the model to describe the response of individual patients 
in which coronary pressure is measured and coronary flow is evaluated with CFD. 
Chapter 1 – Introduction & Background
 
6 
 
 THE CARDIOVASCULAR SYSTEM 
The cardiovascular system distributes blood to tissue and organs throughout the body, 
supplying them with nutrients, such as oxygen, amino-acids, hormones, electrolytes, and 
removing waste products, such as carbon dioxide. The cardiovascular system plays an 
important role in the maintenance of homeostasis, e.g. stabilising the body temperature and pH, 
and it takes part in the immune response. This section presents a description of the anatomy 
and physiology of the cardiovascular system, with particular focus on the haemodynamic 
properties necessary to be represented in a model that is targeted at the description of pressure 
and flow distributions in the system and their changes under a change of physiological state. 
 Anatomy 
1.1.1.1 Heart and systemic circulation 
The cardiovascular system consists of the heart and a closed system of vessels (Figure 1.1).  
The heart is a four-chambered muscular organ, which pumps blood through the vessels 
distributing blood to all the tissues. The heart can be divided into left and right sides, each of 
which comprises an atrium and a ventricle separated by a valve; the tricuspid valve on the right 
side and the mitral valve on the left side. The ventricles are separated from the vascular tree by 
another valve, the pulmonary valve on the right side and the aortic valve on the left side (Figure 
1.1). Within the vascular tree, two main circulations can be identified: the systemic circulation 
and the pulmonary circulation. The systemic circulation brings nutrients and removes waste 
products from the organs such as liver, kidneys, skeletal muscles, cardiac muscle, brain, 
intestine, stomach, etc.; the pulmonary circulation perfuses the lungs enabling exchange of 
oxygen and carbon dioxide in the blood [1, 4]. 
Vessels in different parts of the vascular tree have different structures and different properties. 
Arteries, the vessels that carry the blood away from the heart, are compliant. 
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Figure 1.1: Simplified scheme of the cardiovascular system.  
Figure adapted by OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0) ], via 
Wikimedia Commons- Creative Commons Attribution-Share Alike 4.0 International license copyright 
(https://commons.wikimedia.org/w/index.php?curid=30148235).  
Whilst this generally results in a smoothing of the flow and damping of pressure pulses 
produced by the intermittent ventricular ejection [4, 14], there can also be local amplification 
of pulse pressures in the arteries associated with wave reflections. The typical range of vessel 
diameters is around 25 mm for the aorta decreasing, through a series of bifurcations, for the 
main arteries to 1-6 mm and for the arterioles to 30 μm. Capillaries are the small vessels within 
the tissues in which nutrients and waste are exchanged. They have a diameter of 5-6 μm [4].  
Veins are very compliant vessels, which act as a blood reservoir and enable blood redistribution 
when physiological changes occur. They collect the blood from the upper body (superior vena 
cava) and lower body (inferior vena cava) returning it back to the heart. The diameter varies 
from 30 mm for the vena cava to about 0.5-5 mm for smaller veins [1, 4].  
 
1.1.1.2 Coronary circulation 
The coronary circulation provides nutrients to the heart muscle (the myocardium). Coronary 
arteries originate from the root of the aorta and branch to run over the surface (epicardium) of 
the cardiac muscle (myocardium). There are two main coronary arteries: the left and right 
(Figure 1.2). The left coronary artery divides into two branches to supply the left and the 
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anterior parts of the heart whilst the right coronary artery supplies the right and the posterior 
parts [1, 15]. Blood return from the coronary circulation is primarily via the coronary veins 
which drain into the right atrium [16, 17]. 
 
Figure 1.2: Anatomy of coronary circulation to the myocardium. 
The left and right coronaries originate from the aortic root: the left supplies the left and anterior part of the 
heart, with its two main branches, circumflex and anterior descending, while the right supplies the right and 
the anterior part of the heart. 
Figure by BruceBlaus (Own work) [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0 )], via Wikimedia 
Commons, via Wikimedia Commons- Creative Commons Attribution-Share Alike 4.0 International license 
copyright (https://commons.wikimedia.org/wiki/File%3ABlausen_0256_CoronaryArteries_02.png) . 
 
 PHYSIOLOGY 
Blood circulation is a vital function: every cell in the body needs oxygen to carry out its 
functions and oxygen is supplied by the blood. Simultaneously, waste products derived from 
tissue metabolism need to be eliminated. Other functions of the cardiovascular system are: i) 
to maintain the fluid balance within the body; ii) to distribute the blood appropriately according 
to different activities; iii) to protect the body from infection and blood loss; iv) to maintain 
body temperature within the physiological range; v) to distribute hormones. In this project 
consideration of cardiovascular physiology is limited to the transport of oxygen and carbon 
dioxide and the regulation of blood flow and pressure to distribute blood volumes according to 
the adenosine stimulus. 
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 System physiology 
The cardiovascular system enables an appropriate blood supply to the different organs and 
tissues. The brain, a very delicate and vital organ, has high priority in terms of oxygen supply 
and, in consequence, cerebral blood flow is relatively constant. For other organs, blood flow is 
strongly related to need. For example, the skeletal muscles require more oxygen during exercise 
and the stomach and intestines are the most active organs during digestion; flow to these organs 
increases to meet these needs.  
1.2.1.1 Physiology of regulatory pathways 
The cardiovascular regulation acts to ensure the appropriate distribution of blood throughout 
the body and maintains appropriate blood pressures and flows [1]. There are two types of 
regulation: auto-regulation and neuro-regulation. 
Auto-regulation is a process of local flow regulation. This has a higher impact and importance 
in delicate and vital organs such as the brain, heart and kidneys. The vascular tree in these 
organs responds intrinsically to changes in haemodynamics, aiming to maintain an appropriate 
flow and pressure.  Auto-regulation is driven by myogenic and metabolic stimuli. The first of 
these is directly related to stretching of smooth muscles in the vessel wall which in turn controls 
the artery/arteriolar diameters, in order to create an appropriate pressure gradient and blood 
flow. The second is related to the minimum/maximum thresholds of concentration of 
nutrients/wastes and can increase or decrease the blood flow to meet local requirements. 
Neuro-regulation is a more complex and sophisticated system involving the nervous system 
through the sympathetic and vagal pathways. In the cardiovascular system there are check 
points in the aortic arch and in the carotid artery, where baroreceptors check the pressure and 
chemoreceptors check the oxygen and carbon dioxide levels in the blood continuously. An 
afferent signal is sent from the receptors to the vasomotor centre in the medulla oblongata 
where, in response, an efferent signal is produced and sent back to the cardiovascular system 
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through the sympathetic and the parasympathetic systems. The chemoreceptor response is 
carried just by the sympathetic system, while the baroreceptor response involves both systems. 
The sympathetic system, responsible for the “flight-or-fight response”, acts on the heart and 
vasculature, increasing the heart rate and changing the vascular resistance in order to increase 
the blood flow in the organs involved in activity. 
The parasympathetic or vagal system, responsible for the “rest-and-digest” condition, 
compensates the effects of the sympathetic system by decreasing the heart rate (Figure 1.3). 
The system of regulation described thus far is classified as ‘short-term’ regulation, and acts 
over a timescale from a few seconds to a few minutes. There is also a ‘long-term’ mechanism 
which acts over hours and involves the kidneys and hormonal system. Since the focus of this 
thesis is on the short-term response to the administration of adenosine, a surrogate for an 
exercise state under which coronary flow is maximum, long-term regulation is considered to 
be out-of-scope and not discussed in detail here. 
 
Figure 1.3: Scheme of baroreceptors reflex diagram on cardiovascular system. 
Aortic sinus and carotid baroreceptors send signal to the vasomotor centre in the medulla oblongata through 
the afferent nerves. The information is integrated and the sympathetic and parasympathetic (vagal) systems 
transmit the signal to the effectors: the heart and vessels. The sympathetic system can create different effects 
depending on the target organ. Chemoreceptors act in a similar way, but are confined to the sympathetic 
response. Figure adapted from OpenStax College - Anatomy & Physiology, Connexions Web site. 
(http://cnx.org/content/col11496/1.6/), Creative Commons Attribution-Share Alike 4.0 International license 
copyright (https://commons.wikimedia.org/w/index.php?curid=30148235). 
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 Coronary physiology 
Coronary blood flow differs from the systemic blood flow in the aorta (Figure 1.4) because of 
the phases of cardiac contraction which generate compression of the coronary 
microvasculature. During systole (the ventricular contraction and ejection phase) blood is 
ejected through the aortic valve into the aorta and systemic arteries and pressure and flow in 
the systemic circulation reach a maximum. However, during this phase, the myocardium is 
contracted and the coronary microvasculature is compressed thus impairing coronary flow. 
This explains the diastolic predominance of the coronary flow, an effect which is more 
pronounced in the left coronary system than the right due to relatively high left-ventricular 
pressures [3, 18]. 
 
Figure 1.4: Coronary blood flow and aortic blood flow during cardiac cycle. 
Typical coronary blood flow (red) wave shows a peak during diastole, due to contraction of the ventricle in 
systole, in contrast with the aortic flow that has a peak during systole. 
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1.2.2.1 Local regulation 
While other tissues extract about 25% of oxygen from the blood at rest, because of the high 
density of capillaries (with approximately one capillary for each cardiomyocyte, i.e. the cardiac 
muscle cell), myocardial tissue is able to extract as much as 70% of the oxygen from the blood 
[15]. This high rate of extraction explains why, when the heart is working hard, during exercise 
for example, the myocardium needs access to more oxygen and nutrients and the only way to 
achieve this is to increase coronary blood flow. 
Coronary blood flow (CBF) has been shown to be proportional to myocardial oxygen 
consumption [19-22] and it is driven by the regulation of the coronary resistance vessel tone, 
as the result of a huge number of vasodilator and vasoconstrictor signals. These signals are 
produced by several different mechanisms: 
- the metabolic response in the coronary vessels is determined by pH, carbon dioxide 
concentration and adenosine-tri-phosphate (ATP) concentration. ATP reacts with 
adrenoreceptors to produce adenosine; 
- the endothelium-derived response is sensitive to shear stress and pulsatile strain and 
therefore to blood flow; 
- the autonomic nervous system innervates the coronary vasculature through its sympathetic 
and vagal pathways (the former is activated during exercise to contribute to vasodilation 
in a feed-forward manner, while the latter is the most active during the rest condition); 
- aortic pressure, which determines the pressure gradient between the coronary arteries and 
the right atrium, where the coronary veins empty; 
- myocardial extravascular compression; 
- heart rate and cardiac output.  
The dominant effect is the vasoconstriction/vasodilation of the small arteries and arterioles in 
the myocardium; these contribute 90% of the coronary resistance [20]. 
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 HAEMODYNAMIC MODELS 
The working principles of the cardiovascular system have always fascinated scientists from the 
time of ancient populations [23]. The cardiovascular system can be represented as a closed-
loop circuit (Figure 1.5), in which flow obeys the laws which apply to all physical fluid 
systems: the principles of conservation of mass and conservation of momentum [18]. 
 
Figure 1.5: Basic representation of the cardiovascular system as a closed loop. 
 
 Physics of flow: governing equations 
The principle of mass conservation asserts that the mass flow into a compartment must equal 
the sum of increase in mass in the compartment and the mass flow out. It is essentially 
expressed by the continuity equation (Eq.1.1), where ρ is the density of the fluid and v the 
vector of fluid velocity: 
𝜕𝜌
𝜕𝑡
+ ∇ ∙  (𝜌𝒗) = 0 (Eq.1.1) 
The principle of conservation of momentum, which might be interpreted as an expression of 
Newton’s second law, states that the rate of change of momentum of a fluid element is equal 
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to the forces acting on it and is expressed by Navier-Stokes equation for momentum (Eq. 1.2), 
where ρ is the density of the fluid, v is the fluid velocity vector, p is the pressure, µ is the fluid 
viscosity and f represents the external forces: 
𝜌 [
𝜕𝒗
𝜕𝑡
+ (𝒗 ∙ ∇)𝒗] =  −∇𝑝 + 𝜇∇2𝒗 + 𝜌𝒇 (Eq.1.2)  
Integrating the Navier-Stokes equation along a streamline and assuming a steady state 
condition with incompressible and inviscid fluid, the Bernoulli equation is obtained [24] (Eq. 
1.3), where ρ is the flow density, v is the velocity of fluid, p is the pressure, g is gravitational 
acceleration and h is the elevation of the point above a reference plane: 
𝑝 + 𝜌
𝑣2
2
+ 𝜌𝑔ℎ = 𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡 (Eq.1.3)  
The vascular system can be represented as branching tree with each vessel defined by its length 
and radius. Each of the single vessels offers resistance to blood flow, which can be calculated 
by Hagen-Poiseuille’s law (Eq. 1.4), where µ is the viscosity of blood, L is the characteristic 
length of the vessel and r is the vessel radius: 
∆𝑃 = 𝑃𝑅 ∙ 𝑄 =
8𝜇𝐿
𝜋𝑟4
 𝑄 (Eq.1.4)  
Also the Hagen-Poiseuille law (Eq.1.4) can be derived from Navier-Stokes equation (Eq.1.2), 
assuming a Newtonian fluid, laminar flow, steady state condition in horizontal small tubes, 
where the gravity force can be ignored. These hypotheses can be valid in peripheral vessels, 
such as arterioles and capillaries, where the pulsatility is smoothed by the proximal high-
compliance vessels, i.e. the main arteries.  
From the Hagen-Poiseuille law (Eq.1.4) it is clear that the pressure gradient in the system is 
much more sensitive to a change in vessel radius than to a change in flow. Assuming µ and L 
to be relatively constant, a small variation of radius, which has exponent 4 in Eq.1.4, results in 
a significant variation in pressure gradient [25]. 
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Another important principle applied to the cardiovascular system is the Frank-Starling law, 
which describes the relationship between the cardiac output and venous return. The main aim 
of this mechanism is to synchronise cardiac output and venous return, maintaining the blood 
pressure in the systemic and pulmonary circulations within physiological ranges and thus 
avoiding an unbalanced distribution of blood volume between the pulmonary and systemic 
circulations. The venous return changes according to particular stimuli: for example, it 
decreases when an individual stands up because the central venous pressure decreases; it 
increases during walking because the action of the calf muscles (calf muscle pump) helps to 
return the blood to the right ventricle. This variation of venous return brings about a change in 
left-ventricular filling pressure and, therefore, of stroke volume and cardiac output. The amount 
of blood filling the left ventricle determines the degree of stretch of the ventricular wall, which 
in turn influences the length of the contractile units (sarcomeres) within the cardiac muscle 
fibres. During systole the cardiac muscle fibres contract generating a force proportional to the 
initial stretched length [4, 26, 27]. An increase in contraction is related to an increase in 
myocardial metabolism which, in turn, is associated with an increase in demand for blood flow 
in coronary vessels. 
Several physical quantities can be defined that characterise the operation of the cardiovascular 
system in a particular state, many of which might be measured clinically [28]. These include: 
- heart rate (HR), the number of beats per minute; 
- stroke volume (SV), the amount of blood volume ejected from the ventricle at each beat; 
- cardiac volumes, in particular the end-systolic (ESV) and end-diastolic volumes (EVD) of the 
left ventricle, which provide information concerning the efficiency of the pumping heart; 
- ejection fraction (EF), the ratio between SV and EVD; 
- aortic pressure (Pao), which can be distinguished in systolic, diastolic and mean aortic pressure 
(MAP); 
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- pulmonary pressure, the pressure in the pulmonary artery; 
- cardiac output (CO), the volume of blood ejected into the systemic circulation in one minute.  
CO is related to the heart rate (HR) and stroke volume (SV) as shown below (Eq. 1.5): 
𝐶𝑂 = 𝐻𝑅 × 𝑆𝑉 (Eq.1.5)  
- peripheral resistance (PR), the resistance offered to the flow by the vessels of the systemic 
circulation. A number of factors influence this parameter, including vessel compliance, 
vasoconstriction and vasodilation mechanisms. PR can be estimated from the ratio of the 
mean arterial pressure and the cardiac output (Eq.1.6): 
𝑃𝑅 =
𝑀𝐴𝑃
𝐶𝑂
 (Eq.1.6)  
- pulmonary resistance, the resistance of the pulmonary circulation. In a similar way, this can 
be estimated from the ratio of mean pulmonary pressure and the cardiac output relative to the 
right ventricle. 
 
 Models of cardiovascular system 
Different type of models can be used to represent and study the cardiovascular system. The 
main categories are lumped-parameters (zero-dimensional, 0D) and distributed-parameters 
(one-dimensional, 1D; two-dimensional, 2D; three-dimensional, 3D models). It is necessary to 
select the most suitable type of model depending on what is the aim of the study, on what are 
the features of interest and, moreover, on what are the clinical data available (Table 1.1) [29-
31]. 
0D models are usually used to study the global distribution of pressure, flow and volume of 
blood under different physiological states. They represent the cardiovascular system in 
compartments, lumping together parts of vasculature with similar characteristics, and their 
blood pressure, flow and volume are exclusively a function of time. A system of differential 
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equations solves the conservation of mass, the conservation of momentum and the equilibrium 
between pressure and volume.  
1D models are mainly used to study the wave propagation effect in the vasculature, especially 
for large arteries. Blood pressure and flow are function of time and of the cross-sectional area 
of the vasculature. This type of model requires pressure and/or flow curves and cross sectional 
area of the vessel as boundary conditions. 
Table 1.1: Types of cardiovascular models with the described features and the clinical data required for 
personalisation. 
Model type Described features Clinical data required 
0D Pressure, flow and volume distribution in 
compartments 
P(t), Q(t), V(t) 
Pressure and flow upstream the model 
1D Pulsatility and wave propagation 
P(t, x), Q(t, x), V(t, x) 
Pressure and/or flow curves as 
boundaries, radius variation along the 
vessel 
2D Variation of velocity profile in radial direction in axis-
symmetric conditions 
P(t, x, y), Q(t, x, y), V(t, x, y) 
Images for geometrical properties, 
pressure and/or flow curves as 
boundaries 
3D Complex flow patterns in specific region of 
cardiovascular system 
P(t, x, y, z), Q(t, x, y, z), V(t, x, y, z) 
Images for geometrical properties, 
pressure and/or flow for boundaries 
conditions 
 
2D models enable the study of the velocity variation in the radial direction for an axis-
symmetric vessel model and they are often used in multiscale modelling with 3D models. 
3D models are the most accurate model, where blood pressure and flow have a spatial and 
temporal distribution. Computational Fluid Dynamics (CFD) simulations can capture complex 
flow patterns in small region of the cardiovascular system, such as ventricles, heart valves, 
bifurcations. These type of model require geometrical details of the area of interest and, 
therefore images need to be available and processed. Moreover, boundary conditions in terms 
of pressure and/or flow are essential to perform the simulations. The computational cost for 
these models and the amount of input data increase massively and this is the reason why they 
are used to represent only small portions of the cardiovascular system. 
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For the purpose of this project and for the type of clinical data available, the 0D models have 
been selected. In the following paragraph these model are therefore the focus and they are going 
to be described.   
However, the parameters of the 0D representation of patient-specific coronary stenoses, 
described in Chapter 6, have been determined from three-dimensional computational fluid 
dynamics analyses that represent in particular the convective acceleration and viscous 
dissipation in the complex flow fields and capture the nonlinear relationship between pressure 
gradient and flow. 
 Zero-dimensional or lumped parameters models 
Zero dimensional models (also known as lumped-parameter models) are based on a 
combination of resistive, compliant and inertial elements, arranged in series or in parallel, to 
represent the cardiovascular system or specific part of it (compartment). Within each 
compartment the quantities are assumed to be spatially invariant; only temporal variations are 
represented. Such models can be mono-compartmental, in which the different components are 
merged into a single compartment that includes the properties of each, or multi-compartmental, 
in which the vascular system is divided into separate modelled compartments between which 
it is also possible to evaluate the interactions [30]. The development of these models is based 
on an electric-hydraulic analogy (Table 1.2) and Ohm’s and Kirchoff’s laws. 
Table 1.2: Analogies between hydraulic and electric quantities. 
HYDRAULIC ELECTRIC 
Pressure (P) Voltage (V) 
Flow (Q) Current (I) 
Friction Resistance (R) 
Compliance Capacitance (C) 
Inertial mass Inductance (L) 
Chapter 1 – Introduction & Background
 
19 
 
1.3.3.1 Mono-compartmental models 
The simplest model is the 2-element Windkessel (1889-Otto Frank), a parallel RC circuit 
(Figure 1.6-A). This model was used to study the arterial tree in terms of P-Q relationships 
during diastole, considering pressure decay as characteristic time decay of RC circuit, although 
it cannot represent high frequencies of the arterial load to the ventricle [32]. The resistor 
represents the resistance offered by the network of vessels and the capacitor the arteries’ 
capacity for blood storage [30]. The circuit is described by the following system of equations: 
{ 𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡 = 𝐶
𝑑𝑃
𝑑𝑡
𝑃𝑖𝑛 − 𝑃𝑜𝑢𝑡 = 𝑄𝑜𝑢𝑡 ∙ 𝑅
 
In 1971 Westerhof [33] developed the 3-element Windkessel (Figure 1.6-B), introducing in 
series the characteristic aortic impedance, Z0, which represents the resistance of large conduit 
arteries [34, 35]. Its value is equal to the ratio between the oscillatory pressure and the flow 
rate in the absence of reflective waves:  𝑍0 =
𝑃
𝑄
 . However, in lumped-parameters models the 
characteristic impedance of main arteries, which consists about 5-7% of the peripheral 
resistance, is often represented as a resistor generating small errors at low frequencies [34]. 
The equations that describe the model are: 
{ 𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡 = 𝐶
𝑑𝑃𝐶
𝑑𝑡
𝑃𝑖𝑛 − 𝑃𝑜𝑢𝑡 = 𝑄𝑖𝑛 ∙ 𝑍 − 𝑄𝑜𝑢𝑡 ∙ 𝑅
 
Burattini in 1982 [36] proposed the 4-element Windkessel, introducing an inductance, L, which 
represents the inertial behaviour of blood flow in the arterial vessel [37]. This can be inserted 
in series or in parallel with Z0 and each circuit has different solving equations and different 
values of L (Figure 1.6- C, D). Whilst this model works well at all frequencies, it is difficult to 
estimate a value for the inductance. For this reason the 3-element Windkessel is often chosen 
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to represent the global behaviour of arterial system using physiologically estimated parameters, 
although it is not able to represent wave propagation [34]. 
 
Figure 1.6: Most used lumped-parameter models. 
A) 2 element- Windkessel electrical analogue model. B) Windkessel model with 3 elements. C) 4-element 
Windkessel model with the inductance L in series. D) 4-element Windkessel model with the inductance L in 
parallel. 
More elements can be added to these models and arranged in different ways, aiming to 
represent parts of the vascular system with greater accuracy. Here it should be recognised that 
a value needs to be found for each additional element and often it is not a simple task to define 
or measure this. 
A multi-compartmental model has been chosen as the basis for the current study (see Chapter 
2 for more details). 
1.3.3.2 Modelling cardiovascular system and regulatory pathways  
Inspired by the work of Guyton [38], many scientists have developed different mathematical 
models to represent the cardiovascular system in terms of its multiple aspects and functions 
with the final aim of building a virtual model capable of including the entire human 
cardiovascular system. Several models of varying levels of complexity have been used to 
describe the physiology of the cardiovascular system. A mathematical model of the pumping 
left ventricle was developed by Suga et al. [39]. Both pressure and volume curves of the left 
ventricle were defined. The ratio between pressure and volume during the cardiac cycle 
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represents the contraction activity of the ventricle (E(t)). This depends on the highest value of 
the pressure and volume ratio (Emax) and its relative instant in the cardiac cycle (Tmax). This 
model of the heart has subsequently been widely used by others and adapted for all the cardiac 
chambers. 
Shi et al. [40] describe different models of closed-loop circulation, including the left and right 
heart with the systemic and pulmonary circulations. Both systemic and pulmonary circulations 
comprise different mono-compartmental elements, representing the arteries, arterioles, 
capillaries and veins, arranged in series. Each cardiac chamber is represented by a variable 
elastance with its specific contractility function. The cardiac valves, represented as diodes, 
guarantee unidirectional blood flow. This complete model describes the pressure curves in the 
arteries, veins and heart and the volume curves for the ventricles and atria. The results obtained 
are realistic and physiological in terms of pressure and flow in the atria and ventricles. Curated 
implementations of these models are publicly available from the CellML Model Repository 
[https://models.cellml.org/cellml]. This Repository, established and maintained by the 
Auckland Bioengineering Institute (ABI) [https://www.auckland.ac.nz/en/abi] in New 
Zealand, aims to support the biomedical modelling community by making available a series of 
published models, in a consistent format, that is curated to ensure that the produced results are 
consistent with the original published data. 
A more complete model was developed by Liang et al. [41]. Here, the heart model includes the 
interaction between left and right heart and considers the ventricular inter-septal pressure [42]. 
The model includes different compartments: the vena cava, aorta, cerebral and upper limb 
circulations, pulmonary circulation, renal circulation, splanchnic circulation and lower limb 
circulation. The results are realistic for both the healthy system and that with heart dysfunction. 
One drawback of this model is the large number of parameters which must be defined, 
especially in regional segments of the circulation. This highlights a particular issue that is of 
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fundamental importance to the work that is presented in this thesis: the very simplest models 
are able only to represent the simplest responses, whilst increasing complexity in the model 
can represent more of the physiological phenomena and responses and provide an increasingly 
faithful representation of the systems physiology. This is excellent when the purpose of the 
model is to increase understanding of the system, and to evaluate the likely contributions of a 
multitude of parameters and effects to the system response. However, when the purpose of the 
model is to describe the physiological characteristics and responses of a specific individual, the 
sparsity of the available clinical data upon which the model can be personalised, especially if 
the intent is to use only data that is collected in the standard clinical pathway rather than under 
a research protocol, necessarily limits the number of parameters that can be included in the 
model. 
In recent years, with increasing emphasis on the use of personalised models to describe 
individual cardiovascular physiology, there has been a renewed interest in the identification 
and operation of the simplest models that can be personalised from minimal clinical data [43]. 
It has been demonstrated that even the simplest models, when personalised to the individual, 
might have important diagnostic utility [44]. 
Within this thesis the aim is to select the simplest model that can describe the phenomena of 
interest, in order to facilitate the personalisation of parameters for an individual patient. The 
aim is to predict how an individual responds to a change of state. 
Recently research focus has been concentrated on the definition of the cardiovascular 
regulatory system, or parts of it, with different models, simulating healthy individuals and 
patients with different disease under different conditions. 
Ursino and co-workers [45-53] developed a number of different models to study how the blood 
pressure and the concentration of oxygen influence the response of efferent pathways and the 
local regulation of cardiovascular system. Aortic baroregulation, chemo-regulation as function 
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of the partial pressure of oxygen and carbon dioxide, metabolic regulation driven by the local 
effect of oxygen and carbon dioxide concentrations and the action of lung stretch receptors on 
tidal volume during respiration were implemented. The results obtained show a good 
representation of the effect of each regulatory system analysed for a generic individual, during 
simulation of haemorrhage and variation of the oxygen partial pressure in the aorta. Ursino’s 
models were also used by Fresiello et al.[54] to develop a baroreflex cardiovascular model, 
which can represent the exercise condition in healthy individuals and patient with heart failure, 
providing an educational and clinical tool. In addition Fresiello et al.[55] developed a model 
that can be used for patient-specific purposes using some measured data, including patients 
with VAD devices, drug infusion representation and pre-set disease. 
The same research group developed a 0-D model of cardiovascular system including the 
baroreflex model to study the general effects of early inflation, late inflation and length of 
inflation of the intra-aortic balloon pump (IABP) with particular regard to aortic receptors at 
the site where the device is located [56, 57]. 
Ursino’s regulatory model focuses on a number of effectors (ventricle pumping function, 
systemic resistance, heart rate and venous unstressed volume), which are analysed in more 
depth in Chapter 2. This type of control is relevant for the study of the adenosine response, in 
terms of the aortic pressure and heart rate effects, and for its implementation in the 
cardiovascular model.  
Other complex cardiovascular models with details of vascular compartments and regulation 
mechanisms were implemented with the purpose of understanding specific mechanisms, 
although here the representation of specific individuals is not possible. 
In 2010 Cheng et al. [58] developed an integrated lumped cardio-respiratory model 
(PNEUMA) to study and understand the regulation of sleep in cases of obstructive or central 
sleep apnoea for a generic individual.  
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In 2011 Hester et al. [59] developed a integrative model of human physiology (HumMod), with 
more than 5000 variables to describe cardiovascular, respiratory, renal, musculo-skeletal 
system including the neural, endocrine and metabolic physiology. This complex model is based 
on empirical data from the peer-reviewed literature and the interface allows parameters and 
conditions to be modified manually. Although tuning 5000 variables is impossible for patient-
specific applications, this model is a great tool for investigating the human body and for 
research and education purposes. 
Blanco et al. [60] built a coupled 0D-1D-3D closed-loop cardiovascular model,  with 0D model 
of baroreflex to simulate the generic response to haemorrhage, valvular disease and cerebral 
aneurism and understand the influence of the barocontrol in a generic individual or patient. 
Similarly, Neidlin et al. [61] developed a 3D aortic arch model coupled with a 0D baroreflex 
component to study the cerebral circulation during cardiopulmonary by-pass surgery with a 2-
way coupled fluid-structure interaction. 
Mantero et al. [25] developed a model of the complete circulation including coronaries and a 
control loop to regulate the effect of heart rate on aortic flow. The coronary circulation is 
represented as a single branch in parallel with the systemic circulation and, in order to represent 
the intra-myocardial pressure during systole, the myocardial compliance has a pressure 
generator. The control loop is able to represent different physiological conditions, such as rest 
and exercise, and the response of the heart rate, contractility and cardiac output to the oxygen 
demand, by comparing with a threshold for both coronary and aortic flows. Results show good 
agreement with the natural cardiovascular behaviour. 
Other types of integrated cardiopulmonary models with regulation were published to represent 
the generic system of healthy individuals or groups of patients with certain pathologies in order 
to compare the response to different stimuli such as exercise [54, 62], orthostatic stress test [63, 
64] and Valsalva manoeuvre [58, 65]. 
Chapter 1 – Introduction & Background
 
25 
 
In summary, many lumped parameter models have been developed to describe and to represent 
the physiology of the cardiovascular system. The level of complexity, and processes 
represented in the model, depend on the question or hypothesis addressed. The majority of 
studies focus on the representation of physiological processes and the facility to describe 
known phenomena rather than on the operation for diagnostic or prognostic purposes for an 
individual. Complex models incorporating multiple parameters represent a major challenge; it 
is important to understand the sensitivity of the model outputs to its inputs so that an appropriate 
subset of parameters can be personalised to the individual physiology. For the current study it 
is important to understand which processes are important in this specific context of coronary 
physiology. This is the focus of the next section. 
1.3.3.3 Modelling the coronary system and physiology 
The coronary circulation has recently become a key area of interest for the application of 
lumped parameter models. Largely due to the high incidence of coronary pathologies [25, 66-
75], the coronary circulation is an application of great interest, in which lumped parameter 
models have significant potential both to improve understanding and to represent changes of 
physiological state in an individual. Whilst some of these studies aim to reproduce pressure 
and flow in the coronaries (patient-specific and generic) with mathematical models and use 
them as a tool for understanding and diagnosis, others are more focused on the regulation of 
the coronary circulation. 
Maasrani et al. [70, 72, 73, 76] aimed to simulate the patient-specific coronary blood flow 
before and after coronary bypass grafting. Main coronary branches are represented by mono-
compartment models, using resistors, capacitors and inertances, with parameter values 
obtained from vessel geometry averaged data (length and diameter). These are assumed to be 
the same for all patients. In contrast, the myocardial resistance and aortic pressure are patient-
specific. In this way by knowing the patient coronary artery stenosis location and setting the 
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corresponding values of parameters in relevant branches, it is possible to evaluate whether 
myocardial blood flow is sufficient before and after the treatment. 
Kim et al. [74, 77, 78] developed a 3D model of the aorta coupled with 0D models at the outlets 
representing the different branches. The model also included the coronaries and the left 
ventricle. MRI images and measurements were used to define the patient-specific 3D geometry 
of the aorta and the patient-specific blood flow in some of the aortic branches with brachial 
pulse pressure measurements used to personalise the function of the left ventricle. In this model 
the simple coronary compliance, represented by an ordinary capacitor, was distinct by the 
ventricular contraction activity, represented by a second capacitor with the back pressure 
applied. Simulations at rest and exercise in both healthy and pathological (coronary stenosis) 
conditions were performed, including a number of assumptions with regards to the change of 
cardiac output, heart rate and the peripheral resistance of the coronary circulation. Results of 
pressure, flow and wall shear stress in the coronary circulation showed that the implemented 
model is useful for prediction of specific-patient conditions, although many hypotheses and 
assumptions need to be made to represent the exercise condition. 
Geven et al.[66] developed an in vitro model and a mathematical model for a simplified 
cardiovascular system, which included the heart, the systemic and coronary circulations, in 
order to study and reproduce coronary pressures and flows for both baseline and hyperaemic 
conditions, validating them against invasive measurements in a conscious man. 
Manor et al. [79] described the coronary circulation with a 0D model including the epicardial 
coronaries and the intra-myocardial compartments, where the ventricular pressure is applied. 
The model is able to auto-regulate in case of an obstruction in the epicardial coronaries or in 
case of increase of flow demand, varying the capacitances according to the cross-sectional area. 
Cornelissen et al. [80, 81] studied the control of the blood flow in a generic coronary arterial 
tree consisting of 10 resistors in series, each representing the properties of a class of vessel size. 
Chapter 1 – Introduction & Background
 
27 
 
The model aims to study the interaction of the different control mechanisms (myogenic, 
metabolic and shear stress) governing the coronary blood flow. 
 CORONARY ARTERY DISEASE 
The heart must pump blood continuously in order to avoid tissue ischemia. If blood flow to the 
myocardium is impaired due to pathology, the heart is unable to continue to pump effectively 
and myocardial ischemia and, ultimately in severe cases, death are the consequences. 
The incidence of coronary artery disease (CAD) increases every year all over the world in both 
young and old. CAD is the most common type of heart disease and is related with the life style 
habits (e.g. smoking, a diet high in cholesterol) and with other pathologies such as hypertension 
and diabetes. CAD is caused by plaque formation inside the coronary lumen. This impairs 
blood flow and thus the myocardial tissue does not receive all the nutrients it needs [82]. 
 Clinical investigation 
It is important to diagnose CAD at an early stage in order to avoid complications and symptoms 
such as angina and myocardial ischemia. This is also supported by the huge growth of 
technology in the last century especially with regard to clinical applications. There are a 
number of diagnostic techniques available in clinical practice and each of these provides 
different qualitative and quantitative information. Some examples of these diagnostic 
techniques are angiography (3D angiography, Invasive Coronary Angiography, CT 
Angiography, Quantitative Coronary Angiography, Rotational angiography), Positron 
Emission Tomography (PET), Optical Coherence Tomography (OCT) and Cardiovascular 
Magnetic Resonance (CMR). This thesis focuses on Invasive Coronary Angiography. 
1.4.1.1 Symptoms: Baseline vs Hyperaemia 
It is important to define the impact of a coronary stenosis. The same stenosis might represent 
a different severity if patient has a sedentary lifestyle or an active one. Different lifestyles 
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generate different levels of oxygen demand by the tissues and, therefore, a different workload 
for the heart to achieve the appropriate cardiovascular function. A condition of exercise or 
hyperaemia is thus a valuable way of determining the effect of the stenosis during increased 
myocardial flow. 
1.4.1.2 Invasive Coronary Angiography  
The most common diagnostic method for CAD is Invasive Coronary Angiography (ICA) 
[http://www.nhs.uk/]. ICA is a clinical diagnostic technique used to study coronary vessels in 
symptomatic patients, who are believed to have a significant coronary stenosis. The technique 
consists of inserting a guiding catheter into a peripheral artery (femoral or radial), pushing it 
into the aorta, along the aortic arch and into one of the main coronary arteries. A contrast agent 
is injected through the catheter to make the vessel lumen visible to X-rays. In this way it is 
possible to identify regions where the lumen is reduced (stenosis) and to quantify the occlusion 
(Figure 1.7-left). 
Invasive Coronary angiography produces 2D images of the single coronary and the major 
limitation concerns the overlapping or foreshortening during the acquisition, which does not 
provide a valuable way to estimate the severity of the stenosis. 
 
Figure 1.7: Coronary Angiography (left) and QCA (right) example in a case of stenosis of the circumflex 
coronary artery. 
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In the Quantitative Coronary Angiography (QCA), 2D images of the lumen of the vessel are 
provided as inputs to image reconstruction software in order to create 3D geometries of the 
coronary vessels, determining the contour of the lumen. This allows parameters related with 
the stenosis, such as the lesion length, the reference average vessel diameter, the minimal 
luminal diameter, the severity of stenosis, etc., to be estimated [83, 84] (Figure 1.7-right). 
1.4.1.3 Fractional Flow Reserve index (FFR) 
Following the publication of the results of the DEFER study in 2007, the Fractional Flow 
Reserve (FFR) index has been introduced into clinical practice to provide a more objective 
assessment of the lesions. FFR is a physiological index which gives information about the 
severity of the stenosis in the coronary arteries [5, 85-87]. FFR reflects the pressure drop across 
the stenosis: it is defined as the ratio between the maximum coronary flow in the presence of 
the stenosis and the maximum coronary flow that could be achieved if the stenosis was not 
present [10, 86]. 
The coronary stenosis can be represented as an electric circuit (Figure 1.8), in which PA 
indicates the aortic pressure, PV the venous pressure, PD the distal pressure downstream the 
stenosis, RS is the resistance offered by the occlusion and R is the physiological resistance in 
the coronary microcirculation. 
 
Figure 1.8: Representation of a coronary artery stenosis and myocardial microcirculation with corresponding 
lumped model.  
The pressure guide measures the aortic pressure (Pa) and the distal (Pd) pressure across the stenosis when the 
microcirculation is vasodilated maximally. Pv represents the coronary venous pressure. 
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Considering the hypothesis that PV is null, the resistance R has the same value irrespective of 
the presence of a stenosis and considering Poiseuille’s law, FFR can be expressed as the ratio 
between the distal and the proximal blood pressure (Eq. 1.7): 
𝐹𝐹𝑅 =
𝑄𝑆
𝑚𝑎𝑥
𝑄𝑁
𝑚𝑎𝑥 = 
(𝑃𝐴 − 𝑃𝑉) (𝑅𝑆 + 𝑅)⁄
(𝑃𝐴 − 𝑃𝑉) 𝑅⁄
=
𝑅
𝑅 + 𝑅𝑆
=
𝑃𝐷 − 𝑃𝑉
𝑄
∙
𝑄
𝑃𝐴 − 𝑃𝑉
≅
𝑃𝐷
𝑃𝐴
 (Eq.1.7)  
During ICA, proximal and distal pressures across the stenosis are continuously recorded with 
catheters during intravenous infusion of adenosine, the drug routinely used to stimulate 
hyperaemic conditions. Hyperaemia refers to vasodilatation of myocardial microcirculation 
aiming to emulate the exercise condition, i.e. myocardial resistance decreases and coronary 
flow increases. The Pd/Pa ratio is continuously calculated from rest through to hyperaemia and 
the FFR is identified as the Pd/Pa during hyperaemia. 
During the hyperaemic condition an increase, by a factor of 2, in coronary flow and a decrease 
of the Pd/Pa caused by the vasodilatory response of the myocardial microcirculation is observed 
when compared to resting condition. Myocardial resistance decreases to about 50% of the value 
observed at rest [10]. The variation of Pd/Pa demonstrates that the lesion has less effect at rest 
compared to the hyperaemic state, when the effect of the stenosis dominates and blood flow is 
mainly obstructed by the narrowing, reducing the influence of the microcirculation. 
The cardiovascular auto- and neuro-regulatory mechanisms play primary roles in the 
hyperaemic response at pulmonary, systemic and coronary levels. Aortic pressure and heart 
rate increase as direct effect of adenosine response and the cardiovascular system responds by 
decreasing aortic pressure and heart rate. The evidence of this can be observed in the Pd/Pa 
behaviour, where peak and stable hyperaemic phases are normally achieved [10]. The FFR 
value is within the range [0; 1] with values between 0.75-0.80 indicating that the stenosis is 
responsible for significant myocardial ischemia [9, 10].  
This index is used by clinicians to make decision about the treatment for each patient. 
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Different theories about the influence of haemodynamic conditions on FFR have been exposed. 
According to Pijls and De Bruyne [9, 10], pressure and FFR are independent, because of the 
linear relationship between pressure and flow (Poiseuille’s law). However, Siebes et al. [87] 
demonstrated that in stenotic conditions, where there is likely to be turbulent flow, the pressure 
drop consists of viscous (AV) and inertial (B) losses (Eq. 1.8): 
∆𝑃 =  𝐴𝑉𝑄 + 𝐵𝑄
2 (Eq.1.8)  
Therefore, the stenosis resistance varies according to the blood flow and the approximation of 
FFR as Pd/Pa is imprecise. By calculating the FFR as ratio of resistances, its dependence on 
haemodynamic conditions becomes clearer (Eq. 1.9): 
𝐹𝐹𝑅 =
𝑄𝑆
𝑄𝑁
=
𝑅
𝑅 + 𝑅𝑆
 
(Eq.1.9)  
where R and Rs are strictly related to the haemodynamic conditions determined by disease and 
the pressure gradient. Moreover, Siebes et al. [87] believe that other assumptions made in the 
calculation of FFR as Pd/Pa leads to an incorrect estimation. In particular, the downstream 
pressure PV, which is assumed to be 0, actually depends on the aortic pressure, the venous 
pressure and the slope of the P-Q curve in coronary artery at maximum dilatation. 
In this project the clinical FFR measurement is considered as the ratio between the distal and 
proximal pressure during stable hyperaemia and the resistance of the stenosis is described by 
the quadratic equation (Eq.1.8), which includes viscous and inertial losses. 
 
 Coronary Artery Disease models 
As presented before, mathematical modelling is increasingly used to represent the 
cardiovascular system, whether considering the system as a whole or focusing on specific parts 
of it. In particular, models of coronary artery disease have been developed with different 
purposes, for example to study the wall shear stress, to estimate the myocardial 
microcirculation resistance, to predict the severity of the stenosis and to predict stent 
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deployment. A number of 0-D coronary circulation models have been already mentioned in 
paragraph 1.3.2.3 Modelling the coronary system and physiology. 
Image processing and Computational Fluid Dynamics (CFD) techniques have been integrated 
into a number of diagnostic examination processes such as angiography, Positron Emission 
Tomography (PET), Optical Coherence Tomography (OCT), Cardiovascular Magnetic 
Resonance (CMR). Using these techniques, the 3D structure of the vessel can be reproduced 
to be used in CFD and, thus, estimate different physiological parameters. 
Wellnhofer et al. [88, 89] compared the wall shear stress in the right coronary artery in control 
patients, patients with CAD and patients with aneurysmatic CAD, employing a CFD analysis. 
The angiographic images from each patient were used to define the vessel geometry with the 
complete RCA side branches, with boundary conditions defined from Doppler measurement of 
the total blood flow, divided into branches proportionally to their respective diameters. 
CFD analysis using patient-specific vessel geometries was also employed in the study carried 
out by Morris et al. [13]. Patient-specific geometries were obtained from 2D angiographic 
images from patients with CAD, stenoses were characterised in terms of viscous and inertial 
losses applying CFD analysis and a virtual FFR was estimated applying patient-specific 
pressures as the boundary conditions. 
Li and co-workers [90] reconstructed the coronary geometries with branches using information 
from OCT and 3D-angiography to evaluate the effect of the branches, showing better accuracy 
for determining the blood flow and for shear stress evaluation with more complex models. 
CFD can be also used for simulation of the implanted stent. Naghipoor et al. [91] studied drug 
release from a PLGA eluting stent using a computational study to investigate the growth of 
restenosis, the influence of the coated stent and the viscoelasticity of the arterial wall. This 
approach has the potential to be used as a predictive tool for the follow up-of stented patients.  
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This thesis considers a 0D model for the coronary circulation using the results of previous 3D 
CDF analyses, which characterised the stenosis pressure losses. This previous work was the 
subject of the thesis “Computational Fluid Dynamics modelling of coronary artery disease” 
submitted in 2016 by Dr Paul Morris [92].  
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 CONCLUSIONS AND CLINICAL PERSPECTIVE 
This chapter describes the project background in terms of its clinical and modelling aspects.  
The overall focus is the clinical investigation of coronary artery stenosis. Modelling is used to 
investigate the physiological effects of coronary obstruction under different conditions and 
predict the hyperaemic response to estimate FFR from a patient-specific model. 
FFR has become a valuable tool in the clinical assessment of CAD and in guiding treatment 
decisions. FFR is able to identify ischemia causing lesions [93], improve clinical outcomes 
[94] and reduce long-term costs [95]. Despite these benefits, FFR remains underused (<10% 
patients have this treatment) due to increased procedural time/costs and lack of operator 
expertise; in general clinicians are more familiar with traditional angiography [11]. More 
recently, predictive models of FFR have been developed which provide the proven benefits of 
physiological coronary assessment without the factors limiting widespread use [13]. These 
have been relatively successful, but, because they make assumptions about coronary 
microvascular adenosine response (usually applying population-averaged data), a ceiling of 
accuracy appears to have been reached. The accuracy-defining step is how these models 
represent coronary microvascular physiology and response to adenosine on a patient-specific 
basis [96]. The focus of this thesis is on the development of a lumped-parameter model of the 
cardiovascular system. Features modelling the barocontrol system and the distribution of blood 
volume, adenosine and gases, all necessary to describe the adenosine response during 
hyperaemia, are also described. Clinical data from CAD patients undergoing Coronary 
Angiography are used as inputs for different analyses and classifications, including; 
- tuning of the cardiovascular model at a systemic level and coronary level, 
- identification of the minimum and stable FFR through an objective algorithm, 
- classification of patient hyperaemic response.  
The hypotheses and results associated with each topic will be presented in the rest of thesis. 
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 THESIS OUTLINE 
This PhD project has been organised into five main chapters plus introduction and conclusions. 
This first chapter, Introduction & Background, provides a contextual overview of the relevant 
anatomical and physiological concepts of the cardiovascular system, of the clinical problem 
and of the state-of-the-art in 0D modelling. 
Chapter 2, Modelling the cardiovascular system, provides a description of the 0-D 
cardiovascular model developed in this project in terms of the haemodynamics, the barocontrol 
system and the adenosine pharmacokinetics. 
Chapter 3, Modelling the response to the administration of adenosine, describes the adenosine 
response in a generic individual considering what is reported in the literature. The relative 
influence between the systemic and the coronary circulation justifies the approach of 
personalising the two circulations separately. 
The focus of Chapter 4, Clinical data, is entirely on the data collected during invasive Coronary 
Angiography, which have been processed to develop an algorithm to objectively identify 
maximal and stable hyperaemia and to classify patients on the type of adenosine response. 
Chapter 5, Personalisation of parameters of cardiovascular system, illustrates the 
personalisation process of the global system, which allows to estimate the aortic adenosine 
concentration for each patient.  
In Chapter 6, Local tuning of coronary branches, the focus moves on to the coronary 
personalisation providing a set of different patient-specific inputs to obtain myocardial 
adenosine concentration and resistance during adenosine injection, which have been 
considered to predict the adenosine response on patients’ profile basis. 
Chapter 7, Conclusions and future work, a final overview of the limitations and conclusions of 
this project in terms of results obtained is reported. Also future work and ideas for improvement 
are presented. 
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2 CHAPTER 2   
MODELLING THE 
CARDIOVASCULAR SYSTEM 
 
INTRODUCTION AND PURPOSE 
The primary aim of the project is to construct and validate a computational lumped parameter 
model to represent the cardiovascular system in order to understand the effect of coronary 
lesions under different physiological conditions in a specific individual. The cardiovascular 
model to be introduced and developed in this chapter must include a representation of the 
coronaries and of myocardial flow. Ultimately, the model is applied to seek understanding of 
the physiological response of a specific individual and, because the measured clinical data 
available to support the model personalisation are sparse, the minimal set of parameters that 
need to be personalised to capture the basic characteristic measures of coronary physiology 
must be identified. The impact of the coronary stenosis is more evident during the short-term 
regulation mechanism where myocardial blood flow increases and the myocardial resistance 
decreases. An example of this is observed during the exercise condition, which is simulated 
metabolically during angiography by the infusion of adenosine. 
In this chapter, the focus is on the development of an appropriate 0D model to represent the 
cardiovascular system, including the coronary arteries, to support the aims of the study. A 
published cardiovascular model, featuring representations of the heart and pulmonary and 
systemic circulations, has been extended to include the coronary circulation and the baro- and 
chemo-controls by the integration of other published models. Thus, the model developed is
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 able to represent the blood volume distribution and the species distributions in each 
compartment. The main components of this model are; 
- the cardiovascular circulation described in terms of blood pressure, flow and volume, 
- the short-term regulatory mechanisms, 
- the adenosine pharmacokinetics. 
This chapter provides a description of the implementation of these elements, justifying the 
choices that were made according to the challenges and the problems encountered. 
 
 LUMPED PARAMETER MODEL OF 
CARDIOVASCULAR SYSTEM 
The lumped-parameter model is based on the electric-hydraulic analogy (see Table 1.1) and 
uses electric components such as resistances, capacitances, inertances and diodes to represent 
a hydraulic circuit.  
This thesis is focused on the investigation of coronary flow under a range of physiological 
states, the latter described by a global circulation model operating under appropriate conditions. 
Starting from the global multi-compartmental model for a generic individual developed by 
Korakianitis et al.[40], which represents the whole cardiovascular system including the 
systemic circulation, pulmonary circulation and left and right heart, with respective cardiac 
valves, a coronary circulation divided into left and right branches was added in parallel with 
systemic circulation (Figure 2.1). 
In order to represent the anatomy of the coronary circulation, the coronaries are introduced as 
an RCR circuit originating downstream of the aortic sinus compartment (SAS) and draining 
into the right atrium. To represent the ventricular contraction during systole, a back pressure 
proportional to the ventricular pressure was applied to the coronary compliance [25]. 
Chapter 2 - Modelling the cardiovascular system
 
38 
 
The distribution of volume in each compartment is a function of the initial volume and the 
difference of the inlet and outlet flow. The species distributions, in particular oxygen, carbon 
dioxide and adenosine, were estimated with a mass balance equation. Finally, the baro- and 
chemo-controls systems were introduced by adapting published models, as presented in the 
paragraphs which follow.  
The reasons for this level of complexity in our cardiovascular model are firstly related to the 
implementation and curation in CellML repository and secondly because of its level of 
resolution which could eventually represent different physiological states. 
 
Figure 2.1: Zero dimensional cardiovascular model used in this project. 
Compartments: systemic aortic sinus (SAS), systemic artery (SAT), systemic arteriole (SAR), systemic capillary 
(SCP), systemic vein (SVN), pulmonary artery sinus (PAS), pulmonary artery (PAT), pulmonary arteriole (PAR), 
pulmonary capillary (PCP), pulmonary vein (PVN), left and right ventricles (LV, RV), left and right atria (LA, RA). 
The coronary circulation comprises 2 branches (LC, RC) with the application of back pressure (blue line). 
Adapted from [40]. 
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 Haemodynamic system 
This paragraph develops the equations which describe the haemodynamics for each 
compartment of the model, with respect to blood pressures, flows and volumes. As mentioned 
before, the global model including heart, systemic and pulmonary circulation was published in 
literature by Korakianitis et al. [40] and the equations of the model are reported. 
2.1.1.1 Heart: chambers and valves 
Each cardiac chamber (atria and ventricles) are defined as a variable elastance, which 
represents the contracting function, and a diode, which represents the valve (Figure 2.2). 
 
Figure 2.2: Variable elastance and diode for heart chamber. 
The variable elastances, E(t), are defined by a function of contractility, e(t), as described in 
Eq.2.1: 
𝐸(𝑡) = 𝐸𝑚𝑖𝑛 +
𝐸𝑚𝑖𝑛 + 𝐸𝑚𝑎𝑥
2
 ∙  𝑒(𝑡) (Eq.2.1)  
where EMIN and EMAX are constants defined for each atrium and ventricle (Table 2.1). 
For the atria e(t) is defined as in Eq.2.2: 
𝑒(𝑡) =
{
 
 
 
 
0   𝐼𝐼𝐼𝐼𝐼𝐼𝐼         𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼   𝐼𝐼𝐼𝐼𝐼𝐼   𝑖𝑓    0 ≤ 𝑡 ≤ 𝑇𝑝𝑤𝑏   𝐼𝐼𝐼𝐼𝐼𝐼𝐼𝐼  
1 − cos (
𝑡 − 𝑇𝑝𝑤𝑏 
𝑇𝑝𝑤𝑤
 ∙ 2𝜋)             𝑖𝑓    𝑇𝑝𝑤𝑏 ≤ 𝑡 ≤ 𝑇𝑝𝑤𝑏 + 𝑇𝑝𝑤𝑤
0                                                       𝑖𝑓        𝑇𝑝𝑤𝑏 + 𝑇𝑝𝑤𝑤 ≤ 𝑡 ≤ 𝑇
  (Eq.2.2)  
where Tpww = 0.09∙T, Tpwb = 0.92∙T, considering T = 1 s. 
For the ventricles e(t) is defined as in Eq.2.3: 
𝑒(𝑡) =
{
 
 
 
 1 − cos (
𝑡 
𝑇𝑠1
 ∙ 𝜋)                                 𝑖𝑓    0 ≤ 𝑡 ≤ 𝑇𝑠1   
1 + cos (
𝑡 − 𝑇𝑠1 
𝑇𝑠2 − 𝑇𝑠1
 ∙ 𝜋)                      𝑖𝑓    𝑇𝑠1 ≤ 𝑡 ≤ 𝑇𝑠2
0                                                               𝑖𝑓        𝑇𝑠2 ≤ 𝑡 ≤ 𝑇
 (Eq.2.3)  
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where TS1 = 0.3∙T, TS2 = 0.45∙T. 
The outflow from each chamber or the flow through the valve at its outlet, Qout, is determined 
by the trans-valvular pressure gradient, ΔP, modelled by a smooth diode for each cardiac valve.  
The pressure-flow relationship for a perfect diode is with a quadratic relationship between flow 
and pressure in the forward flow regime. The abrupt change at the origin tends to create 
instability in a numerical solver, and for this reason smoothing was introduced. The smoothing 
parameters were chosen to produce a reasonable behaviour in this region of the system, without 
impacting on the system behaviour during the main periods of systole and diastole. Each 
cardiac chamber is therefore described by the following system of equations:  
 
{
 
 
 
 
 
 
 
 
 
 
 
 
𝑄𝑜𝑢𝑡 =
{
 
 
 
 
 
 
 
 𝐶𝑉 ∙ √∆𝑃                                                                                                   i𝑓 ∆𝑃 ≥   th
𝐶𝑉 ∙ 𝑃0
2√𝑡ℎ
sin (
∆𝑃 − 𝑡ℎ
𝑃0
) + 𝐶𝑉√𝑡ℎ                                                 𝑖𝑓 𝑡ℎ −
𝜋
2
< ∆𝑃 < th
(
𝐶𝑉 ∙ 𝑃0
2√𝑡ℎ
− 𝐶𝑉√𝑡ℎ)
2
(cos(
∆𝑃 − 𝑡ℎ −
𝜋
2
𝑃0
) − 1)        𝑖𝑓 𝑡ℎ −
3𝜋
2
< ∆𝑃 < 𝑡ℎ −
𝜋
2
0                                                                                                             𝑖𝑓∆𝑃 < 𝑡ℎ −
3𝜋
2
𝑝𝑖𝑛 = 𝑝𝑖𝑛𝑖 + 𝐸 ∙ (𝑉 − 𝑉𝑖𝑛𝑖)
𝑑𝑉
𝑑𝑡
= 𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡
∆𝑃 = 𝑝𝑖𝑛 − 𝑝𝑜𝑢𝑡                                                                                                                                  
  
 
where CV [ml s-1 mmHg-0.5] represents the flow coefficient, pout is the pressure downstream of 
the valve, pini and Vini are respectively the pressure and blood volume always present within 
each specific chamber, Qin is the flow in input in the chamber, th is the threshold used to define 
the smooth valve function, arbitrarily chosen below π/2 for the type of sinusoidal curves used 
to define the relationship in the region of null pressure gradient, 𝑃0 is a reference value equal 
to 1 mmHg. Figure 2.3 shows the perfect diode and the smooth diode relationship obtained 
with th=0.25 and th=0.5. In this model a threshold value of 0.5 was selected. 
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Figure 2.3: ΔP - Q relationship obtained with perfect diode and smooth diode. 
ΔP and Q are respectively the pressure gradient and flow across the cardiac valve. The black line indicates the 
perfect diode, the blue and red dashed lines represent the smooth diode using two different thresholds (0.25 
and 0.5 respectively). 
 
2.1.1.2 Systemic and Pulmonary Vasculature 
The systemic circulation is composed of several compartments (Figure 2.1): systemic aortic 
sinus (SAS), systemic arteries (SAT), systemic arterioles (SAR), systemic capillaries (SCP) 
and systemic veins (SVN). The pulmonary circulation has similar compartments: pulmonary 
artery sinus (PAS), pulmonary arteries (PAT), pulmonary arterioles (PAR), pulmonary 
capillaries (PCP) and pulmonary veins (PVN).  
Both systemic and pulmonary sinuses and arteries are represented by a CRL circuit, the veins 
are represented by a CR circuit, arterioles and capillaries are represented by simple resistors. 
The resistances in the different compartments are considered to be linear and result in 
proportional pressure gradient and flow. Their values are not constraint by derivation from the 
Poiseuille’s equation (Eq.1.4), but rather just to reproduce system measurements. The circuits 
and the systems of equations for each component are reported in Figure 2.4. Values used for 
each parameter in the model to represent a generic healthy individual are reported in Table 2.1, 
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except for the coronary parameters which are described in detail in the next paragraph (2.1.1.3 
Coronary modelling).  
 
{
𝐶
𝑑𝑝𝑖𝑛
𝑑𝑡
= 𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡
𝐿
𝑑𝑄𝑜𝑢𝑡
𝑑𝑡
= 𝑝𝑖𝑛 − 𝑝𝑜𝑢𝑡 − 𝑄𝑜𝑢𝑡 ∙ 𝑅
 
 
{
𝑝𝑖𝑛 = 𝑄𝑖𝑛 ∙ 𝑅 + 𝑝𝑜𝑢𝑡
𝑄𝑖𝑛 = 𝑄𝑜𝑢𝑡
 
 
{𝐶
𝑑𝑝𝑖𝑛
𝑑𝑡
= 𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡
𝑝𝑖𝑛 − 𝑝𝑜𝑢𝑡 − 𝑄𝑜𝑢𝑡 ∙ 𝑅 = 0
 
 
Figure 2.4: Circuit components with relative system of equations. 
Artery sinus and main arteries (top), arterioles and capillaries (middle), vein (bottom). 
 
Table 2.1: Values of constant parameters for the model parameters. 
Units: C [ml/mmHg], R [mmHg s/ ml], Z [mmHg s/ ml], L [mmHg s2/ ml], V [ml], P [mmHg], E [dimensionless], 
CV [ml /s mmHg0.5]. 
Left heart and systemic Right heart and pulmonary 
CSAS 0.08 VLVI 500 CPAS 0.18 VRVI 0 
RSAS 0.003 VLAI 400 RPAS 0.002 VRAI 0 
LSAS 0.000062 VLV0 5 LPAS 0.000052 VRV0 10 
CSAT 1.6 VLA0 4 CPAT 3.8 VRA0 4 
RSAT 0.05 PLV0 1 RPAT 0.01 PRV0 1 
LSAT 0.0017 PLA0 1 LPAT 0.0017 PRA0 1 
RSAR 0.5 ELAmax 0.25 RPAR 0.05 ERAmax 0.25 
RSCP 0.52 ELVmax 2.5 RPCP 0.25 ERVmax 1.15 
CSVN 20.5 ELAmin 0.15 CPVN 20.5 ERAmin 0.15 
RSVN 0.075 ELVmin 0.1 RPVN 0.006 ERVmin 0.1 
PSAS0 100 CVao 350 PPAS0 30 CVpu 350 
PSAT0 100 CVmt 400 PPAT0 30 CVtr 400 
 
2.1.1.3 Coronary modelling 
The coronary circulation, in terms of left and right coronaries, was included in the 0D model 
as two Windkessel circuits which originate from the aortic sinus (SAS) and end in the right 
atrium (RA). In this generic model it is assumed that the left and right coronary parameters are 
equal. Each branch is represented by the circuit reported in figure 2.5 and described by the 
following system of equations: 
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 {
 
 
 
 
𝑝𝑖𝑛 − 𝑝𝑐 = 𝑄𝑖𝑛 ∙ 𝑍
𝑝𝑐 − 𝑝𝑜𝑢𝑡 = 𝑄𝑜𝑢𝑡 ∙ 𝑅
𝑑(𝑝𝑐 − 𝑝𝑒𝑥𝑡)
𝑑𝑡
=
𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡
𝐶
𝑝𝑒𝑥𝑡 =
𝑃𝑣𝑒𝑛𝑡𝑟
2
 
Figure 2.5: 0D model of the coronary branches, using an external pressure on the capacitor. 
The ventricular contraction effect on the coronaries was introduced with an external pressure, 
Pext, set to half of the instantaneous left/right ventricular pressure for the left/right coronary. 
This was intended to represent grossly the spatial average of the pressure in the wall of the 
ventricle. The value of the total coronary resistance parameter was calculated with the 
hydraulic Ohm’s law (Eq.2.4) using average values of pressure gradient and coronary flow for 
healthy adults. The pressure gradient is given by the difference of the aortic pressure (100 
mmHg) and the right atrial pressure (15 mmHg), while the average coronary flow is around 1 
ml/s per branch in baseline conditions [97]: 
𝑍 + 𝑅 =
∆𝑃
?̅?
=
100 − 85 𝑚𝑚𝐻𝑔
1𝑚𝑙/𝑠
= 85 
𝑚𝑚𝐻𝑔 𝑠
𝑚𝑙
 
(Eq.2.4)  
Typically, the arterial models represented with the 3-element Windkessel fit pressure and flow 
data distributing the total resistances as 10% in the proximal resistance, Z, and 90% in the distal 
one, R [98]. In the modelling of the coronary circulation, this distribution does not produce 
physiological flow results because of the back pressure applied to the capacitance. When the 
back pressure is active, it generates an outflow from the capacitor, forced to the direction of 
the proximal resistance because of its lower value compared to that downstream. To achieve 
typical coronary flow waveforms, with the characteristic diastolic dominance, the Windkessel 
model for coronary circulation works using the opposite distribution of the resistances. Thus, 
the values of the coronary parameters are: 
𝑍 = 76.5 
𝑚𝑚𝐻𝑔 𝑠
𝑚𝑙
               𝑅 = 8.5 
𝑚𝑚𝐻𝑔 𝑠
𝑚𝑙
   
The coronary capacitances were set to 0.9 ml/mmHg [25]. 
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2.1.1.4 Blood volume distribution 
An average adult male, with height of 1.70 m and weight of 80 kg, was considered to have 
about 5 litres of total blood volume, BV, according to Nadler formula [99] (Eq.2.5, Eq.2.6): 
𝐵𝑉𝑀𝐴𝐿𝐸  (𝑙) = 0.3669 ∙ 𝐻𝑡
3(𝑚3) + 0.03219 ∙ 𝑊𝑡 (𝑘𝑔) + 0.6041 (Eq.2.5) 
𝐵𝑉𝐹𝐸𝑀𝐴𝐿𝐸  (𝑙) = 0.351 ∙ 𝐻𝑡
3(𝑚3) + 0.03308 ∙ 𝑊𝑡 (𝑘𝑔) + 0.1833 (Eq.2.6) 
In the cardiovascular system the total blood volume can be divided into: 
- the unstressed volume, V0, which fills the blood vessels without generating pressure; 
- the stressed volume, which in the no-flow condition would generate an intravascular 
pressure of 7 mmHg [100], known as the mean systemic filling pressure (PMFC) [38, 101-
104]. 
Blood volume (V) and pressure (P) in each compartment are proportional to the compliance 
(C) (Eq.2.7). The variation of the compartmental blood volume is calculated as the difference 
between the inlet flow, Qin, and outlet flow, Qout, (Eq.2.8). 
𝑉 = 𝐶 ∗ 𝑃 + 𝑉0 (Eq.2.7) 
𝑑𝑉
𝑑𝑡
= 𝑄𝑖𝑛 − 𝑄𝑜𝑢𝑡 (Eq.2.8) 
An initial value for V is required for the derivative equation (Eq.2.8) for each compartment. 
To select these values, data was obtained from the literature; the aim was to achieve a realistic 
distribution of blood volume in the system model and thus give realistic values for the 
distribution of the species of interest. The initial value of blood volume in each compartment 
is the average amount of blood that fills the specific compartment under pumping conditions. 
The specific example of the aorta (Figure 2.6) shows a change of volume between the end of 
systole (Vmax) and the end of diastole (Vmin), corresponding to the change of aortic pressure 
(120 and 80 mmHg respectively). The average value of blood volume (Vm) is the value used 
for the initialisation of the system, defined using different percentages of the total blood 
volume. 
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Figure 2.6: Representation of the change of the aortic volume during the systole and diastole. 
The mean aortic volume, Vm, is associated with mean arterial pressure, MAP (= 100 mmHg). The aortic volume 
increases during systole (P=120 mmHg) toward its maximum, Vmax, and it decreases during diastole (P=80 
mmHg) towards its minimum, Vmin. Part of the figure is from Wikipedia Common (author Benutzer:Lupino, 
with public domain). 
The blood volume was distributed based on data in the literature [1] (Figure 2.7), rearranging 
the percentages to take account of a difference in subdivisions of compartments. 
 
Figure 2.7: Distribution of blood volume in the cardiovascular system. 
(Blood volume distribution, Pearson Education, Inc.) 
The total cardiac chambers volume was 387.5 ml, corresponding to 7.75 % of total volume. 
Coronary circulation is not included in the distribution in Figure 2.7. Data from the literature 
with regard to the amount of blood per 100 gr of LV (9 ml/100 gr LV, [105]) and the mass of 
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LV and RV [106, 107], allow the amount of blood volume in the whole myocardium of a 
generic adult to be estimated. If the heart muscle is represented as a hollow sphere (thickness 
of 7.5 mm [108]) filled by 350 ml of blood in the central cavity, which corresponds to the 
cardiac chambers, the mean radius can be estimated and, assuming that blood volume makes 
up 12% of the cardiac tissue [109], the computed volume of blood in the myocardial system is 
then 26 ml which corresponds to 0.52 % of the total blood volume. 
The myocardial blood volume was sub-divided into left and right coronary circulation with 18 
ml (0.36 %) and 8 ml (0.16 %) respectively, hypothesising a dominance of the left heart with 
a ratio between the left ventricle mass and the right ventricle mass of 2.3 [107]. 
The argument above provides a reasonable basis for the approximation of the volume of blood 
in the myocardium. This is an important parameter in the computation of the time-series 
response to adenosine infusion because it dictates the rate of blood ‘turn-over’ and 
concentration in the coronaries builds as the drug arrives in the aorta. Because this is important, 
a complementary estimate was determined by representing the coronary vasculature and 
microvasculature as an idealised branching tree (see Chapter 6). The geometrical branching 
rules were tuned to give an appropriate pressure gradient, based on Poiseuille’s equation, and 
the volume computed. This gross approximation returned a computed volume that is similar to 
that estimated above. As mentioned previously, the initialisation volume in each compartment 
is necessary to provide a sensible distribution of blood volume in the cardiovascular system to 
calculate the concentration of species. The selection of such a complex cardiovascular model, 
which requires also the volume distribution, was made for different reasons. First, the aim was 
to develop a model from a CellML curated model which could be then shared in the repository. 
Second, if exercise needs to be simulated, this model could better represent the effects than a 
simple model. 
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For the systemic distribution, SAS, SAR and SCP compartments had 2%, 2% and 7% of total 
blood volume respectively. SAT volume was considered to be 9%, the sum of muscular and 
elastic arteries (4 and 5%).  
The pulmonary arterial compartment has, in total, 3% of total blood volume and it is distributed 
among PAS, PAT and PAR compartments using the same proportions in the systemic 
compartment, with resulting percentage of 0.45%, 2.1 % and 0.45% respectively. 
Moreover, starting from a value of 64%, the volume of the systemic veins, was set to 62.74% 
in order to redistribute a 0.76% excess in the heart and a 0.5% excess in coronary volume, 
ensuring that the sum of the percentages is 100%. 
The blood distribution and the percentage for each compartment is summarised in Table 2.2. 
Table 2.2: Distribution of blood volume (% BV) in each compartment of the cardiovascular model. 
Compartment % BV Compartment % BV Compartment % BV 
LV 2.75 SAS 2.00 PAS 0.45 
LA 1.22 SAT 9.00 PAT 2.10 
RV 2.66 SAR 2.00 PAR 0.45 
RA 1.13 SCP 7.00 PCP 2.00 
LC 0.36 SVN 62.74 PVN 4.00 
RC 0.16     
 
 Oxygen and carbon dioxide distribution 
2.1.2.1 Physiology 
The most important and vital function of the blood is to carry nutrients and waste. In particular 
oxygen and carbon dioxide are transported between the cells and the lungs. Exchange of these 
gases occurs in the systemic and pulmonary capillaries by diffusion processes driven by 
pressure gradients. Although the specific focus of this thesis is on the representation of the 
response to infusion of adenosine as a pharmacological surrogate for the exercise condition, a 
longer-term goal is to simulate exercise itself. The model has been developed with the 
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possibility of this future extension in mind, and so a representation of oxygen concentration 
and its distribution has been included in the model formulation. 
The concentration of a gas (Cgas) in a fluid is proportional to its partial pressure (Pgas) and the 
solubility coefficient specific for each gas/fluid combination (H) (Henry’s law - Eq.2.9): 
𝐶𝑔𝑎𝑠 = 𝐻 ∙ 𝑃𝑔𝑎𝑠 (Eq.2.9) 
The value of H for oxygen/blood is 0.03 
𝑚𝑙 𝑂2
𝑙𝑏𝑙𝑜𝑜𝑑∙ 𝑚𝑚𝐻𝑔
 [105]; the value of H for carbon 
dioxide/blood is 0.065 
𝑚𝑙 𝐶𝑂2
𝑙𝑏𝑙𝑜𝑜𝑑∙ 𝑚𝑚𝐻𝑔
 [110]. 
The relatively low solubility of oxygen in blood is compensated by the haemoglobin binding 
mechanism. Each molecule of haemoglobin, a protein found in the red cells in the blood, is 
able to bind 1.34 ml O2 at the pulmonary level [111]. The blood concentration of oxygen is 
calculated considering both haemoglobin binding and Henry’s law, as follows (Eq.2.10): 
𝐶𝑂2 = 1.34 [𝑚𝑙 𝑂2] ∙ 𝐶ℎ𝑎𝑒𝑚𝑜 ∙ 𝑆𝐴𝑇[%] + 𝐻𝑂2/𝑏𝑙𝑜𝑜𝑑 [
𝑚𝑙 𝑂2
𝑙𝑏𝑙𝑜𝑜𝑑  𝑚𝑚𝐻𝑔
] ∙ 𝑃𝑂2 [𝑚𝑚𝐻𝑔] (Eq.2.10) 
where Chaemo is the concentration of haemoglobin in blood and its value is 15 
𝑔
100 𝑚𝑙𝑏𝑙𝑜𝑜𝑑
 [111]; 
SAT is the percentage saturation of haemoglobin depending on the partial pressure of oxygen. 
The relationship between the saturation of haemoglobin (SAT) and the partial pressure of 
oxygen (PO2) (Figure 2.8) is described by Hill’s equation [112] (Eq.2.11): 
𝑆𝑎𝑡(𝑃𝑂2) = 100 ∙  
1.39 ∙ 10−4 ∙ (𝑃𝑂2)
2.7
1 + 1.39 ∙ 10−4 ∙ (𝑃𝑂2)2.7
 (Eq.2.11) 
There are other parameters which influence haemoglobin saturation, but for the sake of 
simplicity these are not included in the model. 
In the pulmonary capillaries oxygen is introduced into the blood from the alveolar air and 
carbon dioxide is eliminated from the blood. Typically, the partial pressure of oxygen (PO2) in 
the alveolar air is 100 mmHg, whilst in the alveolar venous blood it is 40 mmHg, corresponding 
to a concentration of 15.2 ml O2/ mlblood; the partial pressure of carbon dioxide (PCO2) in the 
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alveolar air is 40 mmHg, while that in the alveolar blood is 46 mmHg, corresponding to a 
concentration of 3 ml CO2/ mlblood [113]. 
 
Figure 2.8: Haemoglobin dissociation curve. 
The level of saturation of haemoglobin depends on the partial pressure of oxygen. The 2 red dashed lines 
represent the values of pressure and saturation in systemic capillaries (40 mmHg-75%) and pulmonary 
capillaries (100 mmHg-97%). 
In the systemic capillaries the partial pressure of oxygen (PO2) in the systemic arterial blood is 
100 mmHg (i.e. a concentration of 20 
𝑚𝑙 𝑂2
𝑚𝑙𝑏𝑙𝑜𝑜𝑑∙ 
), while in the tissue it is less than 40 mmHg, the 
partial pressure of carbon dioxide (PCO2) in the tissue is more than 46 mmHg, while in the blood 
it is 40 mmHg (a concentration of 2.6 
𝑚𝑙 𝐶𝑂2
𝑚𝑙𝑏𝑙𝑜𝑜𝑑∙ 
) [113] (Figure 2.9). 
 
Figure 2.9: Oxygen and carbon dioxide partial pressures and concentrations in the cardiovascular system. 
The exchange of gases occurs only in the pulmonary and systemic capillaries, while the exchange in the 
vasculature is neglected. Part of the figure was adapted from Cancer Research UK / Wikimedia Commons and 
from UNSHAW/Wikipedia Common, both with Creative Commons Attribution-Share Alike 4.0 
International license copyright. 
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2.1.2.2 Modelling 
To represent the gases exchange and distribution, an equation of mass balance for each gas 
(Eq.2.12) was added to each compartment: 
𝑑 (𝐶 ∙ 𝑉)
𝑑𝑡
=∑𝐶𝑖𝑛 ∙ 𝑄𝑖𝑛 −∑𝐶 ∙ 𝑄𝑜𝑢𝑡 (Eq.2.12) 
where C is the concentration of the species, V the blood volume of the compartment, Qin and 
Qout are respective the input and output flow in and from the compartment, Cin is the 
concentration of the species in the immediate upstream compartment. The assumption of 
instantaneous and homogeneous distribution of gases in each compartment is considered. 
This derivative equation requires initial values for the amount of each species in each 
compartment. These were calculated as the product of the typical concentration in the 
compartment and its volume. For PVN, LA, LV, SAS, SAT, SAR compartments the partial 
pressure of oxygen was set equal to19.8 mlO2/mlblood and the partial pressure carbon dioxide 
equal to 2.6 mlCO2/mlblood. For SCP, RA, RV, PAS, PAT, PAR, PCP, LC and RC the partial 
pressure of oxygen was set equal 15.2 mlO2/mlblood and the partial pressure carbon dioxide 
equal to 3 mlCO2/mlblood. 
A number of assumptions were made in order to represent the gas exchange mechanism in the 
model of the cardiovascular system: 
- i) gas exchange/consumption at the level of the vasculature wall was neglected, and an 
assumption was made that this occurs in the capillaries (systemic, coronary and 
pulmonary) as represented in figures 2.9 and 2.10; 
- ii) the amount of oxygen introduced in pulmonary capillaries (I) was equal to the 
amount of oxygen consumed in the tissues (E) and was calculated as the product 
between the SCP blood volume (Vscp, ml) and difference between the arterial and 
venous concentration (ΔC, mlspecie/mlblood) (Eq.2.13): 
𝐼 = 𝐸 = 𝑉𝑆𝐶𝑃 ∙ ∆𝐶 (Eq.2.13) 
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- iii) the consumption of oxygen/emission of carbon dioxide in the systemic and coronary 
capillaries was constant, while in the pulmonary capillaries it was driven by the phase 
of respiration. During a breath, oxygen was introduced during the inspiration phase and 
the carbon dioxide was eliminated during the expiration phase. A respiration rate of 12 
breaths/min (Tbreath=5 s) was assumed, with inspiration and respiration phases equally 
distributed (Tinsp = Texp = 2.5 s). Therefore, the flow of oxygen introduced into the 
pulmonary capillaries during expiration is null and during inspiration is (Eq.2.14): 
𝑄𝐼𝑁,𝑂2 =
𝑉𝑆𝐶𝑃 ∙ ∆𝐶
𝑇𝑖𝑛𝑠𝑝
 (Eq.2.14) 
In the systemic and coronary capillaries, the flow of oxygen consumed is constant and 
equal to (Eq.2.15): 
𝑄𝑂𝑈𝑇,𝑂2 =
𝑉𝑆𝐶𝑃 ∙ ∆𝐶
𝑇𝑖𝑛𝑠𝑝
∗
 𝑇𝑖𝑛𝑠𝑝
𝑇𝑏𝑟𝑒𝑎𝑡ℎ
 (Eq.2.15) 
The same approach was applied for carbon dioxide. 
- iv) the elimination and introduction of gases at systemic and coronary capillaries levels 
was divided considering the proportions of their respective mean flows to the cardiac 
output (97.4% for systemic and 1.3% for each coronary) (Figure 2.10). 
 
Figure 2.10: Cardiovascular model with gases exchange. 
 Oxygen and carbon dioxide are exchanged in pulmonary capillaries, systemic capillaries and coronary 
capillaries.  
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 Neuro-regulatory and auto-regulatory systems 
Regulation of the cardiovascular system occurs through the neuro-regulatory pathways, which 
involve sympathetic and vagal responses, and local auto-regulatory effect. The physiology of 
these systems has already been explained in Chapter 1 (Paragraph 1.2.1.1 Physiology of 
regulatory pathways). 
Ursino et al. [49, 52, 114] has developed controlled cardiovascular lumped-parameter models, 
distinguishing between splanchnic, extra-splanchnic, skeletal-muscle, brain and coronary 
compartments. The regulatory pathways implemented consist of the barocontrol and 
chemocontrol signals. The original model is in closed-loop with regard to the aortic pressure 
and therefore the barocontrol, while the chemocontrol is in open-loop, meaning that the partial 
pressures of the gases in blood are provided as an input to the model. Also the tidal volume for 
the respiratory compartment is just an output of the model, which does not influence the 0D 
elements of the pulmonary capillaries, where the exchange of gases is not implemented. 
The barocontrol and chemocontrol were incorporated into the cardiovascular model by 
adapting the Ursino models as described in the following paragraphs. Figure 2.11 describes 
how the barocontrol and chemocontrol were implemented in the model, illustrating the 
effectors which were actually modified by the regulation. 
Chemocontrol was implemented as closed-loop, providing the oxygen partial pressure in the 
aorta (SAS) as input for aortic chemocontrol, the oxygen partial pressure in the systemic 
capillary (SCP) for the systemic CSN hypoxic response and the average oxygen partial pressure 
in the left and right myocardium for the heart CSN hypoxic response. 
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Figure 2.11: Scheme of barocontrol and chemocontrol system applied to the cardiovascular model. 
Each block is referenced to the describing equations listed in the following paragraph. 
The central system receives the afferent signals from baroreceptors (influenced by the aortic pressure (PAO)), 
chemoreceptors and the CSN (central nervous system) for hypoxia (both driven by the partial pressure of 
oxygen (PO2)) and from pulmonary stretch receptors (indirectly influenced by the chemoreceptors through the 
tidal volume (VT)). The central system then elaborates the efferent signals propagated through the 
sympathetic and vagal pathways. Sympathetic pathways act on systemic vessels in terms of resistances (Rsys) 
and venous unstressed volumes (Vun_vein), on the heart in terms of left ventricle elastances (ELVmax, ELVmin) and 
heart period (T) and on the pulmonary stretch receptors in terms of tidal volume. Vagal pathways act on the 
heart period (T). A feedback loop is sent back to PAO and VT. 
2.1.3.1 Barocontrol and chemocontrol model 
Following Ursino, the afferent signal to the central system includes: 
- a baro-afferent signal (𝑓𝑎𝑏), expressed as a sigmoid curve (Eq.2.16) based on the first 
order derivative on the aortic pressure (Pao) (Eq.2.17): 
    𝑓𝑎𝑏 =
𝑓𝑎𝑏,𝑚𝑖𝑛 + 𝑓𝑎𝑏,𝑚𝑎𝑥 ∙ 𝑒𝑥𝑝 (
?̃? − 𝑃𝑛
𝑘𝑎𝑏
)
1 + 𝑒𝑥𝑝 (
?̃? − 𝑃𝑛
𝑘𝑎𝑏
)
 (Eq.2.16) 
𝜏𝑝,𝑏
𝑑?̃?
𝑑𝑡
= 𝑃𝑎𝑜 + 𝜏𝑧,𝑏 ∙
𝑑𝑃𝑎𝑜
𝑑𝑡
− ?̃? (Eq.2.17) 
𝜏𝑝,𝑏 = 2.0760 𝑠    𝜏𝑧,𝑏 = 6.37 𝑠       𝑃𝑛 = 92 𝑚𝑚𝐻𝑔 
𝑓𝑎𝑏,𝑚𝑖𝑛 = 2.52 𝑠𝑝𝑖𝑘𝑒𝑠/𝑠      𝑓𝑎𝑏,𝑚𝑎𝑥 = 47.78 𝑠𝑝𝑖𝑘𝑒𝑠/𝑠   𝑘𝑎𝑏 = 11.76 𝑚𝑚𝐻𝑔    
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- a chemo-afferent signal, 𝑓𝑎𝑐, calculated as a first order derivative based on the partial 
pressure of oxygen in the aorta, 𝑃𝑎𝑂2 (Eq.2.18): 
𝑑𝑓𝑎𝑐
𝑑𝑡
=
−𝑓𝑎𝑐 +
𝑓𝑎𝑐,𝑚𝑎𝑥 + 𝑓𝑎𝑐,𝑚𝑖𝑛 ∙ 𝑒𝑥𝑝 (
𝑃𝑎𝑂2 − 𝑃𝑂2,𝑛
𝑘𝑎𝑐
)
1 + 𝑒𝑥𝑝 (
𝑃𝑎𝑂2 − 𝑃𝑂2,𝑛
𝑘𝑎𝑐
)
𝜏𝑐
 
(Eq.2.18) 
𝜏𝑐 = 2 𝑠        𝑃𝑂2,𝑛 = 45 𝑚𝑚𝐻𝑔  
𝑓𝑎𝑐,𝑚𝑖𝑛 = 1.16
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
     𝑓𝑎𝑐,𝑚𝑎𝑥 = 17.07
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
     𝑘𝑎𝑐 = 29.27 𝑚𝑚𝐻𝑔 
                                                  
 
- a pulmonary-afferent signal, 𝑓𝑎𝑝, calculated as a first order derivative based on the tidal 
volume, 𝑉𝑡 (Eq.2.19): 
𝑑𝑓𝑎𝑝
𝑑𝑡
=
−𝑓𝑎𝑝 + 𝐺𝑎𝑝 ∙ 𝑉𝑇
𝜏𝑝
         (Eq.2.19) 
𝜏𝑝 = 2 𝑠                            𝐺𝑎𝑝 = 23.29  𝑙
−1𝑠𝑝𝑖𝑘𝑒𝑠/𝑠  
- a central nervous system (CSN) hypoxic response for the peripheral vasculature 
(𝜒𝑠𝑝, 𝜃𝑠𝑝) and for the cardiac circulation (𝜒𝑠ℎ, 𝜃𝑠ℎ), since they have different threshold 
of minimum oxygen concentration (𝑃𝑂2,𝑛,𝑠𝑝, 𝑃𝑂2,𝑛,𝑠ℎ) (Eq.2.20, Eq.2.21): 
𝑑𝜃𝑠𝑝
𝑑𝑡
=
−𝜃𝑠𝑝 +
𝜒𝑚𝑖𝑛,𝑠𝑝 + 𝜒𝑚𝑎𝑥,𝑠𝑝 ∙ 𝑒𝑥𝑝 (
𝑃𝑎𝑂2 − 𝑃𝑂2,𝑛,𝑠𝑝
𝑘𝑖𝑠𝑐,𝑠𝑝
)
1 + 𝑒𝑥𝑝 (
𝑃𝑎𝑂2 − 𝑃𝑂2,𝑛,𝑠𝑝
𝑘𝑖𝑠𝑐,𝑠𝑝
)
𝜏𝑖𝑠𝑐
  
(Eq.2.20) 
𝑑𝜃𝑠ℎ
𝑑𝑡
=
−𝜃𝑠ℎ +
𝜒𝑚𝑖𝑛,𝑠ℎ + 𝜒𝑚𝑎𝑥,𝑠ℎ ∙ 𝑒𝑥𝑝 (
𝑃𝑎𝑂2 − 𝑃𝑂2,𝑛,𝑠ℎ
𝑘𝑖𝑠𝑐,𝑠ℎ
)
1 + 𝑒𝑥𝑝 (
𝑃𝑎𝑂2 − 𝑃𝑂2,𝑛,𝑠ℎ
𝑘𝑖𝑠𝑐,𝑠ℎ
)
𝜏𝑖𝑠𝑐
 
 
(Eq.2.21) 
 
𝜒𝑚𝑖𝑛,𝑠𝑝 = 7.33 
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
           𝜒𝑚𝑎𝑥,𝑠𝑝 = 13.32
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
     𝑃𝑂2,𝑛,𝑠𝑝 = 30 𝑚𝑚𝐻𝑔       𝑘𝑖𝑠𝑐,𝑠𝑝 = 2 𝑚𝑚𝐻𝑔 
 𝜒𝑚𝑖𝑛,𝑠ℎ = −49.38
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
        𝜒𝑚𝑎𝑥,𝑠ℎ = 3.59 
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
     𝑃𝑂2,𝑛,𝑠ℎ = 45 𝑚𝑚𝐻𝑔    𝑘𝑖𝑠𝑐,𝑠ℎ = 6 𝑚𝑚𝐻𝑔  
     
𝜏𝑖𝑠𝑐 = 30 𝑠           
 
The central system elaborates the afferent signals and produces: 
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- separate efferent sympathetic responses, for the peripheral vasculature (𝑓𝑠𝑝) (Eq.2.22) 
and for the heart (𝑓𝑠ℎ) (Eq.2.23): 
𝑓𝑠𝑝 = {
𝑓𝑒𝑠,∞ + (𝑓𝑒𝑠,0 − 𝑓𝑒𝑠,∞) ∙ 𝑒
[𝑘𝑒𝑠∙(−𝑊𝑏,𝑠𝑝∙𝑓𝑎𝑏+𝑊𝑐,𝑠𝑝∙𝑓𝑎𝑐−𝑊𝑝,𝑠𝑝∙𝑓𝑎𝑝−𝜃𝑠𝑝)]    𝑖𝑓 𝑓𝑠𝑝 < 𝑓𝑒𝑠,𝑚𝑎𝑥
𝑓𝑒𝑠,𝑚𝑎𝑥                                                                                                           𝑖𝑓 𝑓𝑠𝑝 ≥ 𝑓𝑒𝑠,𝑚𝑎𝑥
 (Eq.2.22) 
𝑓𝑠ℎ = {
𝑓𝑒𝑠,∞ + (𝑓𝑒𝑠,0 − 𝑓𝑒𝑠,∞) ∙ 𝑒
[𝑘𝑒𝑠∙(−𝑊𝑏,𝑠ℎ∙𝑓𝑎𝑏+𝑊𝑐,𝑠ℎ∙𝑓𝑎𝑐−𝜃𝑠ℎ)]    𝑖𝑓 𝑓𝑠ℎ < 𝑓𝑒𝑠,𝑚𝑎𝑥
𝑓𝑒𝑠,𝑚𝑎𝑥                                                                                        𝑖𝑓 𝑓𝑠ℎ ≥ 𝑓𝑒𝑠,𝑚𝑎𝑥
 (Eq.2.23) 
𝑓𝑒𝑠,∞ = 2.1
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
          𝑓𝑒𝑠,0 = 16.11
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
         𝑘𝑒𝑠 = 0.0675 𝑠         𝑓𝑒𝑠,𝑚𝑎𝑥 = 60
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
 
  
𝑊𝑏,𝑠𝑝 = 1             𝑊𝑐,𝑠𝑝 = 5            𝑊𝑝,𝑠𝑝 = 0.34           𝑊𝑏,𝑠ℎ = 1             𝑊𝑐,𝑠ℎ = 1
 
 
- a parasympathetic response (Eq.2.24): 
𝑓𝑣 =
𝑓𝑒𝑣,0 + 𝑓𝑒𝑣,∞ ∙ 𝑒
(
𝑓𝑎𝑏−    𝑓𝑎𝑏,0
𝑘𝑒𝑣
)
1 + 𝑒
(
𝑓𝑎𝑏−    𝑓𝑎𝑏,0
𝑘𝑒𝑣
)
+𝑊𝑐,𝑣 ∙ 𝑓𝑎𝑐 − 𝑊𝑝,𝑣 ∙ 𝑓𝑎𝑝 − 𝜃𝑣 (Eq.2.24) 
𝑓𝑒𝑣,∞ = 6.3
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
      𝑓𝑒𝑣,0 = 3.2
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
      𝑓𝑎𝑏,0 = 25
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
             𝑘𝑒𝑣 = 7.06
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
  
𝑊𝑐,𝑣 = 0.2           𝑊𝑝,𝑣 = 0.103      𝜃𝑣 = −0.68 𝑠𝑝𝑖𝑘𝑒𝑠/𝑠
 
- and a ventilator response (Eq.2.25): 
𝑉𝑇 = 𝑉𝑇,𝑁 + ∆𝑉𝑇               
𝑑∆𝑉𝑇
𝑑𝑡
=
−∆𝑉𝑇 + 𝐺𝑉 ∙ [𝑓𝑎𝑐(𝑡 − 𝐷𝑉) − 𝑓𝑎𝑐,𝑛]
𝜏𝑉
 
(Eq.2.25) 
𝐺𝑉 = 0.125
𝑙
𝜈
       𝜏𝑉 = 3 𝑠        𝐷𝑉 = 6 𝑠         𝑉𝑇,𝑁 = 0.583 𝑙       𝑓𝑎𝑐,𝑛 = 3.6 𝑠𝑝𝑖𝑘𝑒𝑠/𝑠  
The efferent signals were then transmitted to the effectors, considering specific delays (𝐷𝜃) 
gains (𝐺𝜃), constant times(𝜏𝜃) and reference values (𝜃0) for each. Sympathetic signals for the 
peripheral effectors (fsp) were used to regulate the peripheral resistance and venous unstressed 
volume and those for the heart (fsh) regulate cardiac elastance (Eq.2.26). The value of each 
effector was then calculated using a first order differential equation (Eq.2.27): 
𝑑∆𝜃
𝑑𝑡
=
{
 
 
 
 −∆𝜃 + 𝐺𝜃 ∙ ln [𝑓𝑠𝑝/𝑠ℎ(𝑡 − 𝐷𝜃) − 𝑓𝑒𝑠,𝑚𝑖𝑛 + 1]   
𝜏𝜃
 𝑖𝑓   𝑓𝑠𝑝/𝑠ℎ ≥ 𝑓𝑒𝑠,𝑚𝑖𝑛        
−∆𝜃
𝜏𝜃
                                                                              𝑖𝑓 𝑓𝑠𝑝/𝑠ℎ < 𝑓𝑒𝑠,𝑚𝑖𝑛
  (Eq.2.26) 
 𝜃(𝑡) = ∆𝜃(𝑡) + 𝜃0 (Eq.2.27) 
𝑓𝑒𝑠,𝑚𝑖𝑛 = 2.66
𝑠𝑝𝑖𝑘𝑒𝑠
𝑠
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As stated at the beginning of this paragraph, the model implemented in this thesis had a 
different compartmental structure to that published by Ursino: the systemic branch in the 
Ursino model consisted of more parallel branches representing different organs (splanchnic, 
extra splanchnic and muscles), whilst in the current project one single branch was considered. 
For this reason, an adaptation was made to the effectors of peripheral resistances and unstressed 
venous volume. In particular, both the capillary resistances and unstressed volume used in 
Ursino’s model were considered in parallel, to give the single peripheral resistance and 
unstressed volume representation used in the current model (Eq.2.28, Eq.2.29): 
𝑅𝑆𝑌𝑆 =
𝑅𝑆𝑃 ∙ 𝑅𝐸𝑃 ∙ 𝑅𝑀𝑃
𝑅𝑆𝑃 + 𝑅𝐸𝑃 + 𝑅𝑀𝑃
    
(Eq.2.28) 
𝑈𝑁𝑣𝑒𝑛 =  𝑉𝑢𝑆𝑃 + 𝑉𝑢𝐸𝑃 + 𝑉𝑢𝑀𝑃   (Eq.2.29) 
Coherently, the equivalent parallel was valid also for the controlled resistances and volumes 
values (Eq.2.30, Eq.2.31): 
𝑅𝑆𝑌𝑆 =
(∆𝑅𝑆𝑃 + 𝑅𝑆𝑃0) ∙ (∆𝑅𝐸𝑃 + 𝑅𝐸𝑃0) ∙ (∆𝑅𝑀𝑃 + 𝑅𝑀𝑃0)
(∆𝑅𝑆𝑃 + 𝑅𝑆𝑃0) + (∆𝑅𝐸𝑃 + 𝑅𝐸𝑃0) + (∆𝑅𝑀𝑃 + 𝑅𝑀𝑃0)
                 (Eq.2.30) 
𝑈𝑁𝑣𝑒𝑛 =  (∆𝑉𝑢𝑆𝑃 + 𝑉𝑢𝑆𝑃0) + (∆𝑉𝑢𝐸𝑃 + 𝑉𝑢𝐸𝑃0)  + (∆𝑉𝑢𝑀𝑃 + 𝑉𝑢𝑀𝑃0)     (Eq.2.31) 
For the heart period (Eq.2.34), both sympathetic (Eq.2.32) and vagal (Eq.2.33) pathways were 
involved in the calculation: 
 
𝑑∆𝑇𝑆(𝑡)
𝑑𝑡
=
{
 
 
 
 
−∆𝑇𝑆(𝑡)+𝐺𝑇,𝑠 ∙ ln [𝑓𝑠ℎ(𝑡−𝐷𝑇,𝑠)− 𝑓𝑒𝑠,𝑚𝑖𝑛 + 1] 
𝜏𝑇,𝑠
      𝑖𝑓   𝑓𝑠ℎ ≥ 𝑓𝑒𝑠,𝑚𝑖𝑛
−∆𝑇𝑆(𝑡)
𝜏𝑇,𝑠
                                                                           𝑖𝑓 𝑓𝑠ℎ < 𝑓𝑒𝑠,𝑚𝑖𝑛
   (Eq.2.32) 
𝑑∆𝑇𝑉(𝑡)
𝑑𝑡
=
−∆𝑇𝑉(𝑡) + 𝐺𝑇,𝑣 ∙ 𝑓𝑣(𝑡 − 𝐷𝑇,𝑣)
𝜏𝑇,𝑣
 (Eq.2.33) 
𝑇 = ∆𝑇𝑆 + ∆𝑇𝑉 + 𝑇0 (Eq.2.34) 
The constants used for each effector for gain, time constant, delay and reference value are 
reported in Table 2.3. 
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Table 2.3: Values of gain, time constant, delay and reference value for each effector. 
Gain Time constant Delay Reference value 
𝐺𝐸𝑚𝑎𝑥,𝑙𝑣 = 0.475 𝑚𝑚𝐻𝑔 ∙ 𝑚𝑙
−1 ∙ 𝜈−1
𝐺𝐸𝑚𝑎𝑥,𝑟𝑣 = 0.282 𝑚𝑚𝐻𝑔 ∙ 𝑚𝑙
−1 ∙ 𝜈−1
𝐺𝑅𝑠𝑝 = 0.695 𝑚𝑚𝐻𝑔 ∙ 𝑚𝑙
−1 ∙ 𝜈−1
𝐺𝑅𝑒𝑝 = 1.94 𝑚𝑚𝐻𝑔 ∙ 𝑚𝑙
−1 ∙ 𝜈−1
𝐺𝑅𝑚𝑝 = 2.47 𝑚𝑚𝐻𝑔 ∙ 𝑚𝑙
−1 ∙ 𝜈−1
𝐺𝑉𝑢,𝑠𝑣 = −265.4 𝑚𝑙/𝜈
𝐺𝑉𝑢,𝑒𝑣 = −74.21 𝑚𝑙/𝜈
𝐺𝑉𝑢,𝑚𝑣 = −58.29 𝑚𝑙/𝜈
𝐺𝑇𝑣 = −0.13 𝑠/𝜈
𝐺𝑇𝑠 = 0.09 𝑠/𝜈
 
𝑇𝐸𝑚𝑎𝑥,𝑙𝑣 = 8 𝑠
𝑇𝐸𝑚𝑎𝑥,𝑟𝑣 = 8 𝑠
𝑇𝑅𝑠𝑝 = 6 𝑠
𝑇𝑅𝑒𝑝 = 6 𝑠
𝑇𝑅𝑚𝑝 = 6 𝑠
𝑇𝑉𝑢,𝑠𝑣 = 20 𝑠
𝑇𝑉𝑢,𝑒𝑣 = 20 𝑠
𝑇𝑉𝑢,𝑚𝑣 = 20 𝑠
𝑇𝑇𝑣 = 2 𝑠
𝑇𝑇𝑠 = 1.5 𝑠
 
𝐷𝐸𝑚𝑎𝑥,𝑙𝑣 = 2 𝑠
𝐷𝐸𝑚𝑎𝑥,𝑟𝑣 = 2 𝑠
𝐷𝑅𝑠𝑝 = 2 𝑠
𝐷𝑅𝑒𝑝 = 2 𝑠
𝐷𝑅𝑚𝑝 = 2 𝑠
𝐷𝑉𝑢,𝑠𝑣 = 5 𝑠
𝐷𝑉𝑢,𝑒𝑣 = 5 𝑠
𝐷𝑉𝑢,𝑚𝑣 = 5 𝑠
𝐷𝑇𝑣 = 2 𝑠
𝐷𝑇𝑠 = 0.2 𝑠
 
𝐸𝑚𝑎𝑥,𝑙𝑣0 = 2.392 𝑚𝑚𝐻𝑔/𝑚𝑙
𝐸𝑚𝑎𝑥,𝑟𝑣0 = 1.412 𝑚𝑚𝐻𝑔/𝑚𝑙
𝑅𝑠𝑝0 = 2.49 𝑚𝑚𝐻𝑔 𝑠/𝑚𝑙
𝑅𝑒𝑝0 = 1.655 𝑚𝑚𝐻𝑔 𝑠/𝑚𝑙
𝑅𝑚𝑝0 = 2.106 𝑚𝑚𝐻𝑔 𝑠/𝑚𝑙
𝑉𝑢,𝑠𝑣0 = 1435 𝑚𝑙
𝑉𝑢,𝑒𝑣0 = 640.74 𝑚𝑙
𝑉𝑢,𝑚𝑣0 = 503.26 𝑚𝑙
𝑇0 = 0.58 𝑠
 
In the current model the unstressed volume in systemic vein (SVN) was introduced based on 
the relationship between pressure (P) and volume (V) in a compliant system assuming that the 
compliance was a constant and was independent of the unstressed volume (Figure 2.12). For a 
certain unstressed volume V0, the pressure P is null and for any volume V the pressure can be 
described as in Eq.2.35: 
𝑃 =
𝑉 − 𝑉0
𝐶
         (Eq.2.35) 
 
Figure 2.12: Pressure -Volume relationship with change of unstressed volume. 
 
2.1.3.2 Validation of the adapted controlled cardiovascular model 
In order to provide some verification that the adapted model of barocontrol is behaving as 
expected, a simulation of haemorrhage was run and the results compared with the original 
Ursino’s results. 
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Haemorrhage causes a response which aims to maintain a constant cardiac output by increasing 
the heart rate to compensate for the decrease in stroke volume whilst increasing the peripheral 
resistance in order to maintain the blood pressure. 
Simulation of haemorrhage can be achieved by introducing a volume leakage (10% of the total 
blood volume was chosen for the simulation reported) in the systemic venous compartment for 
a certain interval of time (5 s). The reaction of the barocontrol system is a short-term one; the 
cardiovascular system is not able to recover the normal condition, since the physiological 
systems required to model the long-term response (such as the kidneys and hormonal systems) 
were not included. 
The model predicts that haemorrhage causes a rapid drop of systemic pressure by 21% (60 
mmHg) of the baseline value. This activates the afferent and efferent pathways and the 
barocontrolled effectors respond as expected (Figure 2.13): both ventricular elastances 
(ELVmax and ERVmax) increase, together with the heart rate (HR) and the peripheral systemic 
resistance (Rsys) and, as a result, the cardiac output decreases. Comparing the results with those 
reported by Ursino [46], it can be seen that trends of change of RSYS, HR, systemic pressure 
(PSYS) and cardiac output (CO) are similar, although the absolute changes are not the same 
(Table 2.4). 
This difference is assumed to be generated by the different compartmental structure of the 
model keeping the original barocontrol coefficients. Reproduction of the same results can be 
achieved tuning the coefficients of barocontrol. This particular point has been investigated for 
the adenosine response, as explained in the next chapter. 
Table 2.4: Effect of haemorrhage stimulation in the barocontrolled model. 
Changes of peripheral resistance (RSYS), heart rate (HR), systemic pressure (PSYS) and cardiac output (CO) during 
the simulation of haemorrhage are compared with results of Ursino’s model [50, 52]. 
Parameter HR RSYS PSYS CO 
Current model 15% 13% −18% −25% 
Ursino’s model 10% 10% −10% −17% 
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Figure 2.13: Effectors response to haemorrhage stimulus in an ideal patient model. 
Heart rate, HR; max left ventricle elastance, ELVmax; max right ventricle elastance, ERVmax ; peripheral systemic 
resistance, Rsys; Unstressed venous volume, Unvein). 
 
 
 Adenosine pharmacodynamics and pharmacokinetic model 
Adenosine is a purine nucleoside which is present naturally within human body. It is an 
ubiquitous extracellular signalling molecule which is involved in many different physiological 
processes, such as energy production through ATP (Adenosine Tri-Phosphate) and blood flow 
regulation [115]. It is very relevant to this project since it is used during angiography to 
stimulate hyperaemia. The aim is to represent its distribution in the model and classify the 
different type of responses observed clinically. 
2.1.4.1 Pharmacodynamics 
Adenosine has different receptors, both intracellular and extracellular. Amongst the 
extracellular receptors 4 types of receptors, able to create different responses, have been 
recognised [115-117]: 
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- A1 receptors are mainly located in myocardial cells and are responsible for a negative 
chronotropic effect (decrease of heart rate) and negative dromotropic effect (inhibition 
of AV node conduction and a prolongation of the refractory period); 
- A3 receptors are mainly located in peripheral compartments and their role is not 
completely known; 
- A2a and A2b receptors are mainly located in the smooth muscle of the vasculature and 
are responsible for vasodilation in most vascular beds and for vasoconstriction in 
kidney and liver circulations. 
Interest in adenosine metabolism has increased over the last 50 years since its effects on the 
cardiovascular system (use in treatment of cardiac arrhythmias and ischaemia for example) 
were discovered [115, 116, 118] and many experimental studies have been performed on 
animals [119-123]. Ventricular and atrial arrhythmias have been treated with the direct 
injection of exogenous adenosine into the heart circulation in order to stimulate dromotropic 
and chronotropic responses and to correct the heart rhythm [116]. 
With intracoronary and intravenous injection, adenosine generates hyperaemia, a condition of 
vasodilation and consequent increase of myocardial blood flow which aims to simulate this 
aspect of exercise. Pharmacological induction of hyperaemia is widely used therapeutically. In 
patients with CAD who undergo diagnostic angiography, the use of adenosine to stimulate 
hyperaemia is potentially less invasive than other hyperaemic stimulation methods such as 
vessel occlusion and, whilst exercise can be considered to be the least invasive method, patient 
movement limits the quality of acquired images [115].  
2.1.4.2 Pharmacokinetics 
During angiography the hyperaemic condition is induced by the intravenous administration of 
adenosine in to the medial cubital vein. A dose of 0.14 mg/ml per kg of patient body weight 
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(BW) is routinely used and the injected solution has an initial concentration (CINJ) of 3 mg/ml 
[115]. The adenosine injection flow (QAD) is calculated as (Eq.2.36): 
𝑄𝑎𝑑 = 
𝑑𝑜𝑠𝑒 ∙ 𝐵𝑊
𝐶𝐼𝑁𝐽
 (Eq.2.36) 
In the model of the cardiovascular system, the flow of adenosine, Qad, is introduced into the 
systemic vein (SVN) and it is assumed that the drug is eliminated in all the vascular 
compartments with a half-life (t1/2) of 7 s [116]. The clearance of the drug, CL, in each 
compartment is expressed as (Eq.2.37): 
𝐶𝐿 = ln2 ∙
𝑉𝑜𝑙𝑢𝑚𝑒
𝑡1/2
 (Eq.2.37) 
A mass balance equation is implemented in each compartment to describe the adenosine 
concentration and its elimination (Eq.2.38). In the systemic vein (SVN) the injection of 
adenosine is also included (Eq.2.39). 
𝑑 (𝐶 ∙ 𝑉)
𝑑𝑡
= 𝐶𝑖𝑛 ∙ 𝑄𝑖𝑛 − 𝐶 ∙ (𝑄𝑜𝑢𝑡 + 𝑄𝑒𝑙) (Eq.2.38) 
𝑑 (𝐶 ∙ 𝑉)
𝑑𝑡
= 𝐶𝑖𝑛 ∙ 𝑄𝑖𝑛 − 𝐶 ∙ (𝑄𝑜𝑢𝑡 + 𝑄𝑒𝑙) + 𝑄𝑎𝑑 ∙ 𝐶𝐼𝑁𝐽 (Eq.2.39) 
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 DISCRETISATION AND SOLUTION METHODS 
Section 2.1 focused on the development of the systems of equations that describe the 
cardiovascular model. 
As stated before, the starting point was a published model and, specifically a model that was 
available publicly from the CellML repository. This model represents an excellent starting 
point, because its implementation had already been curated by the managers of the repository. 
Furthermore, the CellML environment supports experimentation with the alternative solvers 
that might be appropriate for equation systems of this type. However, additions to the system 
that are a required for this specific study include a number of phenomena (neuro-regulation 
and the non-linearity of oxygen partial pressure and concentration relationship) that are not 
readily implemented in CellML. Further details are given in the paragraphs that follow.  
Because of these limitations, the model was exported from CellML - Open Cor 
(http://www.opencor.ws/) into a MATLAB script, and the additional functionality was 
implemented within the MATLAB2015a environment (The MathWorks, Inc). The 
performance of the core model, as exported to MATLAB, was checked against results from the 
original CellML operation. 
 CellML- Open Cor 
The analogue hydraulic model with the species distribution (adenosine, oxygen and carbon 
dioxide) was implemented within the open source software Open Cor 
(http://www.opencor.ws/). Open Cor has been specifically developed to represent 
physiological models and enables a system of differential equations and linear algebraic 
equations to be solved. 
There are different solvers available: Forward Euler, 2nd order Runge-Kutta, 4th order Runge-
Kutta and CVODE. The latter was selected to run the simulations. 
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Implementation of some of the features associated with the baro- and chemo-control and the 
oxygen concentration proved intractable in Open Cor. The first problem was encountered in 
equations for the effectors, where a delay was applied (Eq.2.40), the second in the non-linear 
equation for the calculation of oxygen partial pressure from the concentration (Eq.2.41). 
𝜎𝜃 = 𝐺𝜃 ∙ ln [𝑓(𝑡 − 𝐷𝜃) − 𝑓𝑚𝑖𝑛 + 1]     (Eq.2.40) 
0.00417 ∙ (𝑃𝑂2)
3.7 + (0.28 − 1.39 ∙ 10−4 ∙ 𝐶𝑂2) ∙ (𝑃𝑂2)
2.7 − 𝐻𝑂2−𝑏𝑙𝑜𝑜𝑑 ∙ 𝑃𝑂2 − 𝐶𝑂2 = 0 (Eq.2.41) 
However, since it proved possible to export the curated model directly as a MATLAB code 
and expand the functionality in the MATLAB environment, this was the solution chosen for 
the work described in this thesis. 
 MATLAB 
In MATLAB 2015a there are a number of different functions to solve differential equations. 
The exported code from Open Cor provides the ode15s solver, based on the BDF 1-5. This 
solver uses a variable time-step to solve the differential and linear equations but, once again 
use of this specific solver gave rise to the problems in the introduction of the barocontrol delays. 
The original code with variable time-step was extended in order to store the algebraic 
quantities, checking the convergence by using a loop on the time-step values. Results from 
Open Cor were compared with the results of the post-processing of the algebraic equations in 
MATLAB, as shown in the example in Figure 2.14. Overall the results were unstable and 
unsatisfactory. 
To address this limitation, the solver ode4, was chosen. This is an explicit solver with arbitrarily 
fixed time-step, using the 4th order Runge-Kutta method. The advantages of using a fixed time-
step relate to the possibility of storing non-derivative quantities and manipulation of some 
quantities for averaging, as described in the next paragraphs. 
A sensitivity analysis on the time-step length was carried out in order to find the right 
compromise between simulation duration and accuracy of the results. Different values of time-
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steps (0.000025 s, 0.0001 s, 0.0005 s, 0.001 s, 0.002 s) were used for the simulation and the 
results were compared against the CellML solution. As expected, the smallest time-step 
produced results close to the original solution, while results with the largest time-step showed 
high inaccuracy and instability, especially during the closure of the cardiac valves. It is 
important to highlight that the ode4 solver was modified to allow the storage of variables not 
described by derivative equations (such as cardiac pressures and flows). 
 
Figure 2.14: Comparison between Open Cor results and MATLAB results. 
The MATLAB variable step solver was modified to allow the storage of the flows. Left) Results of heart flows 
obtained with OpenCor. Right). Results of heart flows obtained with MATLAB code using the modified ode15s. 
Legend: Qlao (left atrium output flow); Qlvo (left ventricle output flow); Qrao (right atrium output flow); Qrvo 
(right ventricle output flow). Units: flow in ml/s, x-axis in seconds. 
These variables (for example the left ventricular output blood flow and pressure) are sensitive 
to the time-step and smaller time-steps produce a stable and accurate solution (Figure 2.15 A, 
B), while the derivative variables (for example left ventricular volume) do not show the same 
level of sensitivity (Figure 2.15 C). Interestingly when implementing the same smooth valve 
in Open Cor, the solver requires a time-step of 0.0001 s to run the model with both fixed and 
non-fixed time-step solver (CVODE and 4th order Runge-Kutta respectively), while using the 
diode valve requires a time-step of 0.01 s for the variable time-step solver (CVODE) and 
0.0001 s for the fixed time-step one (4th order Runge-Kutta). 
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The time-step equal to 0.0001 s was selected for the simulation of the model in MATLAB. 
This provides stable left ventricular blood flow during all phases and close to the Open Cor 
solution. 
 
Figure 2.15: Open Cor VS MATLAB results of left ventricle blood flow, pressure and volume. 
A) Blood flow across the aortic valve, with a detail of the closure valve solutions. B) Left ventricular blood 
pressure. C) Left ventricle blood volume. MATLAB results are obtained with different time-steps (dashed grey 
0.002 s, continue red 0.001 s, continue magenta 0.0005 s, continue blue 0.0001 s, continue green 0.000025 s) 
using the smooth valve. Open Cor results are obtained with diode valve (dashed black, 0.01 s time-step, 
CVODE solver) and with smooth valve (dashed red, 0.0001 s time-step, CDVODE solver). 
 
2.2.2.1 Algorithms 
The fixed time-step solver also introduces the possibility to implement different algorithms to 
represent the barocontrol system and to keep track of non-derivative quantities. The following 
sub-sections list, and briefly describe, the algorithms introduced within this type of solver. 
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2.2.2.1.1 Moving average calculation 
The moving average concept was used to introduce the delay for the barocontrol, and smooth 
the response. Without this the control mechanism responds continually to the variations within 
the heart cycle, and the fact that the delay is not generally an integral multiplier of the heart 
period produces non-physiological oscillations in the response. The solution was to calculate 
an average value of a certain quantity across the last cardiac cycle. A detail of the 
implementation is that the average is accumulated based on the fraction of the cardiac cycle, 
even if the heart period changes. 
The fraction of the cardiac cycle varies from 0 to 1 and increases at each instant. It is described 
as the sum of the last value of fraction (𝐹𝑟𝑎𝑐𝑡𝑖−1) and the ratio between the time-step and the 
cardiac period at the current time (𝑇𝑖). When the value of the cardiac fraction is equal or higher 
than 1, it is reset to 0, considering the fraction to be in excess (Eq.2.42): 
𝐹𝑟𝑎𝑐𝑡𝑖 = 𝐹𝑟𝑎𝑐𝑡𝑖−1 +
𝑡𝑖𝑚𝑒𝑠𝑡𝑒𝑝
𝑇𝑖
                 𝑖𝑓 𝐹𝑟𝑎𝑐𝑡𝑖 ≥ 1      𝐹𝑟𝑎𝑐𝑡𝑖 = 0 + (𝐹𝑟𝑎𝑐𝑡𝑖 − 1) (Eq.2.42) 
As described before, the efferent pathways are activated with a specified delay for each effector 
and, therefore, it is necessary to store these quantities in order to consider the value at the 
specified instant in the past. In figure 2.16, a generic signal A(t) is shown and the fractions of 
cardiac cycle are reported for 4 consecutive cardiac cycles with different periods (T1, T2, T3, 
T4). Ideally the delay, applied in the last cycle at a certain fraction of cardiac cycle, has to take 
into account the signal at the same fraction of cardiac cycle. The delay values do not guarantee 
that the same fraction of cardiac cycle is considered. For this reason, for each instant the 
efferent sympathetic signal is smoothed, based on the average of its values occurring during 
the last cardiac cycle. 
A vector containing the signal during the last cardiac cycle was created using a length equal to 
3𝑠
𝑡𝑖𝑚𝑒𝑠𝑡𝑒𝑝 
, where 3 s was chosen as a maximum possible value of cardiac period. Assuming a 
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linear relationship of the signal within the time-step interval, a number of values of the signal 
within the time-step can be calculated at ftk point (Figure 2.17). 
The linear relationship is calculated as (Eq.2.43): 
𝑦 =
𝐴𝑗 − 𝐴𝑗−1
𝑓𝑟𝑎𝑐𝑡𝑗 − 𝑓𝑟𝑎𝑐𝑡𝑗−1
∙ (𝑥 − 𝑓𝑟𝑎𝑐𝑡𝑗−1) + 𝐴𝑗−1 
(Eq.2.43) 
 
Figure 2.16: Implementation of the moving average to apply delays. 
Left) Ideally the delay in A(t) (sympathetic efferent signal) should be applied considering the fraction of period 
in order to be in the same phase of the cardiac cycle. The values of delays do no guarantee to consider the 
same fraction of cardiac cycle. Right) For each instant A(t) is calculated considering the average of the last 
cardiac cycle (highlighted in orange). 
 
Figure 2.17: Scheme of the linear interpolation of the signal for intermediate fraction-steps. 
The graph shows how the values of A(t) (X) are calculated for each intermediate fraction of heart period (ftk) 
considering a linear relationship of A(t) within a time interval (tj-tj-1) or an equivalent fraction period interval 
(fractj-fractj-1). Knowing the coordinates of A(t) at time tj and time tj-1 it is possible to define the straight line 
equation. 
The moving average of the signals was then calculated as the mean within a cardiac cycle. This 
approach of smoothing was applied to the efferent sympathetic and vagal signals and to the 
afferent chemo-signal. Moreover, it can also be applied to the gas concentrations which could 
be used as inputs to the chemo regulation pathways. 
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2.2.2.1.2 Calculation of oxygen partial pressure: interpolation method 
The distribution of oxygen in the cardiovascular system can be expressed as a concentration 
([O2]), calculated from the mass balance implemented in the model or as partial pressure (PO2). 
There is a relationship between these two parameters which takes into account the solubility 
coefficient of the gas in blood (Eq.2.9) and its binding phenomena with haemoglobin (Eq.2.10, 
Eq.2.11). Combining all these equations together, the non-linear relationship between oxygen 
concentration and its partial pressure in blood is expressed as (Eq.2.44): 
0.00417 ∙ (𝑃𝑂2)
3.7 + (0.28 − 1.39 ∙ 10−4 ∙ [𝑂2]) ∙ (𝑃𝑂2)
2.7 − 𝐻𝑂2−𝑏𝑙𝑜𝑜𝑑 ∙ 𝑃𝑂2 − [𝑂2] = 0 (Eq.2.44) 
To solve this non-linear relationship and obtain the value of oxygen partial pressure, an 
interpolation function, interp1, was employed. 
2.2.2.1.3 Cardiac output, stroke volume and ejection fraction for each cardiac cycle 
To define the cardiac output (CO), the stroke volume (SV) and ejection fraction (EF) at each 
cardiac cycle, it is necessary firstly to identify the individual cardiac cycles, within which these 
quantities can be calculated. The concept of fraction of cardiac cycle was introduced in the 
previous paragraph (2.2.2.1.1 Moving average calculation). 
The cardiac output was calculated as the ratio between the difference of the maximum and 
minimum left ventricular volume and the duration of the cardiac cycle (Eq.2.45): 
 𝐶𝑂 =
𝑉𝐿𝑉𝑚𝑎𝑥−𝑉𝐿𝑉𝑚𝑖𝑛
𝑇𝐶𝐶
 (Eq.2.45) 
The stroke volume was calculated as the difference between the maximum and minimum left 
ventricular volume occurring within a cycle (Eq.2.46): 
 𝑆𝑉 = 𝑉𝐿𝑉𝑚𝑎𝑥 − 𝑉𝐿𝑉𝑚𝑖𝑛 (Eq.2.46) 
The ejection fraction was calculated as the ratio between the stroke volume and the maximum 
left ventricular volume (Eq.2.47): 
 𝐸𝐹 =
𝑉𝐿𝑉𝑚𝑎𝑥−𝑉𝐿𝑉𝑚𝑖𝑛
𝑉𝐿𝑉𝑚𝑎𝑥
 (Eq.2.47) 
Chapter 2 - Modelling the cardiovascular system
 
69 
 
The advantage of using the volume data to obtain these other variables is essentially the 
possibility to reduce the time-step for the optimisation process, which is explained in detail in 
Chapter 5, enabling the overall simulation time to be reduced. 
 SENSITIVITY ANALYSIS 
A sensitivity analysis aims at the definition of the influence of the independent variables (or 
inputs) on the dependent variables (or outputs) of the system. There are different methods of 
performing a sensitivity analysis [124, 125]. In this project the One-at-a-time (OAT) sensitivity 
measure was selected. With this method each input value is adjusted by a percentage of its 
original value, while all the other inputs are held constant, and the outputs are then compared 
with the original case values. 
The sensitivity analysis was performed for the non-barocontrol and the barocontrol model. 
With the introduction of the barocontrol, some inputs become outputs and more inputs are 
introduced with the barocontrol constants. Table 2.5 summarises the input and output 
parameters for the non-barocontrolled model and the barocontrolled one in terms of the 
haemodynamic. The input parameters for the non – barocontrolled are: 
- timing parameters related the ventricles and atria and heart period; 
- unstressed cardiac volumes and correspondent pressures; 
- active and passive cardiac elastances and valvular coefficients; 
- resistances, capacitances, inertances; 
- initial blood volumes in the different compartments;  
- unstressed systemic venous volume. 
The output parameters are divided in raw and derived. Among the raw or independent outputs 
there are: the time-discretised pressures, volume and flow in each compartment; the left-
ventricular end diastolic and end systolic volumes. Among the derived or dependent 
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parameters, there are cardiac output, stroke volume, ejection fraction, systolic and diastolic 
pressure, mean arterial pressure and the adenosine concentration in each compartment. 
With the barocontrolled model, the effectors ELVMAX, ERVMAX, RSCP, UNvein, and T are 
substituted by their respective reference values and their resulting values are outputs. In 
addition, a number of barocontrol constants are introduced as inputs, regarding the effectors 
gains, delays and the parameters describing the sigmoid functions of the afferent pathways and 
the logarithmic function describing the efferent pathways. 
The input parameters were changed by a certain percentage of the initial value and the 
normalised variation was calculated for each output parameter, as explained below.  
Each input parameter value (𝑃𝑖) was modified adding or subtracting a percentage from its initial 
value (𝑃𝑖,𝑂𝑅𝐼𝐺) as described in Eq.2.48: 
𝑃𝑖 =
𝑃𝑖,𝑂𝑅𝐼𝐺(100 ± 𝑋%)
100
 (Eq.2.48) 
where X% is a percentage chosen equally to 10%, 20%, 30%, 40%, 50%, 60%,70%, 80%. 
The normalised variation (NV) for each output, Po, and for each ±X% was calculated as shown 
in Eq.2.49. 
𝑁𝑉𝑋% =
√∑ (
𝑃𝑜,+𝑋% − 𝑃𝑜,𝑂𝑅𝐼𝐺
𝑃𝑜,𝑂𝑅𝐼𝐺
)
2
𝑛
1 +√∑ (
𝑃𝑜,−𝑋% − 𝑃𝑜,𝑂𝑅𝐼𝐺
𝑃𝑜,𝑂𝑅𝐼𝐺
)
2
𝑛
1
2
𝑋%
  
(Eq.2.49) 
where N represents the number of time-steps for the time-discretised outputs (pressures, flows 
and volumes) and it is equal to 1 for the outputs discretised over a cardiac cycle. 
Finally a total NV (NVTOT) was calculated as the average of the 𝑁𝑉𝑋% for each couple of 
input/output with the different X% of the input. 
A similar approach was taken to calculate the influence of the heart period on the outputs of 
the model. Different values of heart period (T) within physiological range have been 
considered, in particular 0.54 s, 0.6 s, 0.7 s, 0.8 s, 1 s, 1.1 s, 1.2 s, 1.3 s, 1.4s, 1.5s. The variation 
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of the heart period required an interpolation to produce a uniformly-sample signal for the 
comparison of time-discretised outputs over cardiac cycle. 
The sensitivity analysis described for the parameters above have been run in absence of 
barocontrol for a time of 1 s. Results of the sensitivity analysis are reported in figure 2.18, 
where, among the output, are reported pressures (Panel A), flows and some of the derived 
outputs (CO, SV, EF, PSYS, PDIA) (Panel B), more clinically relevant as explained later.  
The same approach was also used to perform the sensitivity analysis for the barocontrolled 
model increasing the time simulation to 30 seconds, including in the inputs parameters the 
barocontrol constants and the reference values for the effectors, consistent with the list of inputs 
and outputs provided in Table 2.5. Results of the sensitivity analysis of the barocontrol 
effectors and results of the sensitivity analysis of a selection of the barocontrol constants are 
reported in figure 2.19. This selection was made based on the focus of Chapter 3, where the 
adenosine response is implemented for a generic individual. 
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Table 2.5: List of the input and output parameters for the non-barocontrolled and barocontrolled model. 
The barocontrolled model replaces the effectors values with their reference value (in red) and introduces the 
barocontrol constants. 
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Figure 2.18: Sensitivity analysis results for the non barocontrol model. 
Panel A shows the sensitivity analysis with respect to the pressure outputs, Panel B shows the sensitivity 
analysis with respect of the flows outputs and other derivate clinical outputs (CO, EF, Psys, Pdia, SV). The X-
axis reports the outputs and the Y- axis the inputs. The numbers indicate the NV for each couple of 
input/output. 
Chapter 2 - Modelling the cardiovascular system
 
75 
 
 
Fi
gu
re
 2
.1
9
: 
Se
n
si
ti
vi
ty
 a
n
al
ys
is
 r
e
su
lt
s 
o
f 
th
e
 b
ar
o
co
n
tr
o
l m
o
d
e
l.
 
To
p
 P
an
e
l s
h
o
w
s 
th
e
 s
e
n
si
ti
vi
ty
 o
f 
th
e
 e
ff
e
ct
o
rs
 c
o
n
st
an
ts
 w
it
h
 r
e
sp
e
ct
 t
o
 t
h
e
 p
re
ss
u
re
, f
lo
w
s 
an
d
 c
lin
ic
a
l o
u
tp
u
ts
 (
C
O
, E
F,
 P
sy
s,
 P
d
ia
, S
V
).
 B
o
tt
o
m
 p
an
e
l s
h
o
w
 t
h
e
 
se
n
si
ti
vi
ty
 o
f 
th
e
 b
ar
o
co
n
tr
o
l c
o
n
st
an
ts
 w
it
h
 r
e
sp
e
ct
 t
o
 t
h
e 
cl
in
ic
al
 o
u
tp
u
ts
 (
C
O
, E
F,
 P
sy
s,
 P
d
ia
, S
V
, H
R
).
 T
h
e
 X
-a
xi
s 
re
p
o
rt
s 
th
e
 o
u
tp
u
ts
 a
n
d
 t
h
e 
Y
- 
ax
is
 t
h
e
 in
p
u
ts
. 
Th
e
 n
u
m
b
er
s 
in
d
ic
at
e
s 
th
e
 N
V
 f
o
r 
e
ac
h
 c
o
u
p
le
 o
f 
in
p
u
t/
o
u
tp
u
t.
 
Chapter 2 - Modelling the cardiovascular system
 
76 
 
 MODEL OUTPUTS 
The model was operated, for a generic individual, from an initialisation state for 100 s to allow 
the barocontrol to stabilise. The simulation run-time on a normal office desktop was above 24 
hours. 
 Blood pressures, flows and volumes 
In this section the results of detailed beat-to-beat blood pressure, flow and volume are reported 
for each compartment of the cardiovascular model. Figure 2.20 shows the results of blood 
pressure, flow and volume in the cardiac chambers (A), the results of blood pressures (B), flows 
(C) and volume (D) in each compartment of the systemic circulation and in the coronary 
circulation. Note the physiological diastolic dominance of the coronary flow waveforms. 
 
 
Chapter 2 - Modelling the cardiovascular system
 
77 
 
 
 
Figure 2.20: Results of beat-to-beat blood pressures, flows and volumes in each compartment. 
The results presented are for a generic individual model of cardiovascular system. Panel A) Pressures, volumes 
and flows in the heart chambers. Panel B) Pressures in coronary, pulmonary and systemic circulations. Panel 
C) Flows in coronary, pulmonary and systemic circulations. A detail of inlet coronary flows is shown. Panel D) 
Volumes in coronary, pulmonary and systemic circulations. 
 
 Barocontrol effectors 
Barocontrol becomes active 5 s [49] after the simulation starts, allowing to calculate the 
barocontrol effect on effector with highest delay. After an initial settling down period, the 
barocontrol brings the entire system to a stable condition. Figure 2.21 shows the results of the 
change of the six effectors implemented in the model, under barocontrol. 
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Figure 2.21: Barocontrol effectors under activation of the barocontrol in the model. 
From the top left: maximal left-ventricular elastance, maximal right ventricular elastance, systemic resistance, 
venous unstressed volume, heart period, tidal volume. 
 
 Oxygen and carbon dioxide distribution 
For selected compartments (SAS, SCP, SVN, LC, RC), oxygen concentration and its cardiac 
cycle averaged value, partial pressure and saturation are shown in figure 2.22, while carbon 
dioxide concentration and pressure are shown in figure 2.23. 
Values of concentrations, pressures and saturation are consistent with physiological values 
described in paragraph 2.1.2 Oxygen and carbon dioxide distribution. 
The variation of the concentration in both species is caused by the assumption of the 
instantaneous mixing within each compartment.  
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Figure 2.22: Results of oxygen distribution in selected compartments. 
 Oxygen concentration, cycle-averaged concentration, saturation and partial pressure in SAS, SCP, SVN, LC, 
and RC. 
 
Figure 2.23: Results of carbon dioxide distribution in selected compartments. 
Carbon dioxide concentration and partial pressure in SAS, SCP, SVN, LC, and RC. 
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 Cardiac output, stroke volume and ejection fraction 
Cardiac output, stroke volume and ejection fraction are clinically relevant parameters. With 
echocardiography, clinicians measure these parameters to establish the efficiency and 
performance of the heart. The model can also produce these values as output. 
Figure 2.24 shows the cardiac output, stroke volume and ejection fraction obtained from the 
barocontrolled cardiovascular model for a generic individual. The stable values achieved for 
cardiac output (5.6 l/min), stroke volume (87 ml/s) and ejection fraction (64%) are within the 
physiological range. 
 
Figure 2.24: Generic model results of cardiac output, stroke volume and ejection fraction. 
Results were obtained with the barocontrolled cardiovascular model for a generic adult. 
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 LIMITATIONS 
The major limitation of the model is that it represents only some of the features of the 
cardiovascular control system, while others have been ignored. Lumped parameter-model 
represent a significant simplification of the cardiovascular system, compared to more accurate 
modelling approaches, such as 1D and 3D, which are capable to reproduce wave propagation 
of blood pressure and flow and more detailed results of pressure and flow distribution. 
A limitation in this part of the model development is relative to the initialisation of the blood 
volume in each compartment, which is based on data from the literature and not validated 
directly. It is important to mention that the amount of blood in each compartment is not an easy 
parameter to measure. 
The necessity to store the non-derivative variables gave rise to the problem of time-step 
sensitivity, forcing the reduction to a time-step of 0.0001 s for a stable solution. This inevitably 
increases the simulation time in MATLAB. 
A limitation of the barocontrolled model is that it is relatively expensive in computational time. 
For any particular physiological state it is necessary to run the barocontrolled model until it 
reaches stability, since the initial condition is not necessarily the stable one.  
This introduces limitations especially if the model needs to be operated iteratively as part of a 
process of personalisation of a model to fit measured clinical parameters. This is discussed 
further in the next chapters.  
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 CONCLUSIONS 
The 0D model described in this chapter represents the cardiovascular system for a generic 
individual.  
The purpose of this chapter was to extend an existing, published and curated model, to include 
a representation of the coronary arteries and of the species transport that will support the 
modelling of physiological changes under exercise conditions in the following work. 
A closed-loop model of barocontrol was implemented. The effectors respond to any 
perturbation of the blood pressure, and a verification of the operation of the model in the 
context of haemorrhage was performed.  
Results for blood pressure, flow and volume for each compartment can be described. The 
model also enables the calculation of some clinically relevant outputs, such as cardiac output, 
stroke volume, ejection fraction, end-diastolic and end-systolic volumes, and the description of 
the distribution of oxygen and carbon dioxide in terms of concentration and partial pressure 
and saturation.  
The modelling of the adenosine distribution has been mentioned in the current chapter in terms 
of implementation within the model and, in the next chapters, the focus will be on the 
representation of the adenosine response for individuals with a coronary artery stenosis. 
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3 CHAPTER 3   
MODELLING THE RESPONSE TO 
THE ADMINISTRATION OF 
ADENOSINE 
 
INTRODUCTION AND PURPOSE 
In this chapter the model is extended to include a stenosis in the coronary system and to 
represent the cardiac/cardiovascular response to the administration of adenosine, which is used 
in the Catheterisation Laboratory to stimulate hyperaemia. The aims are: 
- to demonstrate that the model is able to reproduce the observations reported in the 
literature related to the intravenous infusion of adenosine; 
- to examine whether simplifications to the model might be possible to facilitate the process 
of personalisation of the model parameters to describe the response of an individual based 
on measured clinical data.  
The extended model predicts systemic pressure and flow distributions, as well as heart rate 
(under barocontrol), and also the time series history of the pressures proximal and distal to the 
coronary stenosis. The latter is used to characterise the transient dynamics of the hyperaemic 
response. 
It is hypothesised that the dynamics of the systemic circulation has significant influence on the 
coronary flow response, because it controls both the proximal (aortic) pressure, driving the 
coronary flow, and the rate at which the adenosine, administered in the veins, reaches the 
coronary inflow. Conversely, the coronary dynamics might have relatively low influence on 
Chapter 3 – Modelling the response to the administration of adenosine 
84 
 
the system dynamics, because the coronaries take a relatively small proportion of the flow and, 
therefore, it might make small perturbations to the global pressure and flow distributions. If 
this hypothesis is proven, then a one way coupling, in which proximal pressure and adenosine 
concentration are computed in a system model and applied as a boundary condition to a local 
coronary model, might be more tractable for recursive operations as part of a parameter fitting 
optimisation process. 
In this chapter also the influence of the proximal, distal pressure and heart rate on the FFR, 
hypothesising different stenosis severity, the influence of the barocontrolled hyperaemic 
response on the adenosine concentration and the influence of the stenosis severity on the delay 
to reach stable hyperaemia are analysed. 
 
 LITERATURE ON ADENOSINE RESPONSE 
As introduced in the previous chapter (Paragraph 2.1.4 Adenosine pharmacodynamics and 
pharmacokinetics model), adenosine is naturally present in the human body. From the 
cardiovascular system point of view, adenosine has 4 types of cellular receptors, which can 
decrease the heart rate, prolong the refractory period of the cardiac cycle, vasodilate the 
peripheral circulation and vasoconstrict some organs such as kidneys and liver.  
Adenosine can produce different effects depending on the method of administration (bolus, 
infusion), the location of administration (intracoronary-IC, intravenous-IV femoral or radial) 
and the dose [116, 126]. 
Recently several experimental studies have sought to understand and to quantify the effect of 
adenosine on the cardiovascular system, especially when it started to be used as part of 
treatment of cardiac arrhythmias and ischaemia. 
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In the bolus injection, adenosine concentration rapidly increases and decreases because of its 
short half-life (<10s) and acts mainly on the electrical signals of the heart, exerting negative 
chronotropic effects on the sinus node and negative dromotropic effect on AV node [116]. 
In contrast, infusion allows the concentration of adenosine to reach a stable value for a longer 
period of time and, therefore, other physiological processes related to cardiovascular regulation 
can be stimulated, including haemodynamic effects. The presence of cyclic response can be 
observed for lower doses, due to cyclic variation of adenosine concentration [126]. 
As mentioned beforehand, intravenous infusion of exogenous adenosine is the gold standard 
method used to induce hyperaemia in patients with CAD to assess the severity of the lesion. 
For this application, adenosine is commonly administrated by femoral infusion with a dose of 
140 μg/kg/min, which is considered the optimal to achieve maximum hyperaemia: above this 
dosage the level of vasodilation does not increase [126, 127]. 
In the next paragraphs, the effect of adenosine response during intravenous infusion is 
described, distinguishing between the systemic and the coronary effects. 
 
 Systemic effects 
Clinical and experimental results have shown different types of systemic adenosine response 
in conscious humans, and also in animals. Variability of the responses can be observed between 
different species and within individuals of the same species.  
Infused adenosine causes vasodilation of the microcirculation (arterioles and small arteries) in 
most of the organs. It is expected then a decrease in the blood pressure, which stimulates the 
barocontrol to restore the baseline condition, increasing the heart rate, as several studies in 
patients and healthy humans have reported [126, 128-133]. Chronologically the pulmonary 
vasodilation occurs first, probably with an immediate stimulation of the reflex regulation which 
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changes the respiratory rates and volumes. Experimental and clinical studies report this type of 
theoretical response. 
Biaggioni et al. [134-136] studied the cardiovascular effects of adenosine on healthy volunteers 
and on patients with severe autonomic failure, in a state of consciousness, aiming to identify 
the importance of the sympathetic reflex and the contribution of the lungs. Results showed that 
IV infusion of adenosine (140 μg/kg/min) in healthy volunteers caused an increase of heart rate 
(30-35 beats/min), an increase of the systolic pressure (10-16 mmHg), an increase of the pulse 
pressure (10-20 mmHg) and a decrease of the diastolic pressure (5-6 mmHg), whilst 
maintaining the mean arterial pressure constant. Also the respiratory rate was constant, 
although the minute ventilation (the ventilation per minute) increased from 7.8 to 14.7 l/min. 
In patients with severe autonomic failure, a different response was observed: the heart rate 
increased by less than 10 beats/min, and both systolic and diastolic blood pressure decreased 
by 40 mmHg. These results suggest the vasodilatory effects of adenosine are regulated by the 
sympathetic system. This was also demonstrated by the measurement of the right peroneal 
nerve activity which showed an increase from 198 to 452 units/min. The study confirmed the 
dose- and site-dependence of the adenosine response in conscious humans.  From the obtained 
results, observations were made to attempt a description of the influence of the respiratory 
stimulation by the adenosine. Considering the short half-life of the drug, the concentration of 
adenosine should be higher in the right circulation than the systemic circulation, and, therefore 
stretch-receptors in heart and lungs and carotid chemoreceptors should be responsible for the 
sympathetic response.  
Pelleg [116] reviewed the adenosine effect on humans, reporting that the infusion of adenosine 
on average increases heart rate by 33 beats/min, systolic blood pressure by 13 mmHg and 
decreases diastolic blood pressure by 8 mmHg. At a pulmonary level, it also increases the 
minute ventilation and decreases the partial pressure of carbon dioxide. Systemic infusion of 
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adenosine causes also a renal effect with reduction of urine production, which might be the 
consequence of the blood pressure drop or a direct vasoconstrictor effect of the adenosine. 
During the hyperaemia stimulated to measure FFR, heterogeneous responses to IV adenosine 
have been observed, although the reason for this diversity is not clear. Adenosine produces a 
dose-dependent decrease in vascular resistances, linked to significant decreases in central 
venous and LV end-diastolic pressures, which stimulate a reflex discharge of the sympathetic 
system in order to increase the cardiac output [129].  
Fuller et al. [117] studied the effects of adenosine infusion at different consecutive doses on 6 
male subjects monitoring the cardiovascular and respiratory effects and the skin temperature. 
Results, considering the dosage of 100 μg/kg/min, showed an increase of heart rate by 25 
beat/min, a non-significant increase in both systolic and diastolic pressure, an increase of skin 
temperature by about 1ᵒC, an increase of tidal volume by 19%, of minute ventilation by 15%, 
a decrease of CO2 partial pressure by 4% and an increase of mean respiratory flow by 22%. 
The insignificant effect on the blood pressure compared with other studies might be related 
with the method of measurement used or the protocol used in terms of duration and dose of the 
infusion. The increase on the skin temperature suggests an activation of the microcirculation, 
while the respiratory effects should be related with the carotid chemoreceptors. A central effect 
was excluded as the adenosine is not able to pass the brain barriers. With regard to the increase 
of heart rate, it might be caused by a compensatory effect for the vascular relaxation, without 
barocontrol activation since the blood pressure is only slightly affected.  
Ogilby et al. [137] compared the haemodynamic effect of adenosine in normal subjects and in 
patients with CAD. Heart rate and systolic blood pressure followed the same trend in both 
categories with similar changes (+20 beats/min, -28 mmHg respectively), cardiac output 
increased slightly more for healthy subjects (3.1 l/min against 2.4 l/min), the total systemic 
vascular resistance decreased by 35% and 42% respectively. In this study also pulmonary 
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pressure data were measured reporting an increase of both mean pulmonary capillary wedge 
(72 % and 127% respectively for normal subjects and patient with CAD) and mean pulmonary 
arterial pressures (55% for normal subjects and 50% for patients with CAD). 
The literature on human response shows contradictory results with respect to the measured 
systemic pressure: some studies show an increase in aortic pressure, others a decrease and 
others a non-significant change. It is therefore challenging to establish categorically what the 
actual effect will be on the aortic pressure for an individual patient. The only certainty is the 
vasodilatory effect of adenosine on the microcirculation of the heart. The vasodilatory effect 
of adenosine on other parts of the systemic circulation is documented, but it appears that 
arterioles in the brain and kidneys are not affected.  
 
 Coronary effects 
It is evident the importance of myocardium behaviour in the diagnostic use of adenosine, such 
as the assessment of FFR. Normally the coronary blood flow is well controlled by the 
myocardial resistances, driven by the autoregulation mechanism. The most important 
parameters to determine coronary blood flow are coronary arterial pressure and myocardial 
oxygen consumption [115, 138, 139].  
The coronary circulation comprises different compartments: main coronary arteries, small 
arteries and arterioles, capillaries and ultimately the venous system. In normal physiology in 
resting condition, 60% of the resistance is given by the arteriolar level, 25% by the capillaries 
and 15% by the venous compartment. Epicardial arteries are considered to have no resistance. 
During hyperaemia the total resistance drops by approximately 65% (86% in the arteriolar 
compartment and 98% in the venular) and the capillaries offer the maximum resistances. For 
the assessment of coronary stenosis, hyperaemia is generated in order to have a minimal 
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resistance and counteract the autoregulation [115]. The direct consequence of myocardial 
vasodilation is the increase of myocardial blood flow (MBF), which is dose dependant, as 
shown by Wilson et al. [126], and can reach even 4 times the baseline MBF. 
Overall it is possible to state that the only coronary effect of adenosine is the vasodilation of 
the myocardial microcirculation, although the actual mechanisms are not known yet. 
 
 MODELLING ADENOSINE EFFECTS ON A 
GENERIC INDIVIDUAL 
In this paragraph the description of the modifications of the model with regard to the IV 
infusion of adenosine effects are explained. 
The systemic response is the most complex one because it involves different mechanisms and 
some are still unknown. The mechanism of vasodilation effect at arterial level is the most 
certain and documented, although it does not happen in all the organs, depending on the type 
of receptors. Arterial vasodilation should cause a decrease in the aortic pressure, which then 
stimulates the barocontrol and chemocontrol system to restore to baseline condition. This is 
what it is expected considering the known effects of adenosine, although experiments have 
demonstrated the existence of other effects. Different types of response have been identified in 
patients and not all of them have a physiologically known explanation. 
Supported by the literature mentioned before, and by our own clinical data, it is assumed that 
the first effect happens in the pulmonary circulation, where arterioles are vasodilated and this 
could potentially cause: 
i) an increase in pulmonary blood volume and consequent decrease in oxygen concentration 
in the pulmonary capillaries, which stimulates the chemoreceptors and therefore the 
respiration. This can be observed in the increase of tidal volume, which aims to restore 
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the oxygen partial pressure. The stimulation of respiration involves also the relaxation of 
lung stretch receptors, allowing a higher airflow in input; 
ii) a pulmonary pressure drop which is then reflected in a lower left ventricular pressure, 
which then activates barocontrol receptors in the aorta.  
The increase in heart rate during adenosine IV infusion might be caused by multiple 
components of its regulation: 
i) the activation of the barocontrol system to compensate the pressure drop and maintain a 
constant cardiac output; 
ii)  the activation of chemocontrol system to restore the oxygen concentration; 
iii) the increase of respiration activity linked to the stretch receptors stimulation; 
iv) a compensation of the negative chronotropic and negative dromotropic effects caused by 
the cardiac A1 receptors of adenosine; 
v) “fight-or-flight” response emotionally driven by the side effects of the adenosine which 
might lead patients to panic. 
Our cardiovascular model, described in the previous chapter, attempts to represent the 
observations in real patients considering the generic individual, conscious of the limitation in 
the representation of the full effects of the cardiovascular response, since the model does not 
include every mechanism. 
The model response to adenosine is represented as a vasodilation in the pulmonary and 
systemic circulations and in the myocardium, each as a function of the adenosine concentration 
in the respective compartments, as explained in the following paragraphs. 
 Inclusion of coronary stenosis 
Since in this project the primary investigation is that of the effect of adenosine on a CAD 
patient, the model is extended to include a mild stenosis in the left coronary branch (Rsten), 
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represented as a resistance in series with the RCR circuit, representing the left myocardial 
compartment, as shown in figure 3.1. 
The ratio between the distal (Pd) and proximal (Pa) pressure across the stenosis is calculated for 
each time-step during all the simulation to determine then the FFR at stable hyperaemia. 
The value of the stenosis resistance, Rsten, was set to 16 mmHg s/ml, generating Pd/Pa ratio 
close to 0.8, which represents the cut-off value for clinical intervention. A long-term aim is to 
use the model in the diagnosis of clinically significant lesions, and so it is important that its 
performance is investigated closely in the threshold region. 
 
 Vasodilation in systemic, pulmonary and coronary compartments  
As mentioned before, literature data suggest that adenosine generates total systemic 
vasodilation and myocardial vasodilation, with a respective drop in the resistances of 30-42% 
and of 70%, acting in the arterioles. 
It is necessary at this point to make a comment on the adaptation of Ursino’s neuro-regulatory 
model onto the one described in this project. Ursino described the systemic circulation as an 
arterial compartment from which develop parallel branches, consisting of the peripheral and 
the venous circulation for the splanchnic and extra-splanchnic circulation. The peripheral 
circulation is the target of the regulatory pathways. In contrast, in the model developed in this 
thesis, the systemic circulation was represented as one single branch but with greater 
differentiation between the vasculature compartments (aorta, arteries, small arteries, arterioles, 
capillaries and veins). The barocontrol is applied on the capillaries compartment, although the 
vasodilation/vasoconstriction is dominant in compartments such as arterioles and small 
arteries. The review of the literature indicated that the adenosine-induced vasodilation is 
understood to act on the arterioles and arteries, and, therefore, it was applied to these 
compartments in the model. Specifically, the vasodilatory effect was applied on the following 
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compartments: the systemic arterioles (SAR), the pulmonary arterioles (PAR) and the left (LC) 
and right (RC) myocardium (Figure 3.1). The vasodilation is assumed to produce a 50% 
decrease in the resistance for all the target compartments (SAR, PAR, LC and RC). This is 
consistent with the results of the experimental studies in literature [140-143], where the 
arterioles’ diameter on average increases by 15-20% when stimulated by adenosine. 
Approximating the arteriolar resistance with Poiseuille’s law, the power to the 4 of the change 
in diameter will determine about 50% decrease in the resistance (Eq.3.1).  
𝑅𝐷
𝑅𝐵
=
1
(1 + 𝑣)4 ∙ 𝐷𝑎𝑟𝑡.,𝐵
4
1
𝐷𝑎𝑟𝑡.,𝐵
4
= {
0.57     𝑖𝑓 𝑣 = 0.15
0.48       𝑖𝑓 𝑣 = 0.2
 
(Eq.3.1) 
where RD is the vasodilated arterial resistance, RB is the baseline arterial resistance, Dart,B the 
average diameter of the arterioles at baseline and 𝑣 represent the variation of the baseline 
diameter due to vasodilation.  
 
Figure 3.1: Model adapted to include adenosine-induced vasodilation.  
Pulmonary arterioles, systemic arterioles and left and right myocardium resistances are dependent on the 
adenosine concentration in the relative compartment. 
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Literature data are not explanatory on how the arteriolar resistances vary in vivo as a function 
of the adenosine concentration. It was observed on humans that adenosine (administrated 
through venous infusion) has a saturation level, beyond which the effects are no longer 
dependent on the concentration [127]. This is also intuitive considering that in vivo arterioles 
cannot physically continuously vasodilate. For these reasons in this model the arteriolar 
resistances, 𝑅𝑥, were described as a linear function of the adenosine concentration in every 
compartment, 𝐶𝐴𝐷𝐸,𝑥, until a saturation value of adenosine concentration, 𝐶𝐴𝐷𝐸,𝑡ℎ, is reached 
above which the resistances were stable (Eq.3.2- Figure 3.2), where 𝑅𝑥,0  is the baseline 
arteriolar resistance, 𝐹𝑅𝑡ℎ is the vasodilation coefficient set to 0.5. 
𝑅𝑥(𝐶𝐴𝐷𝐸,𝑥) = {
𝑅𝑥,0 (1 −
(1 − 𝐹𝑅𝑡ℎ) ∗ 𝐶𝐴𝐷𝐸,𝑥
𝐶𝐴𝐷𝐸,𝑡ℎ
)        𝑖𝑓  𝐶𝐴𝐷𝐸,𝑥 < 𝐶𝐴𝐷𝐸,𝑡ℎ
𝑅𝑥,0 ∗ (1 − 𝐹𝑅𝑡ℎ)                                 𝑖𝑓  𝐶𝐴𝐷𝐸,𝑥 ≥ 𝐶𝐴𝐷𝐸,𝑡ℎ
 
(Eq.3.2) 
 
 
Figure 3.2: Relationship between adenosine concentration and vascular resistance. 
Adenosine concentration and resistance of the compartments where occurs vasodilation are linearly 
dependent. After a concentration threshold value, a saturation is observed when the resistance stays stable 
at its minimum value. 
It is assumed that the IV infusion of adenosine used in the clinical protocol for the FFR 
assessment stimulates the maximum hyperaemia and therefore the Cade,th was selected 
observing the maximum concentration in the coronary compartments. Figure 3.3 shows the 
maximum adenosine concentration in the compartments, starting from the systemic vein where 
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the drug is injected. As suggested by some literature data [134], the steady state response shows 
maximal adenosine concentration at the location at which the adenosine is introduced (SVN), 
and a gradual reduction away from this location. Because of its short half-life (7 s), adenosine 
never achieves a relatively uniform distribution across the system. Table 3.1 reports the 
respective baseline resistance and maximum adenosine concentration for the target 
compartments (SAT, PAT, LC and RC). 
Table 3.1: Values of baseline resistances and maximum adenosine concentration for target compartments. 
Compartment R0 
[mmHg s/ml] 
𝑪𝑨𝑫𝑬,𝒕𝒉 
[mg/ml] 
SAR 0.5 1.29*10-4 
PAR 0.05 3.43*10-4 
LC 76.5 0.90*10-4 
RC 76.5 0.97*10-4 
 
 
Figure 3.3: Steady state adenosine concentration in each compartment. 
 
 Sensitivity analysis  
As stated before, this thesis is focused on the model-based representation of the adenosine 
response for each individual, which as observed both in the literature [120, 129, 144] and in 
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the collected data of the Wellcome study (STH 16467 Wellcome study: an angiogram is all 
you need) can be different from patient to patient. 
To quantify the influence of the parameters in the global circulation model on the local 
coronary circulation, and vice versa, a sensitivity analysis was performed. It is hypothesised 
that, because the coronary flow is a small proportion of the total systemic flow, the system 
model is not strongly influenced by the coronary parameters whilst, in contrast, the coronary 
flow is driven by the aortic pressure and the supply of adenosine to the coronaries is driven by 
the concentration in the aorta and, thus, a strong dependence of coronary flow on system 
parameters is expected. The aim of this section is to prove this hypothesis by quantifying the 
associations between model inputs and model outputs. 
 
3.2.3.1 Relative influence between the global and local circulation: a sensitivity analysis 
The focus of this paragraph is to study how a change in aortic pressure and heart rate, 
correspondent to the clinical measurements during assessment of FFR, influences the 
distribution of the adenosine and its relative vasodilatory effect in a cardiovascular model for 
a generic individual. 
The sensitivity analysis presented in Chapter 2 (Figure 2.18) already suggests that the coronary 
parameters only influence the coronary outputs, while the systemic output are not sensitive to 
these parameters. As can be seen in the results of the sensitivity analysis of the barocontrolled 
model described in Chapter 2 (Figure 2.19), the central pressure of the sigmoid function of the 
barocontrol, Pn, has high sensitivity with regards to both the aortic pressure and the heart rate, 
although there are barocontrol parameters which have an effect on these, such as the reference 
capillary resistance and the gains of the variation of the effectors. 
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To study the heart and the aortic pressure sensitivity, the input parameters selected for this 
specific sensitivity analysis are the Pn for the global system and the stenosis, Rsten, and the 
myocardial, Rmyo, resistances for the local system. 
Table 3.2 reports the values used for each variable, which were changed, one at a time, to 
determine the changes in the outputs associated with these changes in inputs. The reference 
model had Pn equal to 85 mmHg, Rsten equal to 16 mmHg s/ml and Rmyo equal to 76.5 mmHg 
s/ml. The considered output parameters were, for the global model, aortic pressure PAO, heart 
rate HR, cardiac output CO, aortic concentration of adenosine CADE,AO, systemic arteriolar, 
RSAR, and capillary resistance, RSCP, pulmonary arteriolar resistance, RPAR, and finally, for the 
local model, distal pressure PD and left and right myocardial upstream resistances, ZLC and ZRC. 
The PD/PA ratio dependent on both parts of the model was also considered. 
Table 3.2: Values of parameter of the systemic and the local coronary circulation used for the simulation in a 
generic patient. 
 
Parameters Reference values Values changed OAT 
Pn (mmHg) 85 75 95 
Rsten (mmHg s/ml) 16 8 32 
Rmyo (mmHg s/ml) 76.5 50 100 
 
Each simulation time was set to 380 s allowing the barocontrol to reach stability, the adenosine 
injection to last 90 s and to restore to baseline conditions. The simulation results regarding the 
CO are reported for each cycle, as explained in the previous chapter, while signals of HR, 
pressures, adenosine concentrations and resistances are represented in time.  
With respect to the analysis of the time course of the response to adenosine, the variations over 
the cardiac cycle are not important and so, for presentation of the results in the next section, 
the time series signals have been smoothed with a window of 2 s. The period of numerical 
stabilisation from the initial conditions is not important, and so in the figures the results of the 
simulation are presented from t=240 s, 10 seconds before the adenosine starts to be infused. 
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For comparison, the CO signal was normalised on the x-axis with respect to the number of 
cycles. 
The comparison between the reference model results, Ym, and the ones where one single input 
parameter X was increased, Y+X, and decreased, Y-X, was described by a root mean square 
change (RMS), calculated from the average normalised sum between the reference results and 
the changed parameters results, and divided by the difference in percentage of the input change. 
Since for each parameter a higher and a lower value have been considered, the final RMSX is 
the average between the two comparisons with both values for the same parameter. Equation 
3.3 describes the RMS for each parameter. 
𝑅𝑀𝑆𝑋 = 𝑚𝑒𝑎𝑛
(
 
 
∑ |
𝑌𝑚(𝑡) − 𝑌+𝑋(𝑡)
𝑚𝑒𝑎𝑛(𝑌𝑚)
|𝑡=380𝑡=240
𝑁
|
𝑋𝑟𝑒𝑓 − 𝑋+
𝑋𝑟𝑒𝑓
|
      ,
∑ |
𝑌𝑚(𝑡) − 𝑌−𝑋(𝑡)
𝑚𝑒𝑎𝑛(𝑌𝑚)
|𝑡=380𝑡=240
𝑁
|
𝑋𝑟𝑒𝑓 − 𝑋−
𝑋𝑟𝑒𝑓
|
 
)
 
 
 (Eq.3.3) 
where N is the number of sample per signal, Xref  is the reference value for each input parameter. 
A similar approach was used to compare the peak values of the global and local outputs at the 
variation of each of the input parameter, as described in Eq.3.4.  
𝑅𝑀𝑆𝑋,𝑝𝑒𝑎𝑘 = 𝑚𝑒𝑎𝑛
(
 
 
|𝑌𝑚,𝑝𝑒𝑎𝑘 − 𝑌+𝑋,𝑝𝑒𝑎𝑘|
𝑌𝑚,𝑝𝑒𝑎𝑘
|
𝑋𝑟𝑒𝑓 − 𝑋+
𝑋𝑟𝑒𝑓
|
    ,     
|𝑌𝑚,𝑝𝑒𝑎𝑘 − 𝑌−𝑋,𝑝𝑒𝑎𝑘|
𝑌𝑚,𝑝𝑒𝑎𝑘
|
𝑋𝑟𝑒𝑓 − 𝑋−
𝑋𝑟𝑒𝑓
|
 
)
 
 
 (Eq.3.4) 
where Ym,peak is the value of the output parameter at peak from the reference model and Y±X,peak 
is the value of the output parameter at peak obtained when one of the parameters was changed. 
To identify the peak values for each output the following approach was used. For the outputs 
HR, CO and systemic capillaries resistances (RSCP) the global maximum value was considered; 
for the outputs Pa, pulmonary resistances (RPAR) and systemic arterioles resistances (RSAR) the 
global minimum was considered. For the remaining outputs (Pd, Cao, CRC, CRC, ZLC, ZRC and 
FFR) if the global maximum or minimum would have been considered, the peak value would 
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have been wrong, since these outputs have a small negative slope during all the hyperaemia. 
To overcome this problem, a reference value after 50 s the adenosine infusion starts, X(t50), 
was selected observing the output results of the model and making sure that 50 s were sufficient 
to reach stable response for all these outputs. The identification of the starting of the peak 
response consists of a comparison of the relative reference value at t50 with the value of the 
considered output at previous time-steps since the difference is below a threshold value specific 
for each output: respectively of 0.75 mmHg for Pd, 0.00001 mg/ml for Cao, 0.000002 mg/ml 
for CRC and CRC, 0.6 mmHg s/ml for ZLC and ZRC and 0.002 for FFR. These thresholds were 
arbitrarily chosen after a trial and error approach to get satisfactory results visually examined. 
The delays (in time for all the outputs, except in cardiac cycle for CO) necessary for each output 
to reach the peak value in the period following the start of adenosine administration have been 
then considered for comparison. 
3.2.3.2 Influence of the barocontrol on the coronary boundaries outputs 
The coronary boundaries outputs signals calculated with the barocontrolled model (YBARO) and 
with the non-barocontrolled model (YNO-BARO) were compared as shown in Eq.3.5. The signals 
were considered between 240s and 380s time interval, with N samples. 
𝑅𝑀𝑆𝐵𝐴𝑅𝑂 =
∑ |
𝑌𝐵𝐴𝑅𝑂(𝑡) − 𝑌𝑁𝑂−𝐵𝐴𝑅𝑂(𝑡)
𝑚𝑒𝑎𝑛(𝑌𝐵𝐴𝑅𝑂)
|𝑡=380𝑡=280
𝑁
 
(Eq.3.5) 
As explained already in the previous paragraph, for CO, expressed in cardiac cycles, a similar 
index was calculated, where the number of samples is the number of cardiac cycles and the 
signal have been considered proportional to the time interval. 
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 Change of barocontrol parameters 
It has already been demonstrated (Paragraph 2.1.3.2 Validation of the adapted controlled 
cardiovascular model), that the current barocontrolled model can reproduce the observed peak 
pressure drop of about 40 mmHg and peak response of heart rate increase of 20 beats/min in a 
haemorrhagic condition. Operation of the model with the same numerical values of the 
barocontrol parameters as those used to simulate haemorrhage does not reproduce the typical 
decrease of aortic pressure of about 10 - 15 mmHg and increase of heart rate of about 25 
beats/min that is reported in the literature under the administration of adenosine.  
The parameters that require to be changed are the ones related with the heart rate and therefore 
its reference value and its gains related with the sympathetic and vagal ways.  
It was assumed that the same barocontrol processes govern the response to adenosine, but that 
the control parameters should be adjusted to produce the observed magnitude of response. 
Compared with the haemorrhage simulation, the aortic pressure drop is reduced and the 
variation of heart rate is higher. Intuitively, then, the heart rate gain (in absolute value) should 
be increased. The baseline condition should still stabilise at a normal heart rate, and so the 
reference value of the heart period was also adjusted. The original barocontrol parameters of 
reference value and sympathetic and vagal response gains were respectively 0.58 s, -0.13 s/v 
and 0.09 s/v. To obtain the desired behaviour, the reference heart period was set to 0.48 s, 
corresponding to 125 beats/min, and the sympathetic and vagal gains respectively to -0.75 s/v 
and 0.25 s/v. These values were obtained with a trial and error approach.  
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 RESULTS 
Results of the barocontrolled cardiovascular model representing an average individual with a 
stenosis in the left branch of the coronary, generating a nominal FFR of 0.8 in the reference 
state, are presented in this first part of this section. As discussed previously, this was chosen 
because it is the threshold for the intervention decision and so the region of greatest interest for 
operation of the model. 
Because of the requirement to reach stability, each simulation runs for about 8 hours on a 
normal office desktop (DELL, Intel i5). A process of optimisation of the code could reduce the 
simulation time and potentially move it closer to clinical application. 
 
 Analysis of aortic pressure and heart rate response to adenosine 
The cardiovascular model with the barocontrol was tuned to represent the average response 
during IV infusion of adenosine reported by experiments reported in the literature. Figure 3.4 
illustrates the time course of the aortic pressure and heart rate responses computed by the 
model. A decrease of aortic pressure by about 7 mmHg (7%) and a consequent increase of heart 
rate by 15 mmHg (23%) is observed, based on a vasodilation effect in the pulmonary and 
systemic arterioles and in the left and right myocardium of 50% dependant on the adenosine 
concentration in the compartments. These results show agreement with typical literature data 
on these two parameters, and thus it is demonstrated that, with the selection of appropriate 
parameters, the model is able to reproduce a plausible generic response to the administration 
of adenosine. The effects of the adenosine are still not completely known; different responses 
among different individuals have been reported.  
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Figure 3.4: Mean aortic pressure and heart rate response to adenosine. 
The red vertical line indicates when the adenosine starts to be infused and the blue lines when it stops. 
 
 Influence between the global model and the local circulation and 
interpretation of the results 
The sensitivity analysis results are reported in Figure 3.5. The inputs (vertical axis) and the 
outputs (horizontal axis) have been clustered into systemic and coronary elements, with the 
outputs at the boundary between the systems, and part of both, explicitly identified. 
Figure 3.5-A shows the sensitivity considering the entire signal (from t=240 to 380s). As 
expected, it is observed that the influence of the systemic inputs is high for the systemic outputs 
and for some of the coronary outputs, whilst the coronary inputs have high influence only on 
the coronary outputs. The influence of the coronary inputs on the systemic outputs is low. In 
particular, the barocontrol parameter Pn is the one having the most effect on all the outputs. It 
changes the baseline value of the heart rate and therefore influences the cardiac output. It also 
affects the systemic capillary resistance.  
The aortic pressure is also dependent on the Pn value, as well as the coronary pressure distal to 
the lesion. The high value of the dependence of distal pressure on Pn is explained by the fact 
that the distal pressure is dependent on the aortic pressure, which is in turn dependent on the 
Pn. The aortic adenosine concentration is slightly influenced by the Pn and this suggests that 
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also the myocardial adenosine concentrations are slightly influenced by the aortic pressure, as 
reflected also in the myocardium resistances, since the change of adenosine concentration in 
the myocardium changes also the vasodilation curve and values. The highest dependence of 
the left myocardium resistance might be cause by the back pressure from the left ventricle 
which is intuitively more influenced by the Pn compared with the right ventricle pressure 
applied to the right myocardium.  
The FFR is independent of the Pn, consistent with expectation, and it is dependent on the 
myocardium resistance and the stenosis resistance inputs. 
The coronary inputs related to the stenosis and myocardium resistance have very little influence 
on all the systemic outputs and higher influence on the coronary outputs. In particular, the 
stenosis resistance has impact on the distal pressure and on FFR. The initial value of myocardial 
resistance (set equal for left and right branches) has influence on all the coronary outputs, with 
a high value for the myocardial resistances during the adenosine response as expected. Similar 
results were obtained considering the comparison between the peaks of the outputs (Figure 3.5- 
B).  
Figure 3.5- C shows the difference between the delays to peak from the reference state and the 
results varying the inputs (in seconds for all the outputs, except CO which is expressed in 
cardiac cycles) necessary for each output to reach the peak value after the adenosine starts. 
It is observed that the pulmonary arterioles resistance is the first to respond with a reference 
delay of 2.94 s, since the adenosine hits them first.  
The Pn input parameter is the most influencing parameter in terms of the speed of the response 
for all the outputs parameters, both systemic and coronary. The reason for that might be related 
with the fact that an increase/decrease of Pn determines an increase/decrease of the aortic 
pressure, of the heart rate and the cardiac output so that the adenosine distributes 
quicker/slower.  
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Figure 3.5: Sensitivity analysis results about the relative influence of the local and global model. 
A) RMS considering the time series signals. B) RMS considering the peak values. C) Difference of the delay to 
peak for each output to reach the peak value since the adenosine starts. Time necessary to reach peak for the 
reference state (Pn=85 mmHg, Rsten=16 mmHg s/ml, Rmyo=76.5 mmHg s/ml) is indicated in the bottom-row (in 
blue) in s, except for CO in cycles.  
Inputs clustered in systemic (Pn) and coronary (Rsten, Rmyo). Outputs clustered in systemic (HR, CO, RSAR, RSCP, 
RPAR), coronary boundaries (Pa, CAO) and coronary (Pd, FFR, ZLC, ZRC).  
 
The aortic adenosine concentration delay in the peak response is mostly influenced by the aortic 
pressure, and slightly influenced by the coronary inputs. The difference in the delay to reach 
the peak compared to the reference is 0.69 s (2.7% slower) for Pn= 75 mmHg and -0.53 s (2.1 
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% quicker) for Pn= 95 mmHg. With regards to the coronary inputs the difference in the aortic 
adenosine concentration delay in peak response is less than 0.1 s (0.4 %). 
The FFR delays are dependent on the stenosis severity: -3.72 s (10% quicker) for non-severe 
stenosis, and +3.19 s (8.7 % slower) for the severe stenosis. This can be explained by the 
reduction of flow to the myocardium caused by the lesion, which in turn means that the local 
adenosine concentration needs more time to stabilise. This hypothesis seems to be also 
confirmed by the influence of the Rmyo input on the left and right coronary resistance delay: for 
a smaller baseline value of the myocardial resistance the peak response in the right myocardium 
happens 5.56 s (15.2%) before the reference situation, and for a stiffer baseline myocardium 
the peak happens 3.06 s after (8,4%) the reference delay. Again, this is associated with the 
proportional amount of blood flow, relative to the compartment volume, determined by the 
myocardial and the stenosis resistance. The FFR delays in the peak response is also slightly 
influenced by the myocardial resistance: -0.94 s (2.5% quicker) for Rmyo=50 mmHg s/ml and 
+0.46 s (1.2 % slower) for Rmyo=100 mmHg s/ml. Similarly happens with the variation of Pn: 
+1.23 s (3.3% slower) for Pn= 75 mmHg and -1.36 s (3.7 % quicker) for Pn= 95 mmHg. The 
concentration of adenosine in the myocardium requires a different amount of time to get to 
stable values. 
The Pd delay is strongly associated with the stenosis severity: +5.84 s (24% slower) for severe 
stenosis and -3.96 s (16.8% quicker) for the non-severe stenosis. Pd peak delay is also 
influenced by Pn with +3.04 s (13% slower) for Pn= 75 mmHg and -0.83 s (3.2% quicker) for 
Pn= 95 mmHg. 
For some of the outputs parameters (RSAR, RPAR and Pa) the delay to reach the peak with the 
variation of the coronary parameters show a concordant sign for both the input values. These 
are dependent on how the peaks have been calculated. However, their values are less than a 
third of a second and therefore very small compared with other delays above 2 s.   
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Figures 3.6, 3.7 and 3.8 report the time-series response for each output parameter, under the 
variation of each input (Pn figure 3.6, Rsten figure 3.6, Rmyo figure 3.8). The x axis of all graphs 
is time (s), except the CO expressed in number of cardiac cycles. The y axis represents different 
units according to the parameter represented (mmHg for pressures, beats/ min for heart rate, 
mmHg s/ml for resistances, mg/ml for concentration, l/min for cardiac output). 
Figures 3.6, 3.7 and 3.8 show the concentration in the aorta and in the coronaries. It is observed 
that the time to reach maxima hyperaemia in the coronary circulation is highly dependent on 
the delay of the aortic concentration. The time to reach maximum concentration in the aorta is 
about 25 s in all the cases with different pressure, severity of stenosis and myocardial 
resistance. The myocardial concentration in the myocardium reaches its maximum about 10 s 
after the peak within the aorta. The time to reach maximal hyperaemia is therefore 70% 
determined by the global system and 30 % by the local system. 
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 Influence of barocontrol on the coronary boundaries 
The comparison between the outputs obtained with the barocontrolled model and the non-
barocontrolled model is focused on the coronary boundaries output: aortic pressure and aortic 
adenosine concentration. It is intuitively expected that, having the barocontrol activated, the 
heart rate, the left ventricular elastances, the peripheral resistance and the unstressed venous 
volume will be controlled and different from the non-barocontrolled model. This causes a 
difference in all the outputs described previously. As an example, in figure 3.9, the comparison 
of the cardiac output is shown. This output shows different value at baseline (+12% with 
barocontrol) and different amplitude (+0.3 l/min with barocontrol, +1.1 l/min) in the response 
the adenosine vasodilation. 
 
Figure 3.9: Example of model output (CO) obtained with a without barocontrol. 
 
The coronary boundaries parameters will be used for the coupling of the global and local model, 
as explained in the following paragraphs, and therefore the focus of our discussion of results 
will be on these two. Figure 3.10 shows the mean aortic pressure and the aortic adenosine 
concentration obtained with and without barocontrol. As expected, there is a different aortic 
pressure signal with a different value at baseline and a different response to adenosine 
vasodilation in the barocontrolled and non-barocontrolled model results. The drop in pressure 
is higher for the non-barocontrolled model, where the effectors involved in the regulation are 
Chapter 3 – Modelling the response to the administration of adenosine 
110 
  
not changed according to the pressure drop to restore a natural condition as happens with the 
barocontrol model. The baseline value of the aortic pressure is 16% higher in the barocontrolled 
model and the pressure drop is of about 7 mmHg and 16 mmHg respectively for the 
barocontrolled and the non-barocontrolled model. 
Clearly the absolute value of the aortic pressure is strongly influenced by the barocontrol 
mechanism. This is not surprising given the location of the baroreceptors. 
With regards to the aortic adenosine concentration, the time to reach the plateau concentrations 
since the adenosine starts is slightly different by about 3 seconds (44.2 s for the non-
barocontrolled and 47.5 for the barocontrolled). The value of the plateau concentration is also 
different by 0.26*10-4 mg/ml (2.05*10-4 mg/ml for the barocontrolled and 1.79*10-4 mg/ml for 
the non-barocontrolled). This corresponds to an increase of the plateau aortic adenosine 
concentration of 12.6%. 
 
Figure 3.10: Mean aortic pressure (left) and aortic adenosine concentration (right) results with the 
barocontrolled (black) and the non-barocontrolled (red) model. 
The concentration of adenosine in the coronaries is not so strongly influenced. The shape and 
period of the response are very similar with or without barocontrol. In later chapters, when the 
model is personalised to represent individual patients, the systolic and diastolic pressure are 
known. The purpose of the system model is to derive estimates of the concentration because 
these are not measured in the clinical protocol. 
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 LIMITATIONS 
The cardiovascular model used in this project did not include all the compartments in a real 
cardiovascular system. Many physiological/anatomical components were lumped into larger 
compartments, a characteristic of all lumped-parameter models, and overall this particular 
model consists of 16 compartments (Figure 2.1) each of which represents a part of the 
cardiovascular system, as summarised in table 3.3. 
Therefore, it cannot represent the different effect of the adenosine response in different organs 
where different receptors can cause vasodilation or vasoconstriction. 
Table 3.3: Model compartments and their equivalent in the cardiovascular system. 
Compartment Equivalent in cardiovascular system 
LV, LA,  
RV, RA 
4 chamber of the heart respectively: left ventricle, left 
atrium, right ventricle, right atrium 
SAS Aortic sinus 
SAT Systemic main arteries of the different organs in parallel 
SAR Systemic arterioles of the different organs in parallel 
SCP Systemic capillaries of the different organs in parallel 
SVN Systemic veins 
PAR Main pulmonary artery sinus 
PAT Pulmonary main arteries  
PAR Pulmonary arterioles 
PCP Pulmonary capillaries 
PVN Pulmonary veins 
RC Right coronary circulation 
LC Left coronary circulation 
  
The model simulated only the vasodilation in the compartments that were most important for 
the achievement of coronary hyperaemia, which is the main goal of this PhD project, and for 
which clinical data is available from the study cohort that is examined in subsequent chapters. 
As described in the introduction of this chapter, the adenosine mechanisms is not yet 
completely understood and therefore it is difficult to represent faithfully the adenosine response 
in all its mechanisms. In this model the representation of the adenosine effects has been based 
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on the literature data about its effects in parts of the vasculature and on the observed measured 
effects in terms of the blood pressure and heart rate.  In addition, the model described only the 
barocontrol to determine the adenosine response, ignoring the effect of the chemoreceptors at 
pulmonary and aortic level. One of the stated hypothesis with regards to the pulmonary 
response in this chapter was that the vasodilation of the pulmonary arterioles could create 
changes of the oxygen and carbon dioxide concentration, which could stimulate the 
chemocontrol. 
Another limitation in this implementation is about the assumption of the linear relationship 
between myocardial resistance and the adenosine concentration in the myocardium, up to a 
saturation threshold. In a real patient it is known that if the baseline resistance is high it means 
that the myocardium is stiff and its capacity of vasodilation is reduced. Therefore, a different 
slope in the linear relation of the model should be used in order to include this physiological 
aspect. Nevertheless, for the purposes of this chapter, the model is shown to capture the basic 
responses reported in the literature.  
Finally, the length of the simulation was about 8 hours to represent 380s of results, to achieve 
stabilisation from an initial state and to represent the period of adenosine administration. 
Optimisation of execution time was not a focus in this work, but it is a limitation both for the 
use of the model to examine the pharmacodynamics of the system and certainly for any 
potential clinical application for individual patients. 
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 CONCLUSIONS 
The main outcomes of the work presented in this chapter are: 
- the extension of the model to include a coronary artery stenosis and specifically to 
represent the response to the administration of adenosine; 
- the demonstration that the model is able to describe the responses reported in the literature; 
- the quantification of the relative influence of global and local coronary model parameters 
on global and local coronary outputs.  
The complete model, including the barocontrol that is activated by the adenosine 
administration, was able to represent the typical behaviour of the cardiovascular system during 
the administration of the drug through IV infusion, according to the observations reported in 
the literature, with regard to the changes of heart rate and aortic pressure. 
Further improvements could be introduced, such as tuning of chemocontrol in closed-loop to 
take in account other adenosine effects on the oxygen and carbon dioxide variations; the 
variation of the myocardial vasodilation based on the initial value of the myocardial resistance, 
in order to take into account the reduced vasodilatory abilities of a stiff myocardium. 
Moreover, it was demonstrated that the influence of the global system parameters on both 
global and local coronary outputs is strong, whilst local coronary parameters influence only 
local coronary outputs. This information justifies the approach adopted in subsequent chapters 
of this thesis, which assumes that the global model is not dependant on the local model and that 
the boundary conditions in terms of the input concentration of adenosine can be computed by 
a global model and then applied to a local coronary model (i.e. there is a one-way coupling). 
The parameters in the global model can be personalised using individual patient data, and the 
resulting computed adenosine concentrations used to study and to interpret the local coronary 
response.  
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The study of the influence of the barocontrol model on the coronary boundaries outputs shows 
that both heart rate and aortic pressure changes are controlled by this mechanism, but that the 
adenosine concentration in the aorta is less strongly influenced and the shape and timing of the 
response is well-represented even without barocontrol. This is relevant for the current study 
because the number of parameters for a barocontrolled model inevitably increases and therefore 
the tuning for a specific patient requires a higher number of input data to solve the higher 
number of unknowns of the global model.  
In this study the aortic pressure was measured during the angiogram and therefore this 
information is directly available both to personalise the global model and to provide the 
boundary of the coronary model. Other parameters were also measured, but not their response 
to adenosine during hyperaemia. This makes challenging the realisation of a global patient-
specific model with barocontrol. The following chapters explain and develop one-way coupling 
of the global and the local model to identify patient specific parameters, after an analysis of the 
available clinical data of the CAD patients. 
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4 CHAPTER 4      
CLINICAL DATA 
 
INTRODUCTION AND PURPOSE 
This chapter introduces, and analyses, the clinical data collected from patients with CAD who 
underwent angiography in study STH16467.  
General demographic data, comorbidities, echocardiographic data and invasive pressure data 
measured during adenosine infusion were collected. Pressure data were post-processed to 
define proximal and distal pressures, heart rate and FFR at baseline, peak and stable 
hyperaemia, together with the time-response for each patient.  
The adenosine response was classified, based on the outputs of post-processing to ultimately 
identify any relationship between comorbidities and the adenosine response. 
Part of the motivation for this study was to explore whether it might be possible to predict a 
priori the hyperaemic response for the patient, from information about the rest state combined 
with other clinical data, without the need for administration of adenosine. 
A further outcome relates to the development of an algorithm which can identify the peak and 
stable hyperaemic response in a more objective way when compared with the subjective 
evaluation routinely carried out by the clinician during the procedure. The experience and 
subjectivity of the operator have a high impact on the clinical and economic outcomes [145]. 
  
Chapter 4 - Clinical data 
 
116 
   
 CLINICAL DATA 
Clinical data used to explore model-tuning were collected in the course of the development of 
a computational tool for the measurement of FFR [92] for which the work reported in this thesis 
was a contributory element. Informed consent was obtained from patients recruited to the study 
(STH16467) and a cohort of 100 CAD patients, who underwent angiography during the period 
2013-2016 were recruited. Pseudonymisation was performed prior to gaining access to the data; 
no identifiable data were used in the execution of this study.  
 Invasive pressure data 
As discussed in Chapter 1 (Paragraph 1.4.1 Clinical Investigation), during Invasive Coronary 
Angiography, the FFR index is determined as the ratio between the distal and proximal pressure 
across the lesion during hyperaemia. Pressures are measured via catheters inserted through the 
radial or femoral artery. In this specific study adenosine was injected from the radial access. 
The proximal pressure (Pa) is measured at the ostium of the coronary vessel with a manometer 
fitted to the guide catheter, whilst the distal pressure (Pd) is measured by a pressure wire that 
can be moved along the vessel to position the pressure transducer (located 3 cm from the 
catheter tip) downstream of the lesion (Figure 4.1-left). Pa and Pd are measured simultaneously 
with either a Primewire PRESTIGE® (Volcano Corporation, CA, USA) or a PressureWire™ 
X Guidewire (St Jude Medical, MN, USA) system and recorded at sampling frequencies of 200 
Hz and 100 Hz respectively.  
After measuring Pd/Pa at baseline, adenosine is injected to bring about the hyperaemic 
condition. The Pd/Pa ratio is calculated continuously within the software considering the 
average pressures across a number of cardiac cycles; the number cycles can be chosen by the 
operator but the default number is set to 3. Pa and Pd are displayed on a monitor, together with 
the Pd/Pa (Figure 4.1-right). 
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Figure 4.1: Representation of the pressure measurements across a stenosis. 
(Left) Representation of the pressure wires across the lesion and (Right) the Volcano software interface. 
Proximal pressure, Pa, measured with the proximal sensor, is indicated in red in the Volcano software; distal 
pressure, Pd, measured with the distal sensor, is indicated in green in the Volcano software. The pressures are 
reported both as a mean value, at top right, and transient measurements as the continuous signal in the main 
window. The Pd/Pa is shown in yellow on the right.  
 
During the injection of adenosine, the operator must identify the stable hyperaemic condition 
to, thus, obtain the appropriate value of FFR. This is not always a straight-forward task and 
there is often an element of subjectivity involved as the operator moves the cursor on the signal 
to re-visit the Pd/Pa ratio and select the value which best represents the FFR. For this reason, 
operator variability has an important influence both within this phase of estimation of lesion 
severity and may have an impact on the subsequent decision-making process. 
Pressure data were post-processed in two ways: first to obtain the transient pressure signal over 
a cardiac cycle and, second to analyse the transient adenosine response in the local system and 
to identify stable hyperaemia and the variability of the FFR. 
 PROCESSING INVASIVE PRESSURE DATA  
This paragraph describes the post-processing applied to the proximal and distal pressure signals 
for each lesion to i) obtain the pressures averaged over a cardiac cycle and ii) identify the 
phases of adenosine response within the Pd/Pa ratio signal.  
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 Average pressure signal over a cardiac-cycle 
The moving-average signal process requires identification of individual cardiac cycles and of 
rest and hyperaemic periods. It should be noted that the effect of extraneous factors, respiration 
for example, can be seen clearly within the signals, but are not represented in the model. 
Two software tools able to perform the filtering into individual cardiac cycles were available: 
one was embedded in an early implementation of the GIMIAS environment (Graphical 
Interface for Imaging Analysis and Simulation, GIMIAS, 2015), and one in the VIRTUheart 
environment (VIRTUheartTM). Both essentially perform the same operations as shown in figure 
4.2, but for the purpose of illustration, the GIMIAS environment is shown. Pressure data 
collected over a recording period of several minutes were loaded into the software and 
displayed. Shorter windows, identified manually with reference to the patient’s Cathlab notes, 
were extracted to represent baseline and hyperaemic periods (step 1). Within these windows 
the signal was divided into individual cardiac cycles, abnormal cycles (e.g. ectopic beats) were 
rejected (step 2), and the remaining cycles averaged (step 3). 
The period of the cardiac cycle (T) extracted from this analysis was also used in Eq.4.1 to 
compute the average heart rate (HR), expressed in clinical units of beats per minute: 
𝐻𝑅 =
60
𝑇
 
(Eq.4.1) 
The outputs of the first post-processing method are the heart rate and the time series of aortic 
pressure over one cardiac cycle at baseline from which systolic and diastolic pressures were 
obtained. 
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Figure 4.2: Example of the process to obtain the average pressures over a cardiac cycle in GIMIAS. 
Step 1) The region of interest (baseline or hyperaemia) is selected. Step 2) Data is split into cardiac cycles with 
elimination of abnormal cycles, if necessary. Step 3) The pressure signals are averaged over a cardiac cycle. 
 
 Algorithm to identify minimum (FFRMIN) and stable (FFRST) FFR 
Currently the clinical decision protocol for FFR assessment defines a threshold of 0.8; above 
this value the lesion does not need treatment. Typically, the Pd/Pa ratio falls, reaches its lowest 
value, and then stabilises at a very slightly higher level to give a period of stable maximal 
hyperaemia [120, 144], but this ‘overshoot’ of the Pd/Pa ratio is not easily identified in all cases. 
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Furthermore, present guidelines do not specify whether the minimum or the stable Pd/Pa should 
be considered as “the true” FFR [86, 144, 146]. 
The second post-processing method aims to analyse the Pd/Pa ratio signal in order to 
automatically identify the phases of the adenosine response, peak and stable hyperaemia, which 
are typically observed during adenosine infusion after the baseline condition (identified as the 
instant when adenosine starts to be administered), defined as follows: 
1) Peak response, when Pd/Pa ratio reaches its minimum value (FFRMIN) generated by the 
adenosine-induced vasodilation; 
2) Stability, when the Pd/Pa ratio is stable (FFRST). This occurs when the cardiovascular 
system responds to adenosine-induced vasodilation with short-term regulation (baro and 
chemocontrol) bringing it to a balanced response resulting in a flat Pd/Pa.  
The minimum Pd/Pa is easier to identify in the Cathlab, although it is still highly dependent on 
operator interpretation, making sure that there are not artefacts in the pressure signals due to 
the patient coughing or to movement of the wires. 
The algorithm described below identifies the minimum Pd/Pa (FFRMIN) and stable Pd/Pa 
(FFRST). To identify FFRMIN and FFRST two methods were selected to smooth the signal: a 
moving average method (with a window size of 1 beat, 2 beats and 3 beats) and a Fast Fourier 
Transform (FFT) filter. The outputs of these analyses were then compared to the FFR measured 
in the Cathlab (FFRCL), in particular, with regards to the impact on treatment. Table 4.1 
summarises the different processing methods and their respective results. 
Table 4.1: Processing methods and relative results of FFRMIN and FFRST. 
 FFRMIN FFRST 
Clinical FFRCL 
Moving average:1 beat 
                            2 beats 
                            3 beats 
FFRMIN,1B - 
FFRMIN,2B - 
FFRMIN,3B - 
FFT filter - FFRST,F 
 
Chapter 4 - Clinical data 
 
121 
   
4.2.2.1 Moving average  
Moving average smoothing over 1 beat, 2 beats and 3 beats requires the identification of the 
cardiac cycles within the pressure signals. The ECG signal could have been used in this context, 
but this was not available for all patients. 
4.2.2.1.1 Identification of the cardiac cycle  
Identification of the cardiac cycles was based on the proximal pressure signal for each vessel 
investigated. Diastolic pressure was used as the identifier for the start of the cardiac cycle. In 
MATLAB 2015a, the function ‘extrema’ allows all local minima in a signal to be identified. 
However, it cannot distinguish between the real minima of the pressure signal corresponding 
to the diastolic pressure at the end of systole and other minima that might occur due to the 
aortic notch or pressure catheter- induced artefacts. 
For the reasons above, two conditions had to be satisfied in order to select the minima 
corresponding to the diastolic pressure: the minimum values had to fall below a threshold 
(between 65 and 100 mmHg) and must occur within a time interval between 0.54 and 0.70 s. 
The results were inspected visually to ensure that the diastolic pressures were captured 
correctly. In certain cases, adjustment of the thresholds was required. 
Distance in time between minima was stored as the heart period, from which the heart rate was 
calculated. A further output is, thus, the change in heart rate during the adenosine infusion and 
heart rates at baseline and stable hyperaemia were used to analyse the adenosine response. 
Once the cardiac cycles were identified, the Pd/Pa ratio is calculated in each cycle using the 
averaged distal and proximal pressures. 
4.2.2.1.2 Pd/Pa ratio over N beats 
The moving average of the Pd/Pa over N cardiac cycles was then calculated as shown in Eq. 4.2 
with different values of N set to 1, 2 and 3. 
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(
𝑃𝑑
𝑃𝑎
)
𝑖
= 
∑ (
𝑃𝑑
𝑃𝑎
)
𝑖
𝑖
𝑖−𝑁
𝑁
  
(Eq.4.2) 
Figure 4.3 shows an example of a real patient data, the different Pd/Pa over N beats can be 
observed and compared against the raw Pd/Pa. 
 
Figure 4.3: Comparison between the raw Pd/Pa and Pd/Pa averaged over N beats.  
The graph shows the original raw Pd/Pa, calculated as the instantaneous ratio of pressures (in grey), and the 
averaged Pd/Pa ratio over 1 cardiac cycle (in black), 2 cardiac cycles (in blue) and 3 cardiac cycle (in red). Vertical 
lines in magenta represents the start and stop of adenosine infusion. 
 
4.2.2.2 Fast Fourier Transform filter 
Pressure signals measured invasively during angiography can be very noisy. Two principal 
frequencies are usually observed: one with a frequency of about 1.1 Hz (65 beats/min) related 
to the cardiac cycle and respiratory movements with a frequency of 0.2-0.25 Hz (12-15 
breaths/min). An example is shown in Figure 4.4, where the proximal and distal pressures are 
reported. 
Smooth Pd and Pa signals were obtained with the following process using MATLAB 2015a: 
- Fast Fourier Transform (FFT) was applied to decompose the signals in the frequency 
domain; 
- A low band-pass filter was applied using cut-off frequencies of 0.04 and 0.5 Hz, 
corresponding to periods of 25 s and 2 s respectively. The first cut-off value eliminates 
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extraneous frequencies (e.g. cardiac and respiratory oscillations), whilst preserving 
physiological frequencies relating to the hyperaemic response. The second cut-off instead 
eliminates only the cardiac oscillations. 
- An inverse FFR to rebuild the signal in the time domain. 
An example of the results of this signal processing against the original input is shown in figure 
4.5. The filtered signal was used to define the FFRST,f. 
 
Figure 4.4: Proximal and distal pressures signals contain cardiac and respiratory oscillations 
The top graph shows the pressures measured for about 4 minutes and an oscillation at a constant frequency 
is observed. Zooming in for details, the period is about 4 seconds, which is compatible with the respiratory 
movements. 
 
Figure 4.5: Example of real and filtered result on a pressure signal. 
In dashed grey is reported the real pressure signal, in blue the filtered pressure signal with cut-off of 0.04 Hz, 
in red the filtered pressure signal with cut-off of 0.5 Hz. 
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4.2.2.2.1 Identification of the peak response: the minimum Pd/Pa (FFRMIN) 
The minimum Pd/Pa value for the cycle-averaged Pd/Pa was calculated as the global minimum 
over the averaged signal. The results obtained for N equal to 3 will be considered to define the 
FFRMIN,3B, as this is considered to be closest to the Cathlab signal where the default averaging 
window of the software is set to 3 cardiac cycles. The minimum value of Pd/Pa calculated from 
the averaged signals over 1 beat (FFRMIN,1B) and 2 beats (FFRMIN,2B) were also calculated to 
compare their values.  These show the variability of the signal with the smaller averaging 
windows. 
The time response to the peak is calculated as the difference between baseline and peak times. 
4.2.2.2.2 Identification of the stable response: the stable Pd/Pa (FFRST) 
Stable Pd/Pa was calculated from the FFT-filtered signal (FFRST) using the process described 
below.  
A finite central difference scheme was used to calculate the first derivative with a 4th order 
accuracy, as described in Eq.4.3. 
𝑓′(𝑥) =
𝑓(𝑥 − 2ℎ) − 8 ∙ 𝑓(𝑥 − ℎ) + 8 ∙ 𝑓(𝑥 − ℎ) − 𝑓(𝑥 − 2ℎ)
12 ℎ
 
(Eq.4.3) 
 
where h is the sampling interval, arbitrarily set to 7 seconds. As a smaller sampling interval 
captures the signal variation, it makes it difficult to identify the stable part, i.e. when the first 
derivative is null. 
The FFRST was identified as the average value of Pd/Pa ratio during the stable period, identified 
between the first and last instants where the derivative was below a threshold, after the peak 
response.   
The threshold for the first derivative was set to 10-5 and was increased by 5% with an upper 
limit of 10-3. 
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Figure 4.6 shows an example of the graph produced in MATLAB 2015a with all the 
information related to the specific case including:  
- the FFRs measured in the Cathlab, 
- the FFRMIN from the 3 beat moving-average signal, FFRMIN,3B; 
- the FFRST from the filtered signal with cut-offs of 0.04Hz and 0.5 Hz (FFRST,F 0.04Hz, 
FFRST,F 0.5Hz) represented as a straight line which indicates the length of the stable period 
identified; 
- a time indicator of the start and stop of adenosine. 
 
Figure 4.6: Example of algorithm results for the FFRMIN and FFRST. 
The graph reports the FFR measured in Cathlab at baseline (FFR-BL-Cathlab) and at hyperaemia (FFR-HY-
Cathlab), the Pd/Pa signal processed with the 3 beats moving average (blue), and with the FFT filter with cut 
off 0.04Hz (black) and 0.5Hz (dashed red),  FFRMIN,3B(▲),  FFRMIN,f 0.04 Hz (),  FFRMIN,f 0.5 Hz (), and FFRST,f 
0.04 Hz (- - -) and FFRST,f 0.5 Hz (----). The start and end of e adenosine infusion is indicated by vertical lines. 
 
4.2.2.3 Statistical analysis 
FFRs measured in the Cathlab (FFRCL) and the calculated minimum and stable Pd/Pa 
(FFRMIN,3B, FFRST,F 0.5 Hz, FFRST,F 0.04 Hz ) were compared using a 2-tailed paired T-test for each 
group, assuming a normal distribution. 
The variables were compared statistically calculating the mean delta (bias) and the standard 
deviation (SD) and represented graphically by a Bland-Altman plot with limits of agreement 
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of ±1.96 SD. The correlation coefficient between the variables was also calculated. The same 
approach was used to compare FFRMIN,3B with FFRST,F 0.5 Hz and FFRST,F 0.04 Hz to demonstrate 
the common error of overestimation of the lesion severity in choosing the minimum Pd/Pa. The 
statistical analysis was performed in IBM SPSS (IBM Analytics, USA). 
 
 Variability of Pd/Pa at baseline and hyperaemia 
During assessment of stenosis severity, clinicians have to interpret the Pd/Pa signal and choose 
the best representation of the FFR.  This often results in the minimum value with the resulting 
overestimation of lesion severity. Volcano and St.Jude software, employed in angiography, 
report by default the minimum value for Pd/Pa, averaging the pressure signals over a number 
of cardiac cycles, which can be selected to be between 3 and 5 by the operator. 
To calculate the variability of the Pd/Pa during baseline and hyperaemia, the cycle-averaged 
signals over 1 beat, 2 beats and 3 beats, calculated as described in paragraph 4.2.2.1.1 
Identification of the cardiac cycle, were considered. For this purpose, the baseline period was 
identified over 5 consecutive cycles after the start of adenosine infusion. For all three averaging 
regimes (FFR1B, FFR2B, FFR3B), hyperaemia is defined as occurring over the period from the 
minimum to the end of the signal. 
Patients were also classified by heart rate (HR), i.e. as bradycardic (HR<60 beats/min), 
tachycardic (HR>100 beats/min) or normal (60<HR<100 beats/min) and by the presence of 
atrial fibrillation (AF). 
4.2.3.1 Statistical analysis 
Pd/Pa ratio signal variability was estimated by calculating the coefficient of variation (CoV) 
during the period of hyperaemia for each case and for each type of analysis with 1 beat, 2 beats 
and 3 beats and then averaging the results for all cases. The coefficient of variation was 
calculated as the ratio between the standard deviation and the mean value. 
Chapter 4 - Clinical data 
 
127 
   
 CLASSIFICATION OF ADENOSINE RESPONSE 
The proximal and distal pressures recordings were analysed to seek out any trends which could 
be used to classify patients into groups with a similar response and to attempt to link this to 
their profiles in terms of the general demographic data. Instantaneous proximal and distal 
pressures at baseline, peak and stable hyperaemia were calculated with the algorithm described 
previously. 
The average response to adenosine for all patients/lesions was determined by calculating the 
averaged proximal and distal pressures at baseline and hyperaemia across the entire dataset. 
Patient groups were classified from the trends of proximal and distal pressures with respect to 
their respective baseline values, in terms of identifying negative or positive changes for each 
phase. 
The heart rates, at baseline and hyperaemia obtained using the algorithm, were examined to 
determine the average response to adenosine based on this parameter and to understand the 
effects and importance of the barocontrol system. 
A second classification was also made as a result of analysing the Pd/Pa ratio curves by eye and 
identifying groups of patients with similar behaviour. 
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 RESULTS  
 Patient demographic 
One hundred and sixty-three independent coronary lesions were studied in 93 patients.  
Demographic information for these patients is reported in Table 4.2.  
Table 4.2: Demographic data and comorbidities for 93 patients.  
 BMI - Body Mass Index, PVD - Peripheral Vascular Disease, COPD - Chronic Obstructive Pulmonary Disease, 
MI - myocardial infarction. 
Patient demographic Num% - mean (SD) 
Male 75% 
Age (years) 64.7 (SD 10.2) 
BMI 29.3 (SD 4.7) 
Hypertension 65.5 % 
PVD 5.4 % 
Previous MI 40.9 % 
Type II diabetes 22.6 % 
Hyperlipidaemia 77.4 % 
COPD 6.9 % 
Eighty-one lesions were physiologically significant (FFR ≤ 0.80) and 82 were non-significant 
(FFR > 0.80).  The mean FFR measured in the Cathlab was 0.78 (SD 0.15). 
Lesions included: 72 in left anterior descending (LAD) arteries; 40 in right coronary arteries 
(RCA); 33 in circumflex arteries (LCX); 13 in diagonal arteries (DX); 5 in left main stem 
(LMS).  
 
 FFR measurements and algorithm results: impact on treatment 
The distribution of FFRCL, FFRMIN,1 B, FFRMIN,2B, FFRMIN,3B, FFRST,F 0.5 Hz and FFRST,F 0.04 Hz 
are shown in terms of their means, and standard deviations in Table 4.3.  
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FFRMIN,1 B and FFRMIN,2B are reported to demonstrate that, as expected, the minimum value of 
Pd/Pa is influenced by the number of cycles over which the data was averaged.  This issue has 
not been considered in terms of its impact on treatment since, in the Cathlab, the operators 
would choose to average over 3 beats, as they are aware of the beat-to-beat variability of the 
signal. 
Table 4.3: Distribution of FFRCL, FFRMIN,3B, FFRST,F 0.5 Hz and FFRST,F 0.04 Hz for 163 vessels in 93 patients. 
 Mean (SD) 
FFRCL 0.781 (0.15) 
FFRMIN,1 B 0.748 (0.17) 
FFRMIN,2B 0.758 (0.15) 
FFRMIN,3B 0.762 (0.16) 
FFRST,F 0.5 Hz 0.799 (0.15) 
FFRST,F 0.04 H 0.806 (0.15) 
The FFR values measured in the Cathlab during hyperaemia (FFRCL) prior to PCI were 
compared with the results obtained with the algorithm implemented in MATLAB (FFRMIN,3B, 
FFRST,F 0.5 Hz, FFRST,F 0.04 Hz) and the stable FFRs (FFRST,F 0.5 Hz, FFRST,F 0.04 Hz) were compared 
with FFRMIN,3B. The resulting intra-class correlation coefficients indicate high correlation for 
each pair of variables:  
 0.99 (95% CI: 0.987-0.993, P-value < 0.001) for FFRCL - FFRMIN,3B; 
 0.987 (95% CI: 0.983-0.991, P-value < 0.001) for FFRCL - FFRST,F 0.04 Hz;  
 0.941 (95% CI: 0.920-0.956, P-value < 0.001) for FFRCL – FFRST,F 0.5 Hz;  
 0.943 (95% CI: 0.922-0.958P-value < 0.001) for FFRMIN,3B – FFRST,F 0.5 Hz;  
 0.986 (95% CI: 0.980-0.989P-value < 0.001) for FFRMIN,3B – FFRST,F 0.04 Hz;  
 0.949 (95% CI: 0.930-0.962P-value < 0.001) for FFRST,F 0.04 Hz – FFRST,F 0.5 Hz. 
Using the accepted threshold value of 0.8 for PCI intervention, lesions could be reclassified 
based on the different FFRs. 
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With FFRMIN,3B as the arbiter, 92 lesions (56 %) were classified as significant, and 71 (44 %) 
as non-significant. When FFRST,F 0.04 Hz was chosen as the arbiter, 27 significant lesions (16.5 
% lesions -24 % patients) were reclassified as non-significant, resulting in 65 (40 %) significant 
and 98 (60 %) non-significant lesions (Figure 4.7-a). When FFRST,F 0.5 Hz was used 19 
significant lesions (11.6 % lesions -17 % patients) were reclassified as non-significant (Figure 
4.7-b), resulting in a total of 74 (45%) significant and 89 (55%) non-significant lesions.  
Comparing FFRCL and FFRMIN,3B, 9 lesions (5.5 % of lesions, 7.5% of patients) were 
reclassified as significant and 1 lesion (0.6 % of lesions, 1.1 % of patients) was reclassified as 
non-significant (Figure 4.7-c). 
Comparing FFRCL and FFRST,F 0.5 Hz, 12 lesions (7.3 % of lesions, 11 % of patients) were 
reclassified as non-significant  and 1 lesion (0.6 % of lesions, 1.1 % of patients) was reclassified 
as significant (Figure 4.7-d) and, finally, comparing FFRCL and FFRST,F 0.04 Hz, 19 lesions (11.6 
% of lesions, 18 % of patients) were reclassified as non-significant (Figure 4.7-e). 
These results are summarised in Table 4.4. 
Table 4.4: Impact on treatment results across pairs of FFR values. 
 
  FFRCL / 
FFRMIN,3B 
FFRCL / FFRST,F 
0.5 Hz 
FFRCL / FFRST,F 
0.04 Hz 
FFRMIN,3B / 
FFRST,F 0.5 Hz 
FFRMIN,3B / 
FFRST,F 0.04 Hz 
SI
G
N
--
>N
O
N
 S
IG
 
LMS - 2 2 2 2 
LCX - 5 9 8 12 
LAD 1 3 4 5 6 
RCA - 2 4 4 7 
DX - - - - - 
#lesions 1 (0.6%) 12 (7.3%) 19 (11.6%) 19 (11.6%) 27 (16.5%) 
#patients 1 (1.1%) 11 (11%) 17 (18%) 16 (17%) 23 (24%) 
N
O
N
 S
IG
--
>S
IG
 
LMS - - - - - 
LCX 3 - - - - 
LAD 3 - - - - 
RCA 3 1 - - - 
DX - - - - - 
#lesions 9 (5%) 1 (0.6%) - - - 
#patients 7 (7.5%) 1 (1.1%) - - - 
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A paired T-test (2-tailed, 95% CI) was performed for each pair of variables in order to identify 
the average difference between the paired values (bias) and the standard deviation (Figure 4.8):  
- FFRMIN,3B – FFRST,F 0.04 Hz: bias =-0.04, SD=0.03, (p<0.0001) (Figure 4.8-a); 
- FFRMIN,3B –FFRST,F 0.5 Hz: bias =-0.04, SD=0.03, (p<0.0001) (Figure 4.8-b); 
- FFRCL – FFRMIN,3B: bias =+0.02, SD=0.03, (p<0.0001) (Figure 4.8-c); 
- FFRCL – FFRST,F 0.04 Hz: bias =-0.02, SD=0.03, (p<0.0001); (Figure 4.8-d); 
-  FFRCL – FFRST,F 0.5 Hz: bias =-0.02, SD=0.03, (p<0.0001); (Figure 4.8-e). 
The Bland-Altman plots show the impact on treatment as well. Both stable FFRs (FFRST,F 0.04 
Hz, FFRST,F 0.5 Hz ) are, on average, higher by 0.02 compared to FFRCL and by 0.04 compared 
with FFRMIN,3B, with a P-value < 0.001, indicating high statistical significance. The average 
difference between FFRCL and FFRMIN,3B is 0.02 with P-value < 0.001. These results suggest 
that the FFR measured in Cathlab falls in between the minimum and the stable values and 
therefore, if the stable FFR is taken to be the gold standard, the severity of some lesions will 
be overestimated. 
 
Figure 4.7: Impact on treatment decision based on the different FFRs. 
a) FFRMIN,3B VS FFRST,F 0.04 Hz. b) FFRMIN,3B  VS FFRST,F 0.5 Hz. c) FFRCL VS FFRMIN,3B. d) FFRCL VS FFRST,F 0.5 Hz. e) FFRCL VS 
FFRST,F 0.04 Hz. Red indicates lesions reclassified as non-significant and blue lesions reclassified as significant. 
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Figure 4.8: Bland-Altman plots for the each pair of variables.  
a) FFRMIN,3B VS FFRST,F 0.04 Hz. b) FFRMIN,3B VS FFRST,F 0.5 Hz. Panel c) FFRCL VS FFRMIN,3B. d) FFRCL VS FFRST,F 0.5 Hz.  e) FFRCL 
VS FFRST,F 0.04 Hz. Red indicates lesions reclassified as non-significant and blue lesions reclassified as significant. 
Further analysis of those cases showing the largest differences between the FFR recorded in 
the Cathlab and results obtained using the algorithm revealed two underlying issues. In some 
cases, the FFR measured in the Cathlab did not correspond to the Pd/Pa seen in the signal, in 
this situation, the algorithm was able to identify correctly the minimum and stable FFRs. In 
other cases there was no stable period within the hyperaemic response: after reaching a 
minimum value, the Pd/Pa rose again toward the baseline. In such situation, the Cathlab operator 
selects the minimum value, but the algorithm reports a higher value as the period of stable FFR 
is occurring during the recovery transition to baseline. Two explicative examples of these are 
presented in Figure 4.9. 
These results demonstrate the importance of a standard approach for the calculation of FFR, 
but are not able to provide information on whether FFRMIN or FFRSTABLE should be chosen as 
the gold standard. The algorithm described could assist in the standardisation process and, since 
its processing time is about 2 seconds, it would be easy to incorporate this within software 
commonly used to assess FFR. However, here must be also noted that stable hyperaemia must 
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be achieved during adenosine infusion, for the algorithm to work correctly. This is especially 
important for those cases close to the threshold for the correct decision to be made.  
 
Figure 4.9 Examples of cases with large differences between FFRCL and algorithm results. 
FFR measured in Cathlab at baseline (FFR-BL-Cathlab) and at hyperaemia (FFR-HY-Cathlab), the Pd/Pa signal 
processed with the 3 beats moving average (blue), and with the FFT filter with cut-off 0.04Hz (black) and 0.5Hz 
(dashed red), the FFRMIN,3B(▲),the FFRMIN,f 0.5 Hz (). Vertical lines indicate start and end of adenosine infusion. 
 
 
 Timing of adenosine peak response and stability 
Clinically different types of response are observed in terms of pressure behaviour and time. 
The average time taken from the start of adenosine and the peak response is 55.3 (SD 19) s. 
Here, the range is wide from a minimum of 17.55 s to a maximum of 131.42 s. 
Also in the Cathlab, this variability is observed and earlier and later responders are recognised. 
A visual analysis of the Pd/Pa traces obtained with the algorithm was performed in order to 
identify the average time to reach stable hyperaemia. 11 lesions have been excluded from the 
groups of patients described in Paragraph 4.4.1 Patient demographic, because stable 
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hyperaemia was not reached during the recording period. The average time to reach stable 
hyperaemia was 69.41 s with a range of 18.6 s -140 s and standard deviation of 18.6 s. 
The results are consistent with published data [144] on analysis of the Pd/Pa ratio. In particular, 
Tarkin et al. [120] identified different types of adenosine response observing pressure 
behaviour based on the minimum FFR reached within 60 s of the start of adenosine injection. 
With the algorithm used in the current work, the minimum FFR can be identified at any time. 
This is especially relevant for later responders. 
 FFR variability at baseline and hyperaemia 
The coefficient of variation (CoV) was calculated for 1beat FFR variability (CoV1), 2beat FFR 
variability (CoV2) and 3beat FFR variability (CoV3) for both baseline and hyperaemia. 
As expected for both baseline and hyperaemic conditions, the mean CoV1 has highest value 
and CoV3 the smallest, due to the different averages used to define the Pd/Pa. It is evident that, 
by increasing the number of beats, the resulting Pd/Pa traces are smoothed.  
For 83% of lesions studied patients had a normal heart rate, for 4.5 % patients had tachycardia, 
for 9.8% patients had bradycardia and for 4.5 % patients suffered from atrial fibrillation.  
For patients with multiple lesions, the heart rate classes were very similar in terms of 
tachycardia, bradycardia, arrhythmia and normal, with a high reproducibility of the heart rate 
in the different lesion assessment. In 2 patients the heart rate class varied between the 2 (or 
more) lesions’ assessments. This is likely to be caused by the residual effects of adenosine. 
 At baseline CoV1 had an average value of 0.013 (range: 0.00053 – 0.538), for CoV2 the 
average value fell to 0.011 (range: 0.00022 – 0.536), and CoV3 increased again to an average 
value of 0.017 (range: 0.00021 – 0.173). 
At hyperaemia an average CoV1 of 0.0257 (range: 0.0025 – 0.1018), average CoV2 of 0.0191 
(range: 0.0023 – 0.0809) and averaged CoV3 of 0.0153 (range: 0.0017 – 0.0637) were 
observed. During hyperaemia, the number of patients with a variability of above 5% fell as the 
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number of beats average increased from 1 to 3: 14 (12.5 %) patients, 9 (8 %) patients and 7 
(6.3 %) patients for 1 beat, 2 beats and 3 beats respectively.  
CoVs values for each analysis with different beats were averaged for the patients’ groups 
identified based on heart rate, as shown in table 4.5. 
The variability of FFR is always greater for patients with AF, irrespective of the number of 
beats over which the analysis was performed. Differences are less evident between the other 2 
condition, bradycardia and tachycardia. For patients with normal HR, the degree of variability 
of the FFR lies between that of patients with tachy/bradycardia and those with AF.  
When it comes to selecting the value of FFR which best represents lesion severity, because of 
the continuous high variability of Pd/Pa during stable hyperaemia, patients with AF prove to be 
the most challenging from a clinical decision-making perspective.   
Table 4.5: Averaged CoVs calculated for 1 beat, 2 beats, and 3 beats for all lesions and for groups with Atrial 
Fibrillation (AF), Bradycardia, Tachycardia and normal Heart Rate. 
 Baseline Hyperaemia 
 
Mean 
CoV1 
Mean 
CoV2 
Mean 
CoV3 
Mean 
CoV1 
Mean 
CoV2 
Mean 
CoV3 
All lesions 0.013 0.011 0.017 0.026 0.019 0.015 
AF 0.021 0.016 0.013 0.038 0.027 0.022 
Bradycardia 0.006 0.0075 0.0062 0.02 0.013 0.01 
Tachycardia 0.030 0.02 0.02 0.016 0.013 0.011 
Normal HR 0.013 0.011 0.0065 0.026 0.02 0.016 
In each group, the variability of FFR might be sufficient to lead to misinterpretation, especially 
for those cases around the cut-off value. 
The increase of variability of CoV3 for baseline variability might be caused by the selection of 
the baseline period just after the infusion starts. The Pd/Pa might oscillate for a number of 
different reasons, such as movement of the pressure wires or the starting of the adenosine 
response.  
The analysis of baseline variability is important with respect to a recently-developed stenosis 
severity assessment index, the intensity wave-free fractional reserve (iFR). iFR is calculated 
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during baseline as the ratio of the mean distal pressure to the mean proximal pressure during 
the wave-free period within the cardiac cycle. This is automatically identified during diastole 
and, more precisely, between 25% of the way into diastole and 5 ms before the end of diastole. 
During this period pressure and flow are linearly related and the myocardial resistance is 
minimal [147-149]. The iFR was used as part of a hybrid approach where both indices are used 
or it could substitute for FFR, as shown in the clinical trials DEFINE-FLAIR [149] and iFR-
SWEDEHEART[148] and its cut-off value is set to 0.83 . The main advantages of iFR are the 
reduced procedural time and, since no vasodilatory drugs are used, its cost efficiency and less 
pain/discomfort in patients [150]. This physiological index looks very promising so far and it 
could provide an improved measurement protocol that is not compromised by the variability 
of response given by the adenosine administration. 
 
 Classification of the adenosine response 
Processing and analysis of the invasive pressure data enable the patient response to adenosine 
to be classified based on the pressure behaviour and the Pd/Pa ratio curve measured before PCI. 
4.4.5.1  Average adenosine response: pressures and heart rate changes  
Pressures and heart rate at peak and stable hyperaemia identified with the algorithm were 
compared with the baseline condition in order to calculate the change of pressure and of heart 
rate in terms of absolute value and of percentage. Figure 4.10 shows the distributions of change 
of proximal pressure, distal pressure and heart rate between baseline and peak hyperaemia and 
baseline and stable hyperaemia.  
The average proximal pressure at baseline is 94.91 (SD 12.08) mmHg, during the peak 
hyperaemia is 92.59 (SD 12.31) mmHg and at stable hyperaemia is 90.05 (SD 12.76) mmHg. 
Our data therefore suggest that the change in proximal pressure is minimal with a decrease of 
2.32 mmHg (2.37 %) at peak and 4.86 mmHg (3.63 %) at stable hyperaemia. These results are 
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in disagreement with what was published in the literature, where the proximal pressure 
decreases about 10-13 mmHg [116]. 
 
Figure 4.10: Distribution of proximal, distal pressure and heart rate to describe the adenosine response. 
Change of proximal pressure Pa (A), distal pressure Pd (B) and heart rate HR (C) between baseline and peak 
and between baseline and stable hyperaemia. Results are reported as absolute values (left) and percentages 
(right). 
With regards to distal pressure, the average value at baseline is 86.21 (SD 15.33) mmHg, at 
peak hyperaemia is 74.93 (SD 16.51) mmHg and at stable hyperaemia is 74.88 (SD 16.38) 
mmHg. Therefore, the distal pressure decreases by 11.28 mmHg (13 %) and with minimal 
changes between peak and stable conditions. The distal pressure is primarily dependent on the 
severity of stenosis and on the myocardial resistance. 
The average heart rate is 68 (SD 9.94) beats/min at baseline, increases slightly to 69.72 (SD 
11.25) beats/min at peak hyperaemia, increasing further to 75.05 (SD 11.68) beats/min during 
stable hyperaemia. Our observations suggest HR increases of about 1.7 beats/min (2.34 %) at 
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peak and about 13 beat/min (10.35 %) during stable hyperaemia. This is less than the increase 
of about 30 beats/min reported in the literature [116]. 
The discrepancy in effect could be related to duration of adenosine infusion. In most studies 
adenosine was infused for several minutes, or even hours, and, in consequence, long-term 
neurocontrol mechanism may have been simulated. For patients in the present study, the 
infusion lasted between 90 and 120 s and thus probably not affecting long-term neuro-
regulatory system. 
4.4.5.2 Pressure trends between baseline, peak and stable hyperaemia 
Based on proximal and distal pressure at peak and stable hyperaemia, seven types of response 
have been identified (Table 4.6). The seven groups are described in the list which follows in 
terms of average and standard deviations of the change of proximal, Pa, and distal, Pd, pressure 
at peak and stable hyperaemia: 
- Group A: Pa and Pd showed the same trend with a decrease during the peak followed by 
restoration during stable hyperaemia. On average Pa decreased by 6.9 (SD 5.34) mmHg at 
peak and was restored during stable hyperaemia to 1.33 mmHg (SD 3.9) above the baseline. 
Pd decreased by 17.1 mmHg (SD 9.5) at peak and was restored at stable hyperaemia to 4.2 
mmHg (SD 9.7) above the baseline. This response was seen in 65 lesions (46 patients); 31 
LAD, 10 LCX, 16 RCA, 6 DX and 2 LMS. 
- Group B: Pa increased slightly at peak and stabilised during stable hyperaemia, while Pd 
decreased and then was restored to baseline. On average Pa increased by 3.8 (SD 3.6) mmHg 
at peak and decreased during stable hyperaemia to 3.5 mmHg (SD 4.5) below the baseline. 
Pd decreased by 8.4 mmHg (SD 6.1) at peak and was restored at stable hyperaemia to the 
baseline condition (SD 3.6). This response occurred in 44 lesions (38 patients); 21 LAD, 10 
LCX, 8 RCA, 4 DX and 1 LMS. 
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- Group C: Pa decreased at both peak and stable hyperaemia, while Pd decreased and then 
attempted to recover to baseline. On average Pa decreased by 2.7 (SD 2.3) mmHg at peak and 
decreased further at stable hyperaemia by 7.6 mmHg (SD 5.0). Pd decreased by 14.4 mmHg 
(SD 9.1) at peak and increased at stable hyperaemia to 3.5 mmHg (SD 5.3) below the baseline. 
This response occurred in 20 lesions (19 patients): 6 LAD, 3 LCX, 9 RCA and 2 DX. 
- Group D: Pa increased at peak and then dropped during stable hyperaemia below the baseline, 
Pd followed the same trend. On average Pa increased by 9.4 (SD 6.3) mmHg at peak and 
decreased during stable hyperaemia to 6.1 mmHg (SD 7.2) below the baseline. Pd increased 
by 6.1 mmHg (SD 6.3) at peak and decreased during stable hyperaemia to 4.1 mmHg (SD 
6.3) below baseline. This response occurred in 12 lesions (11 patients): 5 LAD, 5 LCX and 2 
RCA. 
- Group E: Pa increased at peak and then dropped below baseline at stable hyperaemia, while 
Pd decreased at peak and continued to decrease during the stable hyperaemia. On average Pa 
increased by 4.8 (SD 3.7) mmHg at peak and decreased during stable hyperaemia to 10.9 
mmHg (SD 7.1) below the baseline. Pd decreased by 4.8 mmHg (SD 3.6) at peak and 
decreased further during stable hyperaemia to 7.5 mmHg (SD 3.3) below the baseline. This 
response occurred in 9 lesions (7 patients): 4 LAD, 3 LCX and 2 RCA. 
- Group F: Pa increased slightly at both peak and stable hyperaemia, while Pd decreased at peak 
and then was restored above baseline. On average Pa increased by 1.1 (SD 0.8) mmHg at peak 
and increased further during stable hyperaemia to 3.5 mmHg (SD 1.9) above the baseline. Pd 
decreased by 12.4 mmHg (SD 9.0) at peak and was restored during stable hyperaemia to 5.6 
mmHg (SD 3.1) above the baseline. This response occurred in 5 lesions (4 patients): 3 LAD 
and 2 LCX. 
- Group G: both Pa and Pd decreased at peak and more at stable hyperaemia, again showing 
the same trend. On average Pa decreased by 2.3 (SD 2.5) mmHg at peak and continued to 
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decrease during stable hyperaemia to 12.6 mmHg (SD 5.2) below the baseline. Pd decreased 
by 6.5 mmHg (SD 4.3) at peak and decreased further during stable hyperaemia to 10.9 mmHg 
(SD 4.3) below the baseline. This response occurred in 2 lesions (2 patients): 1 LAD and 1 
RCA. 
Comparing these results with those in the published literature, some similarities can be seen 
with the classification made by Tarkin et al. [120]. Tarkin also identified seven types of 
response within 310 cases, although not all of them are consistent with the findings of the 
current work in terms of the average values of pressure changes at peak and stable hyperaemia 
compared to baseline conditions and in terms of the frequency of each type of response. One 
of the limitations of the study by Tarkin et al. is related to the definition of the peak phase as 
the minimum Pd /Pa ratio within 60 s from the start of adenosine infusion, whereas in the current 
algorithm the minimum is detected at any time after the start of the infusion. This enables the 
later responders to also be identified correctly. 
In the classification, 2 types of response proposed here (Group E and Group F) occurred for a 
very limited number of patients. This could be related to a particular reaction within these 
patients (panic, movement, fear) or to movements of the pressure wires by the clinicians during 
the procedure and to the catheter position. 
In the classification proposed in this work, a number of patients with multiple lesions presented 
similar adenosine response in all lesions.  In other case patients responded differently for each 
of the lesions and this might be related to a residual effect of adenosine from a previous infusion 
for the earlier assessment of another lesion.  
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Table 4.6: Groups of adenosine response, based on the proximal (black) and distal pressure (red) at peak and 
stable hyperaemia compared with baseline.  
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4.4.5.3 Groups response and patients’ profiles 
The profiles of each patient were analysed for each group of patients based on adenosine 
response, in order to identify any possible correlation with the adenosine response and patient 
condition. 
 Table 4.7 reports the  patient profiles for each group in terms of gender, mean and standard 
deviation of age and BMI, number of obese, overweight and normal weight patients,  smoking 
status (current, ex-smoker, never, unknown) and comorbidities  with regards to: diabetes II, 
hyperlipidaemia,  peripheral vascular disease (PDV), atrial fibrillation (AF), hypertension, 
asthma, chronic obstructive pulmonary disease (COPD), myocardial infarction and its location  
with respect to the treated lesion. Figures 4.11 - 4.13 show the graphs of the single patient 
profile in each of the response groups, classified by gender, BMI (overweight, obese and 
normal), age (>70, between 60 and 70, between 45 and 60 and between 35 and 45), smoking 
status (never, given up, current, unknown), and the pathologies described above. These results 
do not suggest any particular relationship between the group response and the patients’ profiles. 
There is no evidence of any cloud of colours representing the different patients’ characteristics 
with regards of each group. The characteristics of each group are similar with no relevant 
differences, making challenging the prediction of the adenosine response based on the patient 
profile and the pressure trends. 
It is evident that most patients had hyperlipidaemia and hypertension for which they were 
treated and therefore it is not surprising that these two pathologies are not seen to influence the 
type of response. On the other hand, the other comorbidities considered were rare in our cohort 
and it is difficult to make a distinction between those with and without the pathologies. Greater 
numbers of patients with, and without, each comorbidity need to be recruited to detect any 
possible influences on the adenosine response. Another aspect that is not taken into account is 
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the potential effect of a combination of the comorbidities. This would be difficult to assess for 
each single patient depending on the severity of each pathology. 
Table 4.7: Description of the patient profile in each group of adenosine response. 
Peripheral Vascular Disease (PDV), Atrial Fibrillation (AF), Chronic Obstructive Pulmonary Disease (COPD). 
  Group A Group B Group C Group D Group E Group F Group G 
 M/F 52/13 38/6 15/5 8/4 8/1 3/2 1/1 
 Age 62.4 
(10.4) 
65.1 
(8.5) 
66.3 
(10.7) 
66  
(10) 
67.5  
(13) 
66.4 
(7.1) 
62.5  
(6.4) 
 BMI 28.7 (3.0) 
17 obese 
41 ow 
7 normal 
27.8 (4.0) 
13 obese 
20 ow 
11 normal 
28.1 (5.3) 
7 obese 
6 ow 
7 normal 
29.2 (4.3) 
5 obese 
4 ow 
3 normal 
27.6 (7) 
2 obese 
4 ow 
3 normal 
29.7 (7.2) 
2 obese 
0 ow 
2 normal 
29.1 (5.3) 
1obese 
1 ow 
0 normal 
S
m
o
k
in
g
 
Current 4 8 3 1 1 0 0 
Ex-smokers 35 24 7 7 6 4 2 
Never 22 9 10 4 2 1 0 
Unknown 4 3 0 0 0 0 0 
C
o
m
o
rb
id
it
ie
s 
Diabetes II 7 8 5 1 1 1 0 
Hyperlipid. 54 34 16 11 5 3 2 
PDV 4 2 1 2 0 0 0 
AF 2 3 0 0 0 0 0 
Hypertension 36 28 14 11 6 4 1 
Asthma 1 0 0 0 0 0 0 
COPD 3 5 2 1 0 0 0 
MI total 31 15 8 4 3 0 1 
MI same reg. 7 0 1 0 1 0 0 
MI elsewhere 17 9 2 1 2 0 0 
MI unknown 7 6 5 3 0 0 1 
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Figure 4.11: Patients’ profiles of Group A.  
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
        
Figure 4.12: Patients’ profiles of Group B (left) and C (right). 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
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Figure 4.13: Patients’ profiles of Group D, E, F, G (from left to right). 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
 
4.4.5.4 Pd/Pa ratio curves 
The algorithm developed to analyse the raw clinical pressure data produced a Pd/Pa ratio curve 
for each lesion (total 163) and analysis by eye identified five trends: 
- Type 1: decrease followed by a small bump and then a stable state; 
- Type 2: decrease and then stable; 
- Type 3: decrease and the recovery; 
- Type 4: flat. 
- Type 5: decrease followed by multiple bumps; 
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Table 4.8 represents the type of response and reports the number and the vessel of lesions. 
Figures 4.14 – 4.15 show the overall patient profiles in each of the groups identified on the 
basis of the Pd/Pa ratio as described for the previous classification based on the pressures.  
In this classification, it is also not easy to identify any particular group characteristic which 
might aid the prediction of the adenosine response and the limitations are essentially the same 
reported for the previous classification based on pressure behaviour.  
Johnson et al. [144] studied the repeatability of FFR in 190 cases using an algorithm which 
identified the “smart minimum” as the lowest average FFR across five consecutive cardiac 
cycles. Their observations suggest 3 types of response: ‘humped’, ‘classic’ and ‘unusual’. The 
‘classic’ response corresponds to type 2 and type 3 response in the current work and the 
‘humped’ response includes types 1 and type 5, whilst the ‘unusual’ corresponds to the type 4. 
Similar percentages of the humped responses (type 1 and 5), while the classic one has a smaller 
percentage, due to a higher number of patients with flat response (type 4 or unusual) were 
found in the work by Johnson et al. and in the current work. 
Table 4.8: 5 types of response based Pd/Pa ratio, with the total number of lesions and the distinction in type 
of vessels per type of response, with the respective percentages. 
     
Type 1 Type 2 Type 3 Type 4 Type 5 
TOT 98 (60%) 
LAD 46 (28 %) 
RCA 29 (18 %) 
LCX 18 (11%) 
DX 5 (3%) 
TOT 43 (26.4%) 
LAD 22 (13.5%) 
RCA 6 (3.7%) 
LCX 9 (5.5%) 
DX 6 (3.7%) 
TOT 11 (6.8%) 
LAD 6 (3.7%) 
RCA 2 (1.2%) 
LCX 2 (1.2%) 
DX 1 (0.6%) 
TOT 7 (4.3%) 
LAD 1 (0.6%) 
RCA 3(1.8%) 
LCX 2 (1.2%) 
DX 1 (0.6%) 
TOT 4 (2.5%) 
LAD 2 (1.2%) 
RCA - (- %) 
LCX 2 (1.2%) 
DX - (-%) 
 
Chapter 4 - Clinical data 
 
147 
   
 
Figure 4.14: Patients’ profile of response type 1. 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
 
Figure 4.15: Patients’ profile of response type 2, 3 ,4 and 5. 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
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 CONCLUSIONS AND LIMITATIONS 
The algorithm developed for post-processing the clinical data provides an objective tool which 
can be incorporated within software used routinely in the Cathlab to assess FFR, eliminating 
the inter- and intra- operator variability in the interpretation of Pd/Pa ratio. A further 
standardisation is necessary as to whether to choose the minimum or the stable Pd/Pa ratio as 
the clinical diagnostic index upon which the treatment decision is based. From analysis of the 
cases in this study, the minimum is shown to be easier to identify in all patients, including cases 
where the hyperaemic response did not follow the typical trend and a stable phase was not 
reached. 
The use of the algorithm also provided results in terms of pressure trends and heart rate changes 
during the adenosine response. Pressures were used to classify the patient responses to 
adenosine in terms of systemic and coronary circulations.  
Trends in Pd/Pa ratio were also analysed to identify similar responses to adenosine which, in 
turn, can be used to group patients. 
The patient profile for each group of response (based on pressure trends and based on Pd/Pa 
ratio curves) were also analysed to identify any relevant comorbidity or characteristic of the 
patients which could be related with the type of response. Unfortunately, since all the groups 
presented similar characteristics, without any particular difference between them, prediction of 
adenosine response based on patient profiles remains a challenge.  
The results of the classification might be improved through the recruitment of a greater number 
of patients with and without defined comorbidities or characteristics in order to have a high 
statistical impact on the results. 
A limitation of this type of classification may be the lack of consideration of severity and 
combination of more comorbidities in the same patient. 
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5 CHAPTER 5 
PERSONALISATION OF 
PARAMETERS IN THE 
CARDIOVASCULAR MODEL 
 
INTRODUCTION AND PURPOSE 
The physiological status of a patient with coronary artery disease should be taken into account 
in the decision-making process. The same coronary lesion can have different impacts on 
different patients. As the anatomical accuracy of personalised computational models has 
increased with increasing spatial resolution and other improvements in the quality of medical 
images, there is increasing emphasis on the appropriate representation of the boundary 
conditions for the individual, describing their own ‘physiological envelope’. This envelope is 
quantitively represented by the operation of lumped parameter models of the type described in 
Chapter 2. 
The aim of this chapter is to develop a process for personalising a lumped parameter model to 
represent the physiology of an individual patient, especially in the context of diagnostic or 
prognostic application of such a model for a patient with coronary artery disease. The 
likelihood of short term clinical translation and impact for a model is increased if it can operate 
using the data that is already routinely collected in the clinical pathway. Generally, the 
available physiological data is relatively sparse, and therefore the number of parameters that 
can be individually personalised is limited, and it is important to identify both the sensitivity 
of the model to the individual parameters and the outputs that the model must reproduce 
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faithfully to be of clinical value. Specifically, the focus of this and the next chapter is on the 
patient-specific personalisation of a lumped parameter cardiovascular model, which includes 
the global cardiovascular system, in terms of left and right heart and pulmonary and systemic 
circulation, and the local coronary circulation. 
It was demonstrated in Chapter 3 that the local coronary flow characteristics are strongly 
influenced by the global systemic parameters, but not vice versa. It is, therefore, practical to 
separate the model into a global model to represent the system response and to compute the 
parameters at the coronary inlet, and a separate model to analyse the coronary flow with the 
computed inlet boundary condition.  
The idea of using simpler, patient-specific, cardiovascular models as a central component in 
the translation of computational tools to clinical application, driven by the recognition of the 
limitations and general sparsity of routine clinical physiological data that might be available 
for the personalisation process, is gaining traction. An example is the study of Hann et al. [43], 
in which a multi-compartment cardiovascular model was simplified and divided into sub-
systems which were studied independently. Hann described the identification and selection, 
based on sensitivity analysis, of the significant model elements to fit the available data from a 
minimal clinical dataset (although even this, which is based on recordings in the intensive care 
unit, is relatively rich compared with routine clinical data), reducing therefore the parameters 
to be personalised. Another relevant example is the work of Sughimoto et al. [44], in which it 
is shown how the cardiovascular function can be assessed by a cardiovascular model combined 
with clinical data routinely measured, providing an extremely useful tool to the clinicians. 
Schiavazzi et al. [151] developed a similar approach with the sub-model for the heart in patients 
with congenital HLHS (Hypoplastic Left Heart Syndrome) who undergo the Norwood 
procedure to improve the perfusion and the blood oxygenation through surgical intervention 
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[152]. The model consists of the heart model and an RCRCR branch for the systemic and 
pulmonary circulations and the shunt is also included. 
In this thesis, in a first stage, the global cardiovascular model is personalised aiming to obtain 
and reproduce patient-specific outputs during baseline conditions, corresponding to the data 
collected during echocardiography and angiography. In the target application of the study of 
coronary flow changes under the intravenous administration of adenosine, the principal 
relevant output of the global system model is the distribution of the adenosine in all the 
compartments: no measurements of this parameter were made during the clinical process. In 
particular, the concentration in the aortic sinus compartment (SAS) is used, together with 
measured aortic pressure, as the input for the local model of the coronary artery. 
The focus of this chapter is on the personalisation of the global model, with the specific aim of 
estimation of the adenosine distribution during the period of infusion and clearance. In a second 
stage, explained in detail in Chapter 6, the focus moves onto the local system, aiming to 
describe the local response to adenosine correlating the myocardial resistance to the adenosine 
concentration.  Data from 3D simulations of the coronary stenosis together with proximal and 
distal pressure were used to characterize the lesion and to calculate the coronary flow and the 
myocardial resistance. Moreover, the adenosine concentration in the coronary compartment is 
estimated in order to establish a relationship between the myocardial resistance and the 
adenosine distribution. Optimisation processes was employed in both global and local system 
using the respective available data. 
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 CLINICAL DATA: INCONSISTENCY AND 
STRATEGY 
 Clinical data 
Patients with Coronary Artery Disease usually undergo pre-admission appointment, followed 
by echocardiography and finally angiogram. During each of these phases, different patient data 
are measured. 
5.1.1.1 General data 
During the Pre-Admission appointment for their PCI, patients were asked some general 
information, followed by a medical examination. The patient data available from the Pre-
Admission appointment are: 
- Gender, Age and Ethnicity; 
- Height, Weight and Body Mass Index (BMI); 
- Heart rate (HR), Systolic (PSYS) and Diastolic (PDIA) pressure measured with a cuff 
pressure monitor, from which mean arterial pressure (MAP) can estimated (Eq.5.1) [153]; 
𝑀𝐴𝑃 =
𝑃𝑆𝑌𝑆 + 2 ∙ 𝑃𝐷𝐼𝐴
3
 
(Eq.5.1) 
- Medical history with regards of Hypertension, Hyperlipidaemia, Pulmonary hypertension, 
Chronic obstructive pulmonary disease (COPD), Asthma, Atrial fibrillation, Diabetes type 
I, Diabetes type II, myocardial infarction (MI); 
- Smoking status. 
 
5.1.1.2 Echocardiography and Electrocardiography 
Before angiogram, patients usually undergo simultaneously echocardiography and 
electrocardiography. Echocardiography, widely used in diagnosis, is a non-invasive technique 
which produces images of the heart using Doppler ultrasound and provides useful information 
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about the heart and its pathologies, such as cardiomyopathies, heart failure, congenital diseases, 
endocarditis, cardiac valves pathologies, location and extension of damaged tissue from heart 
attack. Electrocardiography is a non-invasive technique to measure heart rate.   
The quantitative data provided by the echo- and electrocardiography are:  
- End-systolic left ventricular volume, ESV;  
- End-diastolic left ventricular volume, EDV;  
- Velocity of blood across the aortic valve, Vao(t);  
- Area of aortic valve, Aao;  
- Heart rate, HR.  
From these measured data, the following are derived:  
- Ejection fraction is calculated from the left ventricular volume measurements (ESV and 
EDV) visualizing 2 chambers and 4 chambers (EF, Eq.5.2);  
- Stroke volume can be calculated from left ventricular volume measurements (ESV and 
EDV) visualizing 2 chambers and 4 chambers (SV2CH, SV4CH - Eq.5.3) and from the 
product between the aortic valve area and the integral of the blood velocity over one 
cardiac cycle (SVLVOT – Eq.5.4);  
- Cardiac output is obtained as the product between SV and HR (CO, Eq.5.5). 
𝐸𝐹2𝐶𝐻/4𝐶𝐻 =
𝐸𝐷𝑉2𝐶𝐻/4𝐶𝐻 − 𝐸𝑆𝑉2𝐶𝐻/4𝐶𝐻
𝐸𝐷𝑉2𝐶𝐻/4𝐶𝐻
 
(Eq.5.2) 
𝑆𝑉2𝐶𝐻 = 𝐸𝐷𝑉2𝐶𝐻 − 𝐸𝑆𝑉2𝐶𝐻       𝑆𝑉4𝐶𝐻 = 𝐸𝐷𝑉4𝐶𝐻 − 𝐸𝑆𝑉4𝐶𝐻       (Eq.5.3) 
𝑆𝑉𝐿𝑉𝑂𝑇 = 𝐴𝑎𝑜 ∙ ∫ 𝑉𝑎𝑜
𝑇
0
 
(Eq.5.4) 
𝐶𝑂 = 𝑆𝑉 ∙ 𝐻𝑅 
(Eq.5.5) 
5.1.1.3 Invasive pressure measurements 
During the angiogram, proximal and distal pressures were measured invasively as described in 
Chapter 4 (Paragraph 4.1.1 Invasive pressure data). The proximal pressure during baseline 
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was cycle averaged using GIMIAS or VIRTUheart (see Paragraph 4.2.1 Average pressure 
signal over a cardiac-cycle) and the length of signal provides the heart rate (HR) during 
angiography, consistent with the pressure curve used for the optimisation. The maximum value 
of the signal represents the systolic pressure (PSYS), while its minimum the diastolic pressure 
(PDIA). MAP can be estimated using the systolic and diastolic pressure (Eq.5.1) or as the real 
mean value of the pressure signal. 
 
  Inconsistency and strategy 
Table 5.1 summarises the available data from each patient, distinguishing between invasive 
and non-invasive data with raw measurements and derived data. 
Table 5.1: Invasive and non-invasive data measured and derived for CAD patients. 
 Non -Invasive Invasive 
 
Pre-
admission 
ECG ECHO 2ch ECHO 4ch DOPPLER Angiogram 
Raw Der. Raw Der. Raw Der. Raw Der. Raw Der. Raw Der. 
Gender             
Ethnicity             
Age             
Height             
Weight             
BMI             
Comorbidities             
HR             
PSYS             
PDIA             
MAP             
CO             
SV             
ESV             
EDV             
EF             
Pa(t)             
Aao             
Vao(t)             
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There is some redundancy in the fields because same parameters were measured with different 
techniques and in different moments. Of course it is impossible for a model to reproduce the 
measured outputs if they are not mutually consistent, which will often, or always, be the case 
when they are measured separately in clinical processes. This emphasises the need for careful 
design of the data protocol to support a modelling study and is discussed further at the end of 
the current chapter. In the following pages, the method employed to adjust the data is described 
and discussed.  
5.1.2.1 Expected physiological ranges of echocardiographic data 
Typical physiological ranges for the clinically measured parameters were derived from the 
literature [154-159]. A summary of the reported ranges of cardiac output, stroke volume, end-
systolic volume, end-diastolic volume and heart rate data at baseline in health and disease (MI, 
Hypertension, CAD, angina) is presented in table 5.2.  
5.1.2.2 Strategy 
Invasive data of aortic pressure are the richest information provided in this work and provides 
a cycle-averaged pressure signal in time. Heart rate, systolic and diastolic pressure can be 
recovered from the trace respectively from the length of the cycle and the maximum and 
minimum pressure. The mean arterial pressure (MAP) could be recovered from average of the 
pressure signal but, consistent with clinical practice when only cuff pressures are available, it 
is computed using Eq.5.1. 
Therefore, the measurements of these data during pre-admission and ECG were not considered. 
As mentioned previously, the stroke volume is estimated in different ways during the 
echocardiography and the results are generally inconsistent, because of the limitations of the 
echocardiogram itself. 
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Table 5.2: Literature data for cardiac output (CO), stroke volume (SV), heart rate (HR), end-systolic volume 
(ESV) and end-diastolic volume (EDV). 
Parameter Values Source 
CO 
[l/min] 
1.9 - 21 with Doppler mitral method 
1.2 - 9.6 with Doppler EDV method           healthy/pathologic 
2.4 - 9.5 with thermodilution method  
F.Lewis et al., 1984 [157] 
6.44 ± 1.26 normal patients 
6.98 ± 0.95 patients with angina 
5.71 ± 153 patients with previous MI 
R.Mcdonough et al.,1974 
[158] 
6.0 ±1.3 for healthy patients 
5.4 ± 1.2 Significant single vessel CAD 
5.7 ± 1.5 Significant multiple vessel CAD 
K.Reryich et al.,1978 [159] 
6.9 ± 1.4 for healthy patients 
5.3 ± 1.8 for patients with heart failure 
K.Laskey et al., 1990 [156] 
SV 
[ml] 
17 - 190 with Doppler mitral method 
13 - 171 with Doppler EDV method         healthy/pathologic 
24 - 89 with thermodilution method 
F.Lewis et al., 1984 [157] 
92 ± 12 normal patients 
109 ± 21 patients with angina 
79 ± 31 patients with previous MI 
R.Mcdonough et al.,1974 
[158] 
76 ± 20 for healthy patients 
63 ± 12 Significant single vessel CAD 
76 ± 18 Significant multiple vessel CAD 
K.Reryich et al.,1978 [159] 
99 ± 12 for healthy patients 
60 ± 21 for patients with heart failure 
K.Laskey et al., 1990 [156] 
37-112 male and females age 61-70 P.A.Cain et al., 2009 [154] 
92 ± 22 for normotensives 
78 ± 14 for hypertensives 
A.Cohen-Solal et al., 1994 
[155] 
HR 
[beats/min] 
69 ± 14.8 normal patients 
65 ± 6.3 patients with angina 
76 ± 16.3 patients with previous MI 
R.Mcdonough et al.,1974 
[158] 
81 ± 13 for healthy patients 
87 ± 13 Significant single vessel CAD 
75 ± 15 Significant multiple vessel CAD 
K.Reryich et al.,1978 [159] 
75 ± 10 for normotensives 
85 ± 13 for hypertensives 
A.Cohen-Solal et al., 1994 
[155] 
73 ± 12 for healthy patients 
95 ± 15 for patients with heart failure 
K.Laskey et al., 1990 [156] 
EDV 
[ml] 
116 ± 31 for healthy patients 
93 ± 20 Significant single vessel CAD 
138 ± 62 Significant multiple vessel CAD 
K.Reryich et al.,1978 [159] 
72-185 male and females age 61-70 P.A.Cain et al., 2009 [154] 
ESV 
[ml] 
40 ± 15 for healthy patients 
30 ± 15 Significant single vessel CAD 
62 ± 50 Significant multiple vessel CAD 
K.Reryich et al.,1978 [159] 
22 - 88 male and females age 61-70 P.A.Cain et al., 2009 [154] 
 
On examination of the study data, it was observed that the calculation of the HR from the CO 
measured with Doppler, where available, and the SV yielded values within the expected 
physiological range based on the SVLVOT from left ventricular outflow tract measurements, but 
not based on the SV2CH/4CH chamber volume measurements (Table 5.3). This suggested that 
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SVLVOT is the most reliable between the two and it was selected for the optimisation. This leads 
to the inability to consider the values of ESV and EDV as they were measured in the echo, 
considering the average between the 2 chamber and 4 chamber views. 
The approach used to resolve this inconsistency and enable use of all the echo parameters as 
target in the optimisation was to consider the data of SVLVOT from the echo, the heart rate from 
the pressure signal at baseline (HRSIG) and the ejection fraction (EF), to estimate the cardiac 
output (COopt) (Eq.5.6), the end systolic and diastolic left ventricle volumes (ESVopt, EDVopt) 
(Eq.5.7, Eq.5.8). 
𝐶𝑂𝑜𝑝𝑡 = 𝑆𝑉𝐿𝑉𝑂𝑇  ∗ 𝐻𝑅𝑆𝐼𝐺 (Eq.5.6) 
𝐸𝐷𝑉𝑜𝑝𝑡 =
𝑆𝑉𝐿𝑉𝑂𝑇
𝐸𝐹
 (Eq.5.7) 
𝐸𝑆𝑉𝑜𝑝𝑡 = 𝐸𝐷𝑉𝑜𝑝𝑡 − 𝑆𝑉𝐿𝑉𝑂𝑇 (Eq.5.8) 
Table 5.3: Comparison between the heart rate (HR) obtained with the SV2CH/4CH and with SVLVOT and the cardiac 
output from echocardiography. 
Case HR =COecho/SV2CH/4CH HR =COecho/SVLVOT Case HR =COecho/SV2CH/4CH HR =COecho/SVLVOT 
1 57.63 56.40 15 192.64 73.59 
2 133.72 63.64 18 89.80 60.11 
3 79.93 74.24 20 51.82 74.60 
4 133.33 83.77 23 217.39 67.63 
5 135.64 95.15 24 112.00 49.47 
6 178.93 61.62 25 114.50 64.79 
7 46.44 61.64 26 140.66 61.19 
8 139.24 74.73 27 129.27 60.43 
9 162.16 52.33 28 141.32 67.99 
10 56.54 53.46 29 101.05 77.33 
11 79.69 59.40 30 148.34 69.38 
12 67.74 52.56 31 125.23 59.64 
13 116.33 61.69 32 342.39 82.25 
14 110.34 43.96 33 121.76 77.69 
From the overall study cohort of 100 patients with coronary artery disease, a sub-cohort of 37 
patients with a complete dataset of (pseudonymised) general clinical data, including 
echocardiographic data and including pressure signals during angiography, were identified. 
The selection criteria were: 
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- echocardiography performed (many patients did not undergo echocardiography before 
angiogram for reason of time and limited number of personnel in the ward); 
- availability of measured stroke volume (SVLVTOT) based on flow through aortic valve, 
considered the most reliable measure of this parameter, and ejection fraction; 
- pressure data were properly collected during angiography. 
Table 5.4 briefly describes this sub-cohort in terms of demographic data, comorbidities and 
smoking status (as an identified risk factor). These data were not used for the model 
personalisation process, but are used later to seek associations between the clinical phenotype 
and the measured response to adenosine. 
Table 5.4: Demographic data, comorbidities and risk factors in the sub-cohort (37 patients). 
Demographic information is gender, age, BMI (Body Mass Index). Comorbidities are: type II diabetes, 
hyperlipidaemia, Peripheral Vascular Disease (PVD), Hypertension, Chronic Obstructive Pulmonary Disease 
(COPD), and previous myocardial infarction (MI). Risk factor is smoking status. 
Patient demographic Num% - mean (SD) 
Male 73% 
Age (years) 65 (SD 11) 
BMI 29.26 (SD 4.9) 
Hypertension 62.1 % 
PVD 8.1 % 
Previous MI 51.3 % 
Type II diabetes 8.1 % 
Hyperlipidaemia 67.5 % 
COPD 5.4 % 
Smoking status:  Never 24 % 
 Ex-smoker 64.8 % 
Current 8.1 % 
Raw data used for the parameter personalisation of the cardiovascular model for each 
individual in the sub-cohort included: 
- gender, height and weight measured during the pre-angiogram medical examination; 
- stroke volume estimated with Doppler (SVLVTOT); 
- average ejection fraction measured during echocardiography visualising 2 and 4 chambers; 
- heart rate, systolic pressure and diastolic pressure and mean arterial pressure calculated 
from the cycle-averaged proximal pressure signal. 
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Derived data from the listed above are: cardiac output, end diastolic left ventricle volume and 
end systolic left ventricle volume. Table 5.5 shows in red which data were chosen as input for 
the optimisation. Table 5.6 reports all the data and summarises them with the respective mean, 
median, standard deviation, range, minimum and maximum of each parameter. 
The optimisation was performed for all the 37 patients and the obtained results were compared 
with the original data, used as target. The simulations were run considering the baseline 
proximal pressure as target. Optimising the hyperaemic condition requires another type of cost 
function, but there were not measurements available during the hyperaemic state, except of 
pressures. It is not possible therefore to use the echocardiographic data which were measured 
in absence of adenosine effect. 
Table 5.5: Clinical data used for the optimisation process in red. 
 Non -Invasive Invasive 
 
Pre-
admission 
ECG ECHO 2ch ECHO 4ch DOPPLER Angiogram 
Raw Der. Raw Der. Raw Der. Raw Der. Raw Der. Raw Der. 
Gender             
Ethnicity             
Age             
Height             
Weight             
BMI             
Comorbidities             
HR             
PSYS             
PDIA             
MAP             
CO             
SV             
ESV             
EDV             
EF             
Pa(t)             
Aao             
Vao(t)             
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Table 5.6: Optimisation input data of 37 patients in the sub cohort. 
Columns report: gender, height (cm), weight (kg); systolic pressure, diastolic pressure and MAP (mmHg);  heart 
rate (HR- beats/min); stroke volume (SVLVOT -ml); ejection fraction (EF-%); cardiac output (COopt-l/min), end 
diastolic left ventricle volume (EDVopt-ml) and end systolic left ventricle volume (ESVopt-ml).  
 Case Gen. Height Weight  P_sys P_dia MAP HRsign SVLVOT EF CO  EDV  ESV  
1 M 179 88.3 158 64 95.32 52.9 73.4 70 3.88 104.86 31.46 
2 F 159 69.1 139.8 71.3 94.15 57.7 55 38.2 3.17 143.98 88.98 
3 M 179 103 111.2 72.4 85.34 64.8 62.1 52.5 4.02 118.29 56.19 
4 M 169 82.3 122.4 73 89.47 81.63 57.3 35.8 4.68 160.06 102.8 
5 M 173 68.7 150.9 84.7 106.8 90.6 53.6 71.5 4.86 74.97 21.37 
6 F 160 87.8 151.1 75.4 100.6 68.8 81.3 56.4 5.59 144.15 62.85 
7 F 158 89 177.3 71.43 106.7 61.2 75 53.45 4.59 140.32 65.32 
8 M 175 103 112.1 52.7 72.52 64.1 39.1 57.7 2.51 67.76 28.66 
9 M 170 81.2 121.2 65.3 83.94 60.5 73.6 29.5 4.45 249.49 175.9 
10 M 179 84.1 126.6 52.1 76.94 49.6 103.2 59.6 5.12 173.15 69.95 
11 M 176 89.6 109.7 60 76.57 71.3 88.1 61.6 6.28 143.02 54.92 
12 M 168 92.6 98.9 56.5 70.67 63 122.9 71 7.74 173.1 50.2 
13 M 185 107 104.5 57.9 73.47 62.8 72.3 53.3 4.54 135.65 63.35 
14 M 170 80.8 158.7 68.2 98.37 59.4 92.4 46.6 5.49 198.28 105.9 
15 M 182 83 151.8 76 101.2 49.6 109.2 44.9 5.42 243.21 134.0 
16 M 183.1 113.1 108.7 64.11 78.97 56.06 110.2 65.8 6.18 167.48 57.28 
17 F 152 57.9 102.1 70.94 81.32 77.62 60.6 52.75 4.7 114.88 54.28 
18 M 190 140 122.5 77.5 92.51 67.7 110.2 55 7.46 200.36 90.16 
19 M 175 75 120.1 70.7 87.22 62.03 73.3 58.4 4.55 125.51 52.21 
20 M 166 83.1 140 60.4 86.92 66.1 73.2 49.3 4.84 148.48 75.28 
21 M 180 82 124.1 62.18 82.79 65.72 85.9 68.2 5.65 125.95 40.05 
22 F 162 59 151.8 68.24 96.11 61.5 53.1 47.9 3.27 110.86 57.76 
23 M 168 126 114.1 69.5 84.35 83.2 49.6 70.5 4.13 70.35 20.75 
24 F 157 72.1 184 58 100.0 61.9 103.5 61.7 6.41 167.75 64.25 
25 F 156 68.2 151.8 76.6 101.7 74.5 56.6 56 4.22 101.07 44.47 
26 F 152 62.2 161.4 64 96.46 80.4 46.3 58.8 3.72 78.74 32.44 
27 M 183 78 125.3 63.5 84.08 73.7 119.3 63.8 8.79 186.99 67.69 
28 M 182 91.8 174.1 79.7 111.2 51.8 87.7 42.7 4.54 205.39 117.69 
29 M 183 96.1 126.4 72.3 90.37 67.8 116.2 55.9 7.88 207.87 91.67 
30 F 168 92.2 122.9 69.1 87.01 75.1 75 67.4 5.63 111.28 36.28 
31 M 187 92 106 58.5 74.35 75.1 83.6 57.2 6.28 146.15 62.55 
32 M 183 110 116.7 64.4 81.85 54.4 115.7 48 6.29 241.04 125.34 
33 M 161 55.9 98.1 70.6 79.75 80 76.6 42.8 6.13 178.97 102.37 
34 M 172 109 157.5 53.7 88.32 73.4 60.5 54.9 4.44 110.2 49.7 
35 M 168 73.6 109.18 65.37 79.98 65.13 44.1 51.6 2.87 85.47 41.37 
36 F 155 68.9 148.37 73.61 98.54 63.5 60.6 54 3.85 112.22 51.62 
37 M 185 89.4 90.87 65.46 73.93 80.68 56.5 25.7 4.56 219.84 163.34 
Mean - 171.6 86.6 131.1 67.0 88.37 66.9 77.8 54.3 5.1 148.3 70.5 
Median - 172.0 84.1 124.0 68.2 86.97 65.1 73.6 55.0 4.7 144.0 62.6 
Std.D - 10.8 18.6 24.5 7.8 10.6 10.1 23.8 11.1 1.4 49.8 37.1 
Range - 38.0 84.1 93.1 32.6 40.54 41.0 83.8 45.8 6.3 181.7 155.1 
Min - 152.0 55.9 90.9 52.1 70.67 49.6 39.1 25.7 2.5 67.8 20.8 
Max - 190.0 140.0 184.0 84.7 111.2 90.6 122.9 71.5 8.8 249.5 175.9 
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 GLOBAL TUNING OF CARDIOVASCULAR MODEL 
Despite its apparent simplicity and limitations, the cardiovascular model described in Chapter 
2 and in Chapter 3 contains a high number of parameters: 
- 54 parameters are related to the hemodynamic part, including the initial blood volumes, 
resistances, compliances, inertances, cardiac elastances, valvular coefficients; 
- 45 parameters are related to the barocontrol system. 
It is evident that the development of a personalisation process for a model with so many 
parameters is not trivial. It is likely to be unstable numerically, especially given the sparsity of 
relevant clinical physiological information.  
In this chapter a subset of the parameters of the basic systems physiology model, excluding 
both chemocontrol and barocontrol, is personalised to each individual in the sub-cohort using 
the sparse clinical data available. The justification for omitting the barocontrol is that two of 
the key parameters that are governed by the barocontrol mechanism, heart rate and aortic 
pressure, are directly measured during the period of administration of the adenosine. 
The tuning of the global model parameters aims to reproduce the echocardiographic data and 
the invasive proximal pressure data during baseline. The first step is to select the 
personalisation inputs and outputs and the second step is the optimisation process. 
 
 Selection of inputs and outputs for parameter personalisation  
The non-barocontrolled model is provided with inputs and produces outputs which can be 
classified as raw and derived. The parameters personalisation considers some of the input 
model to be defined, and therefore to be classified as unknown-outputs, and some of the model 
outputs to be known for each patient and therefore classified as input of the personalisation. 
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Table 5.7 indicates the inputs and outputs (raw and derived) from the non-barocontrol model 
and those for the parameter personalisation process.  
The heart rate is an input parameter for both the model and the personalisation. The parameter 
personalisation process used 9 inputs which were model-outputs. These were: ejection fraction 
(EF), stroke volume (SV), from which cardiac output (CO), left ventricle end-systolic (ESV) 
and end diastolic (EDV) blood volumes were derived. An additional input was the invasive 
measurement of the aortic pressure signal over a cardiac cycle (Psat(t)), from which aortic 
systolic (PSYS) and diastolic (PDIA) pressures and mean arterial pressure (MAP) were derived.  
The pressure signal provides a rich set of information and potentially is possible to personalise 
a number of parameters equal to the number of samples. However, in truth, it is not known how 
the model parameters influence the single sampling points of the signal and how they are 
related between themselves. Moreover, the model is a non-linear system and this causes an 
even higher complexity of the definition of independent parameters to define the outputs. 
The outputs of the parameter personalisation were selected from the model inputs with 
sensitivity value (NVs, Chapter 2- Figure 2.18) above an arbitrarily selected threshold of 0.1 
with regards of the inputs chosen for the parameter personalisation: heart period (T), passive 
(ELVmin) and active (ELVmax) left ventricle elastances, systemic (Rscp) and pulmonary (Rpcp) 
capillary resistances, systemic arterial capacitance (Csat), initial blood volumes in left atrium 
(Vlai), left ventricle (Vlvi), systemic vein (Vsvni) and unstressed systemic venous volume 
(Unveini).   
The threshold of 0.1 has selected based on the values of sensitivities obtained with the 
sensitivity analysis, in order to not select too few or too many variables for the personalisation 
process, according to the available clinical data. 
Furthermore, a second selection was done to reject some of these input data for different 
reasons: 
Chapter 5 – Personalisation of parameters in the cardiovascular model 
 
163 
  
- the initial blood volumes in systemic vein (Vsvni), left atrium (Vlai), left ventricle (Vlvi) and 
unstressed systemic venous volume (Unveini) were already estimated as proportion of the 
total blood volume as shown later in Paragraph 5.2.2.3.1 Preliminary tuning and therefore 
they cannot be changed to keep constant to total blood volume; 
- the heart period T was known from the patient data; 
In conclusion, the optimisation process aimed to personalise ELVmax, ELVmin, Rscp, Csat and 
Rpcp at baseline condition. This is in agreement with published data on sensitivity analysis of 
cardiovascular models [125, 160-163]. These five parameters are indicated in red in the outputs 
of the parameter personalisation of table 5.7. 
Table 5.7: List of inputs and outputs (raw and derived) of the non-barocontrolled model and the parameter 
personalisation. 
In red are indicated the model input parameters with sensitivity value above 0.1 (see Figure 2.18 about 
sensitivity analysis results). From these parameters only 5 were selected to be output for the parameters 
personalisation: ELVmax, ELVmin, Rpcp, Rscp, Csat. In blue are indicated the clinical data which are model outputs 
and were used as input in the parameter personalisation. 
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 Optimisation process 
The second step of the global personalisation, and the most challenging, is the optimisation 
process. It consists, in turn, of two main phases: the definition of an objective function and the 
selection of a suitable algorithm to solve the problem. 
5.2.2.1 Definition of the objective function 
The objective function is used to evaluate the difference between the model outputs (m) and 
the clinical data (t). In this project the objective function had to take in account the 9 patient-
specific parameter personalisation inputs: stroke volume (SV), ejection fraction (EF), cardiac 
output (CO), the left-ventricle end systolic blood volume (ESV) and the left ventricle end 
diastolic blood volume (EDV), measured aortic pressure (Pa (t)) during baseline over one 
cardiac cycle and the correspondent systolic pressure (PSYS), diastolic pressure (PDIA) and mean 
arterial pressure (MAP). Among these outputs, there were some dependent ones, which were 
obtained from the others: 
- systolic (PSYS) and diastolic (PDIA) pressures were calculated as the maximum and the 
minimum pressure of the signal of aortic pressure over one cardiac cycle, obtained as 
described in paragraph 4.2 Invasive pressure data processing; 
- MAP, estimated as clinical definition (Eq.5.1). 
- CO, ESV and EDV are function of SV, EF and HR as described in Eq.5.6, Eq.5.7, and 
Eq.5.8.  
The objective function, 𝑓𝑐, was defined as the sum of the normalized root mean square errors 
for each output as shown in Eq.5.9: 
𝑓𝑐 = (
𝐶𝑂𝑚 − 𝐶𝑂𝑡  
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(Eq.5.9) 
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where the subscripts m and t indicate the origin of the data respectively from the model outputs 
and from the clinical data. 
The aortic pressure in a cardiac cycle both from the model and the target were considered in 
terms of fraction of cardiac cycle, where N is the number of fraction-step of the pressure signal. 
This will be useful in a second step when aiming to introduce the barocontrol system, because, 
as observed in the sensitivity analysis, changing some parameters can cause also a change in 
the heart period and it will be difficult to compare the signals of different length.  
Moreover, an interpolation was used to up sample or down sample the output from the model 
and have the same length of the patient data, again to compare them. 
The cost function described in Eq.5.9 implicitly contains weights due the relationships between 
the dependent and independent parameters. 
5.2.2.2 Searching algorithm 
MATLAB Optimisation Toolbox provides a large number of options and solvers for 
optimisation problems considering constraints, number of variables, type of objective function, 
linearity of the problem. These functions require an initial state, which is not easy to define for 
all the parameters. In case of a solution space with multiple local minimums, the solution is 
obviously dependent on the initial state. 
There are other algorithms that do not require an initial state and they will explore the solution 
space in order to find the minimum. Even so, these algorithms can produce different solution 
for the same problem. Examples are the Genetic Algorithm and the Multistart. 
Another alternative to these algorithms is the Unscented Kalman Filter (UKF), which belongs 
to the family of the Kalman Filters. These are used to estimate unknown variables using 
measurements data over the time for non-linear systems. 
In a published study from Lungu et al. [164], a combination of algorithms were used in order 
to overcome the limitations of each of them, with very positive results. In this study a similar 
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approach was, therefore, applied, using firstly the genetic algorithm to provide an initial guess 
to the optimisation solver selected. 
5.2.2.2.1 Genetic algorithm 
The genetic algorithm (GA) is a method for solving optimisation problems using the concept 
of natural selection: a population of individual solutions is generated at each step and the 
algorithm selects the best to be parents of the next generations using concepts of selection, 
mutation and crossover. In this way over generations, the solution evolves toward the optimal. 
GA creates randomly an initial population. For each step the fitness value for each individual 
is calculated and the best are selected as parents for the next generation using mutation and 
crossover factors to combine them. GA requires as input the objective function (described in 
Paragraph 5.2.2.1 Definition of the objective function) and the number of variables involved in 
the process. It is possible to define also lower and upper boundaries in order to limit the 
solution space within physiological ranges and therefore the simulation time.  Other options 
can be defined in the GA: 
- the function tolerance (TolFun) equal to 10-6 by default; 
- the population size (PopulationSize) set to 5; 
- the number of generations (Generations) set to 20; 
- the crossover factor (0.8 by default); 
The advantage of the GA is that it is not necessary to supply an initial guess which can be 
misleading in the condition of multiple local minimum. 
A limitation of the use of GA is related with the solutions, which can be different if the 
simulation runs multiple times, especially in cases of flat solution space. For this reason, the 
solution of GA can be refined using it as initial guess for a specific solver that aims to identify 
the minimum. 
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5.2.2.2.2 “fminsearch” and “fminsearchbnd” 
MATLAB provides a number of implemented functions designated to minimize problems. One 
of those is “fminsearch”, used for unconstrained non-linear optimisation with multiple 
parameters. The method used by this specific function is derivative-free and uses the simplex 
search method of Nelder-Mead, which explores the solution space around the provided initial 
guess, x0. Comparing the fitness values between the different points individuated in the space, 
the algorithm investigates around the initial guess using different approaches: reflection, 
expansion, contraction outside or inside, or shrink. 
The solution of GA was used as initial guess for “fminsearch” and the maximum number of 
iterations was set to 100. 
“fminsearchbnd” is a modified version of “fminsearch” which includes the possibility to 
define the boundaries for the parameters to tune and produce a solution within the physiological 
ranges. 
5.2.2.3 Simulation details 
Each simulation produced the results for 30 s, necessary time for the model to reach stability 
from the initial condition provided, and the last complete cardiac cycle was used to compare 
with the target output values. 
The lower and upper boundaries (LB, UB) for the variables were defined considering values 
from studies published in the literature [155, 156, 165, 166] and are shown in table 5.8. 
Table 5.8: Lower and upper boundaries used for the variables. 
ELV: ml/mmHg; C: ml/mmHg; R: mmHg s/ml. 
Variable LB UB 
ELVMAX 1 6 
ELVMIN 0.01 0.99 
CSAT 0.05 2 
RSCP 0.1 2.3 
RPCP 0.05 1 
Chapter 5 – Personalisation of parameters in the cardiovascular model 
168 
 
5.2.2.3.1 Preliminary tuning 
Among the general patient data (Paragraph 5.1.1.1 General data), gender, weight (Wt in kg) 
and height (Ht in m) were used to calculate the total blood volume (BV) of each patient using 
Nadler formula [99] (Eq.5.10, Eq.5.11): 
𝐵𝑉𝑀𝐴𝐿𝐸  (𝑙) = 0.3669 ∙ 𝐻𝑡
3(𝑚3) + 0.03219 ∙ 𝑊𝑡 (𝑘𝑔) + 0.6041 (Eq.5.10) 
𝐵𝑉𝐹𝐸𝑀𝐴𝐿𝐸  (𝑙) = 0.351 ∙ 𝐻𝑡
3(𝑚3) + 0.03308 ∙ 𝑊𝑡 (𝑘𝑔) + 0.1833 (Eq.5.11) 
The total blood volume is used to define the distribution of blood volume, V, in all the 
compartments (Eq.5.12) and the capacitance values, C, (Eq.5.13) using the proportions of the 
generic model: 
𝑉𝑖,𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑉𝑡𝑜𝑡,𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 ∙ 𝑉𝑖,𝑔𝑒𝑛𝑒𝑟𝑖𝑐
𝑉𝑡𝑜𝑡,𝑔𝑒𝑛𝑒𝑟𝑖𝑐
    𝑓𝑜𝑟 𝑖 = 𝑎𝑙𝑙 𝑐𝑜𝑚𝑝𝑎𝑟𝑡𝑚𝑒𝑛𝑡𝑠 (Eq.5.12) 
𝐶𝑖,𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑉𝑡𝑜𝑡,𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 ∙ 𝐶𝑖,𝑔𝑒𝑛𝑒𝑟𝑖𝑐
𝑉𝑡𝑜𝑡,𝑔𝑒𝑛𝑒𝑟𝑖𝑐
   𝑓𝑜𝑟 𝑖 = 𝑆𝐴𝑆, 𝑆𝑉𝑁, 𝑃𝐴𝑆, 𝑃𝐴𝑇, 𝑃𝑉𝑁  (Eq.5.13) 
where the subscripts i,specific and i,generic indicate the value of blood volume or capacitance 
in each compartment respectively for a specific patient and for a generic individual, while the 
subscripts tot,specific and tot,generic are referred to the total volume respectively for the 
specific patient and for the generic individual. 
The cardiac output (CO) was used to define the total systemic resistance, in order to redistribute 
it using the same proportions of the generic model. The total systemic resistance in the generic 
model, 𝑅𝑠𝑦𝑠,𝑡𝑜𝑡,𝐺, was previously calculated as the ratio between the mean arterial pressure 
(MAP) and the cardiac output (CO) (Eq.5.14). 
𝑅𝑠𝑦𝑠,𝑡𝑜𝑡,𝐺 =
𝑀𝐴𝑃𝐺
𝐶𝑂𝐺
=
𝑃𝑆𝑌𝑆,𝐺 + 2 ∙ 𝑃𝐷𝐼𝐴,𝐺
3 ∙ 𝐶𝑂𝐺
=
107.6 + 2 ∙ 74 𝑚𝑚𝐻𝑔
3 ∙ 4.62 𝑙/𝑚𝑖𝑛
= 1.107 𝑚𝑚𝐻𝑔
𝑠
𝑚𝑙
 
(Eq.5.14) 
Using the same equation, the total systemic resistance is calculated for each patient (Eq.5.15) 
and then redistributed among the systemic compartments (Eq.5.16): 
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  𝑅𝑠𝑦𝑠,𝑡𝑜𝑡,𝑠𝑝 =
𝑀𝐴𝑃𝑠𝑝
𝐶𝑂𝑠𝑝
=
𝑃𝑆𝑌𝑆,𝑠𝑝+2∙𝑃𝐷𝐼𝐴,𝑠𝑝
3∙𝐶𝑂𝑠𝑝
 (Eq.5.15) 
𝑅𝑖,𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 =
𝑅𝑡𝑜𝑡,𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 ∙ 𝑅𝑖,𝑔𝑒𝑛𝑒𝑟𝑖𝑐
𝑅𝑡𝑜𝑡,𝑔𝑒𝑛𝑒𝑟𝑖𝑐
   𝑓𝑜𝑟 𝑖 = 𝑆𝐴𝑆, 𝑆𝐴𝑇, 𝑆𝐴𝑅, 𝑆𝑉𝑁 (Eq.5.16) 
The mean arterial pressure, MAP, obtained as a function of the systolic and diastolic pressures 
(Eq.5.1), is an estimation of the real mean of the pressure signal. This might generate an 
underestimation of the overall systemic resistance. On the other hand, systolic and diastolic 
pressures can be non-invasively measured and therefore these definition of MAP increases the 
number of patients on which the personalisation can be applied, without an invasive pressure 
measurement.  
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 RESULTS AND DISCUSSION 
 Ideal patient: validation of the optimisation process 
An ideal patient (male, 180 cm, 80 kg) was considered to validate and test the optimisation 
with the forward problem, knowing already all the parameters value and the outputs (Chapter 
2, Paragraph 2.1.1 Haemodynamic system). 
The set of input parameters for the optimisation (EF, SV, CO, HR, EDV, ESV, PA(t), PSYS, 
PDIA, MAP) were calculated as result of the original values of all the input parameters of the 
model. 
Results of the fitness value of GA and fminsearchbnd are reported graphically in figure 5.1. 
The fitness value obtained with GA reaches its minimum at 0.82 and with fminsearchbnd solver 
it decreases at 0.099. Comparing the pressure curve over a cardiac cycle after the stabilization 
of the model, it is observed that the solution of fminsearchbnd is closer to the original one 
(Figure 5.2).  
Table 5.9 reports the comparison between the model inputs and outputs against the optimisation 
results of inputs and outputs. 
 
Figure 5.1: Results of the optimisation used for the validation on the ideal patient. 
Left) Genetic Algorithm fitness values. Right) “fminsearchbnd” fitness values. 
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Figure 5.2: Comparison between the original aortic pressure of the ideal patient over one cardiac cycle and 
the results obtained with GA and then refined with fminsearchbnd.  
The simulation lasts about 3.5 hours. 
Table 5.9: Original values of tuned and target parameters for the ideal patient model were compared with the 
solution of the optimisation and the error in % was reported. 
Parameters Original value Optimized value Error % 
RPCP 0.25 [mmHg s/ml] 0.1 [mmHg s/ml] -59% 
RSCP 0.52 [mmHg s/ml] 0.57 [mmHg s/ml] 9.9% 
CSAT 1.6  [ml/mmHg] 1.6 [ml/mmHg] 0% 
ELVMAX 2.5 [ml/mmHg] 2.5 [ml/mmHg] 0% 
ELVMIN 0.1 [ml/mmHg] 0.13 [ml/mmHg] 30% 
CO 4.62 [l/min] 4.6 [l/min] 0.51% 
SV 71.13 [ml] 70.77 [ml] 0.51% 
EF 60% 60% 0% 
PSYS 107.6 [mmHg] 107.4 [mmHg] -0.18% 
PDIA 74 [mmHg] 74.1 [mmHg] 0.12% 
MAP 85.2 [mmHg] 85.3 [mmHg] 0.12% 
HR 65 [beats/min] 65 [beats/min] 0% 
ESV 47 [ml] 47 [ml] 0% 
EDV 118.15 [ml] 117.73 [ml] -0.35% 
Figure 5.2 suggests that the number of generations and populations of GA are small, and 
therefore it cannot analyse in detail the solution space. A simulation with 50 populations and 
1000 generation was run in order to prove that the GA would find a closest solution when the 
solution space is better explored. Figure 5.3 shows the comparison between the results with 
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‘original’ GA (5 populations - 10 generations) and with a ‘wider’ GA (50 populations - 1000 
generations). As expected, the solution with higher number of population and generation 
provided the GA solution very close to the original pressure curve. Despite the accurate 
exploration of the solution space, the simulation time increases about 5.5 times. The 
optimisation with the ‘original’ GA lasted about 3.5 hours, while the use of ‘wider’ GA rose 
the simulation time to 19.5 hours. 
‘Original’  GA     (3.5h) ‘Wider’  GA      (19.5h) 
 
Figure 5.3: Comparison of GA solutions obtained with different number of populations and generations. 
 Left) Optimisation results with ‘original’ GA (5 populations, 20 generations); Right) Optimisation results with 
‘wider’ GA (50 populations, 1000 generations). 
In conclusion, from the results it can be seen that the optimisation process provides a solution 
close enough to the original one for the ideal patient, with a maximum error of the tuned 
parameters of -59% regarding the pulmonary capillary resistance, 30% for the ELVmin and 
about 10% for the Rscp, while for the target parameters the errors are all close to 0 (Table 5.9). 
The high error for RPCP is due to its relatively low sensitivity. In figure 2.18 in Chapter 2, its 
NV values for all the output parameters were reported and they were smaller than the other 4 
parameters. A few simulations were run with different value of RPCP to verify how influent it 
is on the output parameters and results are shown in table 5.10. 
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Table 5.10: % error measured for each output (CO, SV, EF, PSYS, PDIA, ESV, and EDV) whit different values of 
RPCP. 
RPCP 
[mmHg s/ml] 
CO SV EF PSYS PDIA ESV EDV 
0.06 -1.30% -1.30% 0.04% -1.45% -1.71% -1.39% -1.33% 
0.10 0.48% 0.48% 0.16% 0.19% -0.05% 0.09% 0.32% 
0.15 2.63% 2.63% 0.31% 2.16% 1.74% 1.88% 2.33% 
0.20 3.98% 4.69% 0.46% 4.01% 3.56% 3.60% 4.26% 
0.40 -0.11% 12.12% 1.04% 10.83% 10.17% 9.80% 11.19% 
The high error for the ELVmin is contradictory with the sensitivity results obtained in chapter 
2. This parameter resulted in a high sensitivity with the regards of the cardiac output and stroke 
volume and, yet, despite the value 30% higher of what expected, our input data were recovered, 
suggesting that CO and SV were not sensitive to ELVmin. An analysis more detailed of the 
sensitivity results of chapter 2 showed that for values above the initial value of ELVmin the 
sensitivity for CO and SV was lower, while for values below it, the sensitivity was high. 
Therefore, the average reported in the results show a high sensitivity for this parameter.  
With regards of the systemic capillary resistance, the error of 9.9% between the optimisation 
results and the original model is due by the underestimation of the total resistances and 
consequently of the systemic resistances defined as a proportion of the total resistance as 
described in the paragraph 5.2.2.3.1 Preliminary tuning.  The calculation of the total systemic 
resistance as in Eq.5.15 and Eq.5.16 considers null the venous pressure. In addition, the mean 
arterial pressure calculated as in Eq.5.1 is slightly different from the mean value of the pressure 
signal. 
 
  Real patients’ cases 
The parameter personalisation was then applied to the real patient data, always considering a 
non-controlled cardiovascular system and the manipulated clinical data for consistency. 
The mean fitness value was 0.16 (range: 0.11 - 0.23). Table 5.11 shows the comparison of the 
model results with the target values in terms of mean, maximum, minimum, median and 
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standard deviation. Figure 5.4 shows the distribution of the error for each parameter with a 
Box-and-Whisker plot. The highest mean errors of 2.68% and 1.23 % were obtained 
respectively by the diastolic pressure (PDIA) and the systolic pressure (PSYS). The reason of 
some relative high errors in this cohort of 37 patients’ simulation for some outputs might be 
due to the range of the boundaries conditions imposed for all patients. Some parameters values 
resulted too close to the boundaries extremes, indicating that it was probably necessary a wider 
range of solutions to explore. To define a wider solution space for each variable it is necessary 
a study of the relative uncertainty. 
Table 5.12 reports the results of the personalised parameters for each patient obtained with the 
optimisation process. As can be observed, boundaries ranges for some patients were already 
modified considering the poor result with the previous ones. In blue are highlighted the values 
obtained with wider boundaries for some parameters. In red are highlighted those which might 
need to use wider boundaries to improve the tuning reducing the errors. For the RPCP, its small 
influence compared to the other parameters was also demonstrated in the ideal patient model 
and, therefore, it might not change the results or the errors were already small. 
As an example, figure 5.5 shows the comparison of pressure signal over one cardiac cycle 
obtained for patient 9 with the GA and the fminsearchbnd. 
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Table 5.11: Results of parameter personalisation using consistent data. 
Mean, minimum, maximum, median and standard deviation of the comparison between the clinical data and 
the results of the optimized model. Cardiac output (CO), stroke volume (SV), ejection fraction (EF), systolic 
pressure (PSYS), diastolic pressure (PDIA), end diastolic left ventricle volume (ESV), end systolic left ventricle 
volume (EDV). 
 CO SV EF PSYS PDIA MAP ESV EDV 
Mean 0.34% 0.35% 0.52% 1.23% 2.68% 1.80% -1.17% -0.19% 
Min -0.69% -0.68% -2.96% -2.49% -5.18% -2.20% -16.77% -3.92% 
Max 1.73% 1.73% 4.93% 4.28% 15.76% 6.73% 5.90% 3.25% 
Median 0.28% 0.31% 0.59% 1.34% 2.21% 1.54% -0.92% -0.24% 
ST.Dev 0.53% 0.53% 1.23% 1.35% 5.12% 2.36% 3.46% 0.98% 
 
 
Figure 5.4: Box-and-Whisker distribution of errors between the consistent clinical data and the model results 
obtained with the parameter personalisation. 
The boxes represent the lower and upper quartiles, the error bars represent the range between 1.5 times the 
first and third interquartile range and the dots outside the boxes represent the extreme outliers, i.e. the data 
out of the range between 1.5 times the first and the third interquartile range. 
 
Figure 5.5: Aortic pressure results from optimisation for patient 9. 
(Dashed black) Original aortic pressure signal over one cardiac cycle; (blue) aortic pressure result from GA; 
(red) aortic pressure result of fminsearchbnd. 
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Table 5.12: Results of the personalisation of the model for each patient. 
ELVMAX and ELVMIN: ml/mmHg; CSAT: ml/mmHg; RSCP and RPCP: mmHg s/ml. The percentage indicate the errors. 
Pat. ELV
MAX 
ELV
MIN 
CSAT RSCP RPCP %CO %SV %EF %PSYS %PDIA %MAP %ESV %EDV 
1 5.32 0.11 0.50 0.56 1.13 0.49 0.59 0.93 3.60 4.64 -0.12% -2.51 -0.34 
2 1.58 0.11 0.59 1.17 0.97 0.32 0.30 0.75 2.75 0.07 4.07% -0.92 -0.45 
3 2.09 0.17 1.21 0.77 0.95 0.17 0.17 0.66 0.23 -1.27 1.39% -1.22 -0.49 
4 1.22 0.06 0.93 0.71 0.99 0.04 0.05 0.45 0.88 -3.19 -0.62% -0.66 -0.41 
5 7.00 0.34 0.68 0.91 0.22 1.24 1.20 4.93 4.28 -5.18 -1.33% -16.7 -3.92 
6 2.46 0.03 0.71 0.64 1.00 0.24 0.37 0.82 1.84 5.77 -0.72% -1.53 -0.46 
7 2.76 0.08 0.42 0.88 0.93 0.39 0.39 0.90 2.12 9.70 3.81% -1.55 -0.52 
8 4.39 0.49 0.40 1.17 1.00 0.51 0.62 1.06 2.01 0.87 5.50% -1.89 -0.44 
9 0.71 0.03 0.89 0.67 0.81 -0.06 0.01 -0.34 -0.99 4.79 1.46% 0.49 0.35 
10 1.88 0.03 0.86 0.46 0.99 -0.69 -0.68 -0.97 1.62 12.9 2.01% 1.72 0.29 
11 2.05 0.17 1.34 0.43 0.18 0.51 0.49 0.76 2.24 -0.99 6.73% -1.51 -0.28 
12 2.15 0.10 1.99 0.29 0.23 0.63 0.64 -0.27 -0.45 2.78 0.55% 1.58 0.91 
13 1.77 0.26 1.01 0.59 0.09 0.07 0.07 -0.64 -0.05 2.94 1.27% 1.44 0.71 
14 1.56 0.10 0.63 0.66 0.07 -0.49 -0.49 -1.02 0.54 9.72 1.52% 1.40 0.52 
15 1.13 0.01 0.99 0.62 0.84 -0.29 -0.29 -0.18 2.19 7.88 4.79% 0.04 -0.10 
16 1.95 0.05 1.89 0.39 0.88 0.08 0.11 0.40 2.38 0.87 5.04% -1.07 -0.29 
17 1.96 0.07 1.86 0.61 1.00 0.22 0.22 0.66 1.55 -4.90 1.57% -1.19 -0.45 
18 1.38 0.09 1.93 0.43 0.39 1.23 1.23 0.87 1.45 -2.00 -2.20% -0.71 0.36 
19 2.41 0.16 1.09 0.70 0.41 0.32 0.32 0.52 1.82 1.81 -0.48% -0.93 -0.20 
20 1.86 0.10 0.67 0.71 0.58 0.86 0.86 1.42 2.72 -3.69 1.82% -1.97 -0.57 
21 3.37 0.07 0.92 0.50 0.89 0.02 0.02 -0.05 1.07 5.49 -0.25% 0.19 0.07 
22 2.76 0.17 0.39 1.16 0.70 0.15 0.15 0.30 1.22 8.23 3.29% -0.42 -0.15 
23 6.00 0.39 0.81 0.78 0.92 1.47 1.47 3.58 2.02 -1.53 4.54% -10.9 -2.19 
24 2.95 0.03 0.46 0.54 0.64 -0.43 -0.43 -0.27 0.87 15.7 0.07% 0.28 -0.16 
25 3.65 0.12 0.49 0.94 0.97 0.48 0.48 0.80 1.09 3.96 6.63% -1.33 -0.32 
26 5.54 0.37 0.29 1.16 0.09 0.84 0.84 0.94 0.63 -0.29 2.53% -1.44 -0.10 
27 1.95 0.03 1.34 0.32 0.44 -0.04 -0.04 0.08 -0.75 0.77 0.22% -0.25 -0.11 
28 1.50 0.11 0.59 0.94 0.06 -0.23 -0.23 -0.55 1.87 7.16 0.02% 0.72 0.31 
29 1.42 0.06 1.55 0.38 0.28 0.00 0.00 -0.12 1.15 2.61 4.40% 0.28 0.13 
30 3.67 0.18 1.06 0.58 0.56 1.13 1.13 0.95 1.83 -3.01 1.93% -1.79 0.18 
31 1.81 0.19 1.14 0.41 0.14 -0.09 -0.09 -0.18 -0.78 3.77 -0.73% 0.34 0.09 
32 1.00 0.08 1.52 0.42 0.24 0.39 0.39 -2.96 1.18 4.91 1.61% 5.90 3.25 
33 1.00 0.01 2.00 0.45 0.81 1.73 1.73 1.60 -2.49 -0.22 3.14% -1.06 0.14 
34 3.37 0.16 0.29 0.75 1.00 0.18 0.18 0.47 0.16 10.9 -1.15% -0.85 -0.29 
35 2.80 0.28 0.83 1.09 0.86 0.41 0.41 0.78 3.16 -3.38 4.54% -1.21 -0.37 
36 3.02 0.18 0.51 1.02 0.50 0.43 0.41 1.34 -0.02 5.85 -0.40% -2.53 -0.94 
37 0.55 0.13 2.00 0.58 0.05 0.03 0.03 0.42 1.64 -2.52 2.90% -0.54 -0.40 
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 Results of aortic adenosine concentrations 
The personalised model was run to produce the aortic adenosine concentration specific for each 
patient. The hypothesis is that different heart rate, pressure and cardiac output might influence 
the delay and the maximum value of plateau adenosine concentration, and that this might be 
responsible for the different myocardial responses observed clinically. 
For each patient with the personalised model, the maximum aortic concentration and the time 
to reach plateau were calculated.  
The average value of CAO was 3.03 ∙10-4 mg/ml (SD 7.83∙10-5, range: 1.09∙10-4 - 4.59 ∙10-4 
mg/ml) and of the time to reach plateau was 56.3 s (SD 8.2). The concentration necessary to 
reach hyperaemia is not defined in the literature. Measure of the adenosine concentration in 
vivo is not simple, because of the short half-life. A number of protocols were developed 
involving ad hoc syringes and adenosine blockers [116, 167-169].  Inconsistency was found 
between the results, caused eventually by the technique or the species involved in the study 
(dogs, humans, pigs). In particular, Biaggioni et al.[167] measured in men the plasma 
concentration of adenosine in the arterial blood at hyperaemia of 1.1 ± 5 ∙10-4 mg/ml. Our 
patient-specific results produced a higher value on average of the maximal aortic concentration, 
although of the same order of magnitude. Considering the short half-life of the drug also the 
location from where the sample is taken influences the results. 
The protocol of adenosine infusion is designed to allow all individuals to reach hyperaemia: a 
dose proportional to the body weight of the individual and the duration of the infusion is usually 
of 90-120 minutes. Results of the time to reach plateau from the patient-specific model suggest 
that a major component of the response time during adenosine infusion is largely influenced 
by the systemic cardiovascular system, as already studied also in Chapter 3. This highlight the 
importance of a global cardiovascular system able to represent the specific individual to study 
the adenosine response, extremely dependent on it.  
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From the modelling it can be identified that some patient-specific parameters determine the 
maximum aortic concentration and the time to reach the maximal hyperaemia. The results 
suggest that an infusion of 90 seconds is long enough to stimulate the maximum hyperaemia 
in all patients. 
Figure 5.6 shows the relationship with the clinical parameters: HR (A), CO (B), MAP (C), ESV 
(D) and EDV (E). It is observed that the maximum concentration is directly proportional to 
CO, ESV and EDV, while less influence is observed for MAP and HR. The time to reach the 
plateau is on the other hand indirectly proportional to HR and CO, and directly dependent on 
MAP and EDV.  
The correlation coefficients in all the relationships are less than 0.5, with a maximum value of 
0.35 between maximum concentration and CO (Panel B-left). This indicates that the 
correlations are weak. 
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Figure 5.6: CAO and time to plateau for each patient modelled with the personalised model. 
Panel A) HR (beat/min). Panel B) CO (l/min). Panel C) MAP (mmHg). Panel D) EDV (ml). Panel E) ESV (ml). 
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 Limitations 
The major limitation of the model is related to the incomplete representation of the real 
physiology in the cardiovascular system, such as neglecting the regulation system, limiting 
therefore the possibility of an accurate prediction and personalisation of the adenosine 
response. 
Secondly in order to simplify the process of personalisation, the cardiovascular model was 
divided into global and local systems under certain assumptions, which bring furthermore lack 
of physiological representation. 
With regards of the global personalisation, the most important limitation is represented by the 
clinical data from echocardiography which were not in themselves consistent. Several 
approximations were considered to bring consistency within the clinical data. It might be 
arguable the selection of the ejection fraction to define the other parameters, because it is itself 
calculated from the ratio of the left-ventricular volume, which were not considered. Another 
possibility would be to consider the measured EDV and calculate the other parameters, 
although it may happen that the stroke volume is equivalent or higher than the EDV and, 
therefore, non-physiological ejection fractions could be obtained. 
Moreover, the inconsistency of the patients’ data is also produced by the non-simultaneous 
measurements of echocardiographic data and invasive baseline pressures. 
The coronary circulation was considered equal for everyone, since the focus in this chapter was 
on the global model. 
Other limitations are related to the simulation time. As shown in the results, some cases 
produced high errors in the comparison the target values and the model results. This can be 
caused by the boundaries conditions, which may need to be wider for some cases, or by the 
number of populations and generations used for the GA and the number of iterations for 
fminsearchbnd. An increase of these parameters will certainly increase the possible 
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combinations of values and determine a better solution. These parameters were limited to a 
certain value respectively in order to obtain results for each case in about 3.5 hours in a normal 
office desktop. 
With regards to the pharmacokinetic model of the adenosine, the assumption of an 
instantaneous distribution of the drug in each compartment represents an important limitation 
for the representation of the real physiological phenomenon. The assumption of a null 
adenosine concentration before the start of injection is another limitation of the model, given 
by the lack of measurement of this parameter.  The subdivision in compartments and such small 
half-life of the drug produces plateaus of concentration in each compartment towards different 
values, while physiologically a homogenous concentration in the blood after a certain time 
elapse is expected. 
With regards to the maximal adenosine concentration, literature data do not provide 
information of what adenosine concentration is necessary to generate hyperaemia and therefore 
it is difficult to validate the model results. 
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 CONCLUSIONS 
The patient-specific model developed in this project allowed to represent baseline conditions 
of patients, aiming to reproduce the aortic pressure and the echocardiographic data measured 
during baseline/rest. 
The personalised model suggests that each patient shows a different maximum of aortic 
adenosine concentration and it is mainly dependent on the HR, CO and EDV. Therefore, when 
investigating the response to adenosine, it is important to have an associated systemic 
cardiovascular system representing the specific patient and his/her adenosine infusion transient 
profile in the systemic circulation.   
The time to reach plateau has also been analysed, considering that this might be an important 
parameter in the protocol of administration of adenosine to reach maximal hyperaemia. It is 
mainly dependent on the HR and shows a range of values between 45 and 90 s.  
The model results suggested that the adenosine infusion protocol should provide a time of 
infusion long enough to reach maximal hyperaemia in all individuals, although it is difficult to 
conclude if also the maximal concentration is sufficient to generate the maximal hyperaemia 
in all the patients. 
The main outcome of this part of project is the concentration of adenosine in the aorta which 
is used as input in the local coronary model of the specific patient, as shown in the next chapter. 
As future work, the patient-specific model needs to be improved in terms of the barocontrol 
parameters, which requires a higher number of measurements to set a parameter personalisation 
process with a higher number of variables to personalise. 
The optimisation process requires quite long time to run and therefore an improvement in the 
code is necessary to bring the model into clinical usage. 
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6 CHAPTER 6          
LOCAL TUNING OF CORONARY 
BRANCHES 
 
INTRODUCTION AND PURPOSE 
Personalising the local coronary circulation is the aim of this part of the project. The main 
objective is to define the relationship between the myocardium resistance and the adenosine 
concentration in the myocardium to classify the different adenosine responses in each patient. 
As discussed in chapter 4 patients were classified based on the pressure trend and the Pd/Pa 
ratio, as shown also in other studies published in the literature [120, 144]. 
In this chapter the aims are to define for each patient the parameters that better describe the 
myocardial vasodilation and the adenosine distribution and to classify patients based on these 
parameters. This requires a description of the myocardial blood volume and its change during 
adenosine vasodilation, in order to describe the distribution of the drug within the compartment. 
The blood volume change is estimated using a tree structure to describe the myocardium and 
its vasodilation during hyperaemia. 
The patient - specific condition in terms of the demographic information and the comorbidities 
are also investigated in order to find any relationship with the adenosine response, focusing on 
those factors which are expected to have the strongest influence on the myocardium properties. 
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 MODELLING LOCAL CIRCULATION: INPUTS 
AND OUTPUTS 
The adenosine response of the local coronary circulation is studied in isolation, taking as an 
inlet condition the computed adenosine concentration in the aorta, to identify the relationship 
between the myocardial resistance and the adenosine concentration. 
 Hypotheses 
6.1.1.1 Model of the coronary branches 
The coronary branch was modelled as 2 resistances in series (Figure 6.1): RSTEN representing 
the stenosis and Rmyo for the myocardial microcirculation. The difference between aortic 
pressure (Pa) and distal pressure (Pd) represents the pressure gradient across the lesion and 
determine the blood flow through the branch.  The pressure downstream of the myocardial 
resistance, corresponding to the peripheral venous pressure  (2-8 mmHg [10, 105]) could have 
been taken from the personalised global model, but since its value is small compared to the 
proximal and distal pressure, it is was assumed to be null.  
 
Figure 6.1: Model of local coronary circulation. 
Pa and Pd are the pressures measured during angiogram, the stenosis and the myocardium are represented by 
resistances (RSTEN and Rmyo), C is the myocardial compliance, CADE is the adenosine concentration, Q is the blood 
flow through the vessel.  
A number of inputs to solve the model are listed below: 
1. Patient-specific proximal and distal pressures as function of time, Pa(t) and Pd(t); 
2. Aortic adenosine concentration, CAO(t), calculated within the global circulation (Chapter 5); 
3. a simplified pressure-flow relationship for the specific stenosis, based on a quadratic fit to 
a pair of computational fluid dynamics analysis. The convective acceleration term might be 
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expected to be quadratic, as expressed by the Bernoulli equation whilst that associated with 
the viscous losses might be linear; 
4. patient-specific body surface area (BSA) index, based on gender, height and weight used to 
estimate the myocardial blood volume. 
The solution of this model for each lesion produced a time-series signal for the following: 
1. the myocardial resistance, Rmyo(t), from which values at baseline and hyperaemia (Rmyo,B 
Rmyo,H) were extracted considering the results of the algorithm presented in Chapter 4; 
2. blood flow, Q(t); 
3. myocardial blood volume, MBV(t); 
4. myocardial adenosine concentration, Cmyo(t). 
The main assumption considered for the local personalisation has already been discussed in 
Chapter 3. This consists of the consideration of a high influence of the global model on the 
local, but not vice versa. From the patient specific global model obtained in Chapter 5, the 
time-dependent aortic concentration of the adenosine was calculated and applied as input to the 
coronary branch to estimate the concentration of adenosine in the myocardium. 
 Haemodynamic inputs: pressure gradient and aortic 
concentration of adenosine 
The pressure signals were smoothed in order to represent the average pressures, eliminating 
the variation during each single cardiac cycle. The pressure gradient for each lesion was 
smoothed with a window size of 5 seconds. 
Following this preliminary signal processing, in some lesions the pressure drop across the 
lesion was negative, especially when there was only a small gradient. Measurements errors of 
the pressures might have been caused by an imprecise calibration of the pressure catheters or 
movements of the patient during the procedure. 
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To overcome this, the pressure gradient signals that contained a negative value were shifted 
upwards so that the temporal minimum of the signal is 1 mmHg. This is an arbitrary threshold 
but since it affects primarily only very mild lesions, for which the processing chain is in any 
case not well-suited, it is considered to be an acceptable process. It allowed the processing of 
data from lesions that had low gradients at rest but became significant under hyperaemic 
conditions. Some testing was performed to demonstrate that the selection of this particular 
threshold did not strongly affect the final results of the processing relative to the selection of a 
lower threshold. An example is reported in Figure 6.2. 
 
Figure 6.2: Examples of the post-processing results of the raw pressure data to obtain the pressure gradient 
across the lesion. 
The example on the left is relative to a normal case without negative pressure gradients; the example on the 
right presented negative pressure gradient (ΔPorig) and the signal was shifted on the y-axis (ΔPmod). The top 
graphs show the raw proximal (Pa) and distal (Pd) pressure and the smooth pressure of proximal and distal 
pressure; the bottom graphs report the smoothed pressure gradient (on the right both original and modified 
signals). 
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The aortic concentration of adenosine obtained with the personalised global model was 
smoothed with a window of 2 s in order to eliminate the cardiac cycle variation, due to the 
approximation of instant homogenous mixing in each compartment. 
 
 Haemodynamic outputs: blood flow and myocardial resistance 
The calculation of blood flow and myocardial resistance required the definition of the stenosis 
resistance, which is nonlinear and taken to have a quadratic and a linear component. The steady 
state pressure gradient across the stenosis as a function of flow is determined by a quadratic 
equation as reported in Eq.6.1. 
∆𝑃(𝑡) = 𝑍1 ∙ 𝑄 + 𝑍2 ∙ (𝑄(𝑡))
2 (Eq.6.1) 
The coefficients Z1 and Z2 were computed based on the analysis of a pair of steady state 3D 
computational fluid dynamics (CFD) analyses for each patient-specific lesion. This was 
performed as part of a previous PhD project carried out by Dr. Paul Morris [92] in the 
Mathematical Modelling in Medicine Group at the University of Sheffield. The current project 
used the computed linear and nonlinear coefficients: further details on the method of 
computation are presented in the Appendix. Given the measured pressure gradient, ΔP(t), and 
the characteristic parameters for each lesion it was possible to evaluate the blood flow (Eq.6.2): 
𝑄(𝑡) =
−𝑍1 +√𝑍1
2 + 4 ∙ 𝑍2 ∙ ∆𝑃(𝑡)
2 ∙ 𝑍2
 (Eq.6.2) 
And, assuming the myocardial resistance linear, it can be determined from Eq.6.3: 
𝑅𝜇(𝑡) =
𝑃𝑑(𝑡)
𝑄(𝑡)
 (Eq.6.3) 
 
It is recognised that this process for computation of flow, and therefore of myocardial 
resistance, is only robust when there is confidence in the measured pressure gradients. For very 
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mild lesions the pressure gradient measurements are unlikely to be sufficiently accurate, 
especially at baseline, to support a reliable estimate of myocardial resistance. 
6.2.1.1 Myocardial resistance at baseline and at hyperaemia 
The myocardial resistance at baseline (Rmyo,BL) was obtained as the average value of the 
computed myocardial resistance during the 5 s before the adenosine infusion starts. 
The myocardial resistance at hyperaemia (Rmyo,HY) was considered as the myocardial resistance 
corresponding to the period of stable hyperaemia, described in Chapter 4. 
 
 Myocardial blood volume as function of myocardial resistance 
The main challenge in this part of the project was related with the definition of the myocardial 
volume in time (MBV(t)) during the vasodilation to define the concentration of the adenosine 
in the myocardium as described in the next paragraph. 
The myocardium has been object of studies for many years. Nevertheless, the quantification of 
the myocardial blood volume is still a challenging task, despite the extensive information 
available on myocardial blood flow, which has been largely studied using different techniques 
such as Doppler or contrast echocardiography, cardiovascular magnetic resonance (CMR), 
Positron Emission Tomography (PET), Single Photon Emission Computed Tomography 
(SPECT), Computed Tomography (CT), Thermodilution [170-179]. 
Experimental data on myocardial blood volume were mostly associated with invasive studies 
on animals [174, 180-184]. Other, less invasive, studies were conducted on patients or healthy 
volunteers, including some type of stimulation of the cardiovascular system to observe the 
response of the blood volume in the myocardium [175, 176, 185-188]. 
Several studies [181-183] identified the intracoronary blood volume as a function of 
myocardial blood flow and perfusion pressure in canine hearts. Myocardial blood volume is 
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usually reported as a volume per unit mass of myocardium, typically ml/100gr to normalise for 
heart size. The intracoronary blood volume varies between 7 to 20 ml\100gr with a respective 
perfusion pressure from 50 to 180 mmHg. Other experimental studies on dogs [174, 180, 184] 
demonstrated that the myocardial blood volume is also function of the myocardial oxygen 
consumption, the severity of stenosis in the coronary arteries, the specific coronary vessel and 
the condition (resting or hyperaemia). Reported values of the total blood volume in the 
coronary circulation in humans are within a range of 11 to 17.5 ml/100 gr of myocardium. 
Further studies on animals and humans [180, 187] demonstrated that the hyperaemic stimulus 
increased the myocardial blood flow due to the vasodilation, but the myocardial blood volume 
did not change substantially. 
Experimental studies on dogs carried from Crystal  et al. [180] studied the effect of adenosine 
on coronary open-capillary density. The estimated blood volumes in epicardial, middle and 
endocardial region of the ventricle wall were all about 4-5 ml/100g each and they were not 
influenced by the adenosine effect. On the other hand, the myocardial blood flow increased 
massively with the adenosine infusion. 
Other studies on patients aimed to measure the myocardial blood volume. Indermühle et al. 
[187] studied the change of myocardial blood volume before and after angioplasty on 30 
patients using contrast  ultrasound. The blood volume increased after the angioplasty in the 
majority of the patients on average from 6.7 to 9.8 ml/100 gr. 
Values of myocardial blood volume measured post mortem varied from 1.6 to 9.4 ml/100 gr of 
myocardium [105]. 
Other research groups worked on the modelling of the myocardium [109, 189, 190]. Briunsma 
et al. [189] employed 0D models (RCR) to represent the coronary circulation in the left 
ventricular wall divided into 8 layers from endocardium to the epicardium. The blood volume 
in the myocardium, proportional to the dimension of the vessels, was set to 9.4 ml/100gr LV 
Chapter 6 – Local tuning of coronary branches 
190 
 
and it was proportionally distributed into the arteriolar, capillary and venular compartments for 
each of the 8 layers. The model simulates prolonged systole and diastole and evaluates the 
blood volume in each compartments of coronary circulation. In the prolonged systole, in veins 
and arteries the volumes reduced to zero, while in capillaries stayed almost stable to 4 ml/100gr 
LV. 
The research group of J.Spaan and N. Smith [109, 190, 191] worked on the 3D reconstruction 
of coronary circulation of animals hearts using the cryomicrotome technique. This supports the 
study of the perfusion profile of a specific coronary circulation.  
Other studies were conducted to invasively identify the level of vasodilation of the small 
arteries and arterioles in the myocardium under effect of adenosine infusion. The majority of 
the experiments were conducted in ex-vivo animals’ hearts. 
In 1989 Kanatsuka et al. [142] studied the vasodilatory effects on anesthetised dogs hearts. 
Adenosine acts on coronary vessels with diameter smaller than 150 μm. The study shows that, 
for higher doses, vessels with diameter of about 50 μm vasodilated by 55%, whilst vessels with 
diameter smaller than 150 μm vasodilated by 20-30 %. The change of diameter was dependent 
on the adenosine dose and on the initial vessel diameter itself, as demonstrated also by Yada et 
al. [169] in vessel with diameter between 100 μm and 40 μm. 
Chilian et al. [140] measured a change in diameter of 30-40 % for vessels between 50 and 80 
μm in dogs hearts. Hein et al. [192, 193] studied in ex-vivo pig coronary arterioles the 
adenosine induced-vasodilation associated with the arterial endothelium. Results showed a 
vasodilation dependent on the dose of adenosine and on the basal tone and in the control 
samples a change in diameter of 45 % in vessels of 85 μm diameter was observed. 
According to Feliciano et al. [194] the vasodilatory response to adenosine involves different 
arterial compartments. Physiologically, when the myocardial oxygen demand increases, 
adenosine is released and its targets are primarily the small coronary arterioles with diameter 
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smaller than 100 μm. In particular, arterioles with diameter between 25-45 μm are dilated first, 
in a second phase arterioles with diameter between 50 and 80 μm are vasodilated due to 
metabolic and myogenic reaction. As consequence, arterioles (80-150 μm) and small arteries 
(140-400 μm) vasodilate as well since their endothelium responds to change in blood flow. 
Cornelissen et al. [80, 81] developed a model for the coronary circulation (vessels with 
diameter between 20 and 400 μm), described by 10 compartments in series. An optimisation 
process was used to define a compartment-specific parameter as a function of the number and 
diameter of vessels, pressure, blood viscosity and vessel tone. They attempted to describe the 
coronary vasodilation in terms of myogenic, flow-induced and metabolic components, all 
combined together. Some discrepancy arose when comparing the model results with the 
experimental results, due to the approximations made on the vessel tone. Moreover, the 
coronary reserve of the model reached a value of 2, while in human is about 3-4. 
In summary there are conflicting statements in the literature with regard to whether changes in 
myocardial blood volume are significant. Several papers provide measures of the dilation as a 
function of the diameter of the vessel, supporting the assumption that the volume does change, 
whilst others report that the volume changes are not significant.  
For the purpose of this project the strategy is to employ a tree-structure model in which radius 
changes can be applied to each generation, according to the literature consensus, and to use an 
optimisation process to define the patient specific tree parameters that are consistent with the 
change of myocardial resistance. The personalised tree model was used to estimate the 
variation of myocardial blood volume during the hyperaemic response according to the 
variation of the myocardial resistance to estimate the myocardial adenosine concentration 
during hyperaemia. 
 
Chapter 6 – Local tuning of coronary branches 
192 
 
6.2.2.1 Myocardium modelled as a tree-structure 
A tree-like structure was developed to represent the circulation from a coronary artery to the 
capillaries of its perfused area (Figure 6.3). 
 
Figure 6.3: Tree-structure example with 4 generations.  
A number of assumptions were made: 
- each parent vessel divides into 2 symmetric daughter vessels; 
- the starting radius for each specific vessel was obtained from the geometries obtained from 
the segmentation and 3D reconstruction used for the CFD simulation. When this data was 
unavailable, a starting radius of 2 mm [195] was considered. 
- the minimum possible radius at the end of the tree-structure, corresponding to the 
capillaries, is 2.5 μm [4] 
- length (ld) and radius (rd) of daughter vessels were defined on the radius of the parent vessel 
(rp) as in Eq.6.4 and in Eq.6.5 [196, 197]: 
𝑟𝑑 = 𝛼 ∙ 𝑟𝑝 (Eq.6.4) 
𝑙𝑑 = 𝛽 ∙ 𝑟𝑑 (Eq.6.5) 
- a third parameter, γ, was introduced to represent the vasodilation as the change in radius 
for the target vessel of the metabolic vasodilation induced by adenosine as described in 
Eq.6.6: 
𝑟𝑣𝑎𝑠𝑜 = 𝛾 ∙ 𝑟𝑏𝑎𝑠𝑒 (Eq.6.6) 
where rvaso is the radius at hyperaemia and rbase is the radius at baseline condition. 
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The target vessels for particular processes were chosen based on the literature data. 
Arterioles and small arteries, in the radius range 10 µm and 200 µm, were the target of 
metabolic vasodilation. 
- the total resistance (Eq.6.7) was calculated solving the parallel and series parallel and 
series of vessels resistances, each of which is described by Poiseuille’s formula. 
𝑅𝑇𝑂𝑇 = ∑
1
2𝑁−1
∙ (
8 ∙ 𝜇 ∙ 𝑙𝑁
𝜋 ∙ 𝑟𝑁
4 )
𝑁𝑚𝑎𝑥
𝑁=1
 (Eq.6.7) 
where 𝑙𝑁 is the length of the  vessel in the N
th generation, 𝑟𝑁 is the radius of the N
th 
generation, 𝜇 is the blood viscosity (3.5∙10-3 Pa∙s), Nmax is the last generation with smallest 
radius. This particular assumption does not allow to represent wave propagation and 
reflection effects in the coronary model. In this project the clinical data do not support the 
possibility to represent these phenomena and moreover the pressure data are considered 
averaged over the cardiac cycles and is out of the purpose of this project to represent the 
elasticity of these vessels and how this might affect the pressure and curve curves.  
- the total volume was calculated by the sum of the volume of each vessel. 
 
6.2.2.2 Optimisation for the tree-structure myocardial model 
The optimisation aims to define the best combination of these 3 parameters: α, β and γ to 
reproduce the baseline resistance, Rmyo,BL, and the hyperaemic (or minimum) resistance, 
Rmyo,HY, measured for each patient as described above, and an estimate of the patient-specific 
blood volume, obtained as follows: 
1. VB (Eq.6.8) was computed as a function of the gender-dependent mass of the left ventricle 
indexed by the BSA (Body Surface Area index - Eq.6.9) and the density of blood volume 
per gram of tissue (9 ml/100 gr LV [105]): 
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𝑉𝐵(𝑚𝑙) =
{
 
 
 
 𝐵𝑆𝐴(𝑚2) ∙ 73(
𝑔𝑟
𝑚2
)  ∙ 0.09
𝑚𝑙
𝑔𝑟 𝐿𝑉
        𝑖𝑓 𝑚𝑎𝑙𝑒
𝐵𝑆𝐴(𝑚2)  ∙ 63(
𝑔𝑟
𝑚2
) ∙ 0.09
𝑚𝑙
𝑔𝑟 𝐿𝑉
    𝑖𝑓 𝑓𝑒𝑚𝑎𝑙𝑒
 (Eq.6.8) 
  
𝐵𝑆𝐴 (𝑚2) = √
ℎ𝑡 (𝑐𝑚) ∙ 𝑤𝑡(𝑘𝑔)
3600
 (Eq.6.9) 
 
2. Rmyo,HY is obtained as described in the previous paragraph about the haemodynamic 
outputs in this current chapter (Paragraph 6.2.1.1 Myocardial resistance at baseline and 
at hyperaemia). 
The objective function for the optimisation process takes in account the tree targets as described 
in Eq.6.10: 
𝑓𝑐 =  (
𝑅𝑚𝑦𝑜,𝐵𝐿,𝑚 − 𝑅𝑚𝑦𝑜,𝐵𝐿,𝑡
𝑅𝑚𝑦𝑜,𝐵𝐿,𝑡
)
2
+ (
𝑉𝐵,𝑚 − 𝑉𝐵,𝑡
𝑉𝐵,𝑡
)
2
+ (
𝑅𝑚𝑦𝑜,𝐻𝑌,𝑚 − 𝑅𝑚𝑦𝑜,𝐻𝑌,𝑡
𝑅𝑚𝑦𝑜,𝐻𝑌,𝑡
)
2
 (Eq.6.10) 
where m indicates the model results and t the target. 
The optimisation was performed in MATLAB using fminsearch with boundaries for α, β and 
γ respectively of 0.6-0.9, 20-70, 1-1.8 [197, 198], and an initial solution for each parameter 
equal to 0.76, 52 and 1.2 respectively. The number of iterations was set to 5000, with default 
tolerance value which will automatically stop the simulation when it converges. 
For a generic myocardium with starting radius of 2 mm, a volume of 13 ml and an overall 
resistance at baseline Rmyo,BL of 72 mmHg s/ml, obtained from a physiological pressure gradient 
of 80 mmHg between the main artery and the capillaries and a blood flow of 1.1 ml/s, and 
imposing the range of vasodilation target vessel published in literature (radii between 10 to 200 
μm), for the generic model a vasodilation factor, γ, was computed that was out of the reported 
physiological range over 50%. Physiological ranges of vasodilation changes were obtained 
considering then a wider range between 7 and 200 μm and this range was used for all the 
patients’ studies.  
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6.2.2.3 Relationship between myocardial resistance and myocardial volume 
The myocardial blood volume and the myocardial resistance were considered to be related by 
a factor, CBL-HY, which describes the proportion of variation of resistance and variation of 
volume between baseline and peak/stable hyperaemia as shown in Eq.6.11: 
𝐶𝐵𝐿−𝐻𝑌 = −
(
𝑅𝑚𝑦𝑜,𝐵𝐿 − 𝑅𝑚𝑦𝑜,𝐻𝑌
𝑅𝑚𝑦𝑜,𝐵𝐿
)
(
𝑉𝐻𝑌 − 𝑉𝐵
𝑉𝐵
)
 (Eq.6.11) 
where the hyperaemic volume was computed from the personalised parameters in the tree 
model and the baseline volume and resistances are the inputs to the personalisation process. 
Two coefficients CBL-HY were calculated considering the generic test model results and the 
results obtained with stable resistance and stable blood volume. 
Substituting the value of stable myocardial resistance and blood volume with the respective 
values at the same instant of time, as expressed by Eq.6.12, the relationship between the 
myocardial resistance and the myocardial blood volume at each instant in time is obtained as 
in Eq.6.13: 
𝐶𝐵𝐿−𝐻𝑌 = − 
(
𝑅𝑚𝑦𝑜,𝐵𝐿 − 𝑅𝑚𝑦𝑜(𝑡)
𝑅𝑚𝑦𝑜,𝐵𝐿
)
(
𝑉(𝑡) − 𝑉𝐵𝐿
𝑉𝐵𝐿
)
 (Eq.6.12) 
𝑉(𝑡)     = 𝑉𝐵𝐿 ∗
(
 1 +
(
𝑅𝑚𝑦𝑜,𝐵𝐿 − 𝑅𝑚𝑦𝑜(𝑡)
𝑅𝑚𝑦𝑜,𝐵𝐿
)
𝐶𝐵𝐿−𝐻𝑌
)
  (Eq.6.13) 
 
 Myocardial pharmacokinetics 
Under the hypothesis of an instant homogeneous mixing and an instantaneous constant 
myocardial blood volume, the concentration of adenosine within the myocardium (Cmyo) was 
calculated with the mass balance (Eq.6.14), which is the same as the other compartments as 
explained in Chapter 2 (Paragraph 2.1.4 Adenosine pharmacodynamics and pharmacokinetic 
model): 
Chapter 6 – Local tuning of coronary branches 
196 
 
𝑉𝑚𝑦𝑜
𝑑(𝐶𝑚𝑦𝑜)
𝑑𝑡
= 𝑄𝑖𝑛 ∙ 𝐶𝑆𝐴𝑆 − (𝑄𝑜𝑢𝑡+𝑄𝐸𝐿) ∙ 𝐶𝑚𝑦𝑜 (Eq.6.14) 
where CSAS
 is the concentration in the aorta, Qin and Qout are respectively the input and output 
flow in the branch, QEL represents the amount of drug metabolized by the vessels (clearance) 
Vmyo is the volume in the myocardium. 
By definition, QEL is a function of the drug half-life time (thl) and the volume of blood in the 
myocardium (Eq.6.15). 
𝑄𝐸𝐿 =
𝑉𝑚𝑦𝑜 ∙ ln 2
𝑡ℎ𝑙
 (Eq.6.15) 
The half-life of the adenosine was considered equal to 7 seconds, as in the global model 
(Chapter 2- Paragraph 2.1.4 Adenosine pharmacokinetic and pharmacodynamics). 
The 1st order derivative equation for the Cmyo (Eq.6.14) was solved using the Euler backward 
differentiation method, as indicated in Eq.6.16: 
𝐶𝑚𝑦𝑜,𝑖 =
𝑉𝑚𝑦𝑜,𝑖 ∙ 𝐶𝑚𝑦𝑜,𝑖−1 + ∆𝑡 ∙ 𝑄𝑖 ∙ 𝐶𝑆𝐴𝑆,𝑖
𝑉𝑚𝑦𝑜,𝑖 + ∆𝑡 ∙ (𝑄𝑖 + 𝑄𝐸𝐿,𝑖)
 
(Eq.6.16) 
 Statistical analysis 
Paired T-test analysis was performed to correlate the targets and the optimisation results in 
terms of myocardial resistance and myocardial blood volume. In particular, the results with 
peak and stable hyperaemic myocardial resistance were compared. Results are presented using 
linear correlation and Bland-Altman plots. 
Results of α, β and γ are reported in terms of average value and standard deviation and 
graphically with Whisker plots. 
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  CLASSIFICATION OF ADENOSINE RESPONSE 
 Classification based on the myocardial resistance trends 
Using the characteristics of the stenosis, Z1 and Z2, and the pressure gradient at baseline, peak 
and stable hyperaemia, obtained from the measured pressure signals using the algorithm 
described in chapter 4, the corresponding values of the myocardial resistance during the 
response to adenosine infusion was computed, solving the equations reported in Eq.6.2 and 
Eq.6.3. The absolute and percentage changes in myocardial resistance under the infusion of 
adenosine were identified. The aim was to classify the patients’ response, ultimately to 
determine whether the hyperaemic pressure gradient can be predicted reliably from baseline 
measurements given the broader information in the patient record. The lesions were also 
divided into four groups based on the location (LAD, DX together, RCA, LCX and LMS) to 
explore whether the response might be artery-dependent. 
A common method for distributing total resistance at the terminations of multiple branches in 
a 1D or 3D arterial tree is to use Moore’s Law [199], recognising that the distal resistance at 
any one branch is likely to be related to the radius of that branch (in the healthy state). To 
support the testing of this hypothesis in this cohort the outlet radius (rout) for each vessel was 
extracted from the 3D volume mesh.  
It was reported in recent studies [200, 201] that, for severe stenosis, the myocardial resistance 
at baseline tends to be lower because of an adaptation of the body to maintain the same 
myocardial blood flow. In this case the vasodilatory ability of the myocardial resistance is 
partially impaired or limited. This hypothesis was also tested in the current cohort by plotting 
the myocardial resistances at baseline and stable hyperaemia against the FFR reported in the 
Cathlab (FFRCL) and the stable hyperaemia FFR (FFRHY) and against the Z2, as indicators of 
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the stenosis severity. Moreover, patients’ characteristics were also considered in order to 
identify possible influence of gender, age, BMI, smoking status, myocardial infarction event.  
For this type of classification, 81 lesions were taken in account.  
Statistical analysis (un-paired T-test and One–way ANOVA) was performed within GraphPad 
Prism (GraphPad Software, La Jolla California USA).   
 
 
 Classification on the relationship between adenosine 
concentration and myocardial resistance 
The analyses discussed in the previous section are concerned with the identification of key 
features of the adenosine response, but do not examine the dynamic nature of the response.  
The measurements in the study cohort support the analysis of this dynamic, using the local 
model of the coronary branch to produce time series results for the myocardial resistance (Rmyo) 
and the adenosine concentration (Cmyo).  
In this paragraph the focus is the influence of the myocardial parameters on the adenosine 
response observed effectively in the myocardium itself. From the previous modelling results 
(Chapter 3 and Chapter 5) it is evident that the systemic circulation is the major driver of the 
maximal concentration and time response in the myocardium. So hypothesising the same aortic 
concentration profile, the aim was to understand how the stenosis and the myocardial properties 
impact on the myocardial response. For this it was necessary to isolate the systemic and the 
global influence on the signal of the myocardial resistance and adenosine concentration 
obtained from the local tuning model. 
FFR at stable hyperaemia (FFRHY), myocardial resistance at baseline (Rmyo,BL) and hyperaemia 
(Rmyo,HY) were analysed to seek associations with: 
- values of the maximal adenosine concentrations in the aorta (CAO,max) and in the 
myocardium (Cmyo,max); 
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- the difference between CAO,max  and Cmyo,max as absolute and percentage values;  
- the difference between the respective time to reach the plateau for the maximal 
concentrations.  
The delay of the myocardium response is caused by the intrinsic delay in the aortic 
concentration and it might be also caused by the delay in the myocardial reaction to 
vasodilation associated with a certain value of myocardial concentration.  
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  RESULTS AND DISCUSSION 
 Classification based on the myocardial resistance trends 
The available data from the previous study using CFD analysis to define the patient specific 
stenosis characteristics supports the analysis of 81 lesions in total to classify patients based on 
the myocardial resistance as absolute value and percentage in change. 
6.4.1.1 Patients demographic and lesions’ characteristics 
In total 81 lesions (62 patients) were considered for this analysis and the demographic 
description is shown in table 6.1. 
5 lesions were located in the diagonal (DX), 47 in the left anterior descendent (LAD), 2 in the 
left main stem (LMS), 15 in the coronary artery (RCA) and 12 in the left circumflex (LCX). 
Table 6.1: Demographic data and comorbidities of the sub-cohort (62 patients) used for the classification of 
adenosine response based on the myocardial resistance change. 
Peripheral Vascular Disease (PVD), Chronic Obstructive Pulmonary Disease (COPD), myocardial infarction 
(MI). 
Patient demographic Num% - mean (SD) 
Male 70% 
Age (years) 61.8 (SD 9.4) 
BMI 28.7 (SD 3.9) 
Hypertension 51.7 % 
PVD 1.6 % 
Previous MI 38.7 % 
Type II diabetes 22.6 % 
Hyperlipidaemia 59.7 % 
COPD 0 % 
Smoking status:  Never 25.8% 
 Ex-smoker 46.7 % 
Current 12.9 % 
 
The average Pd/Pa measured in the Cathlab during baseline is 0.84 (SD 0.15) and the average 
FFR is 0.72 (SD 0.15). 
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The lesions were selected with the criteria of a value of Pd/Pa reported in the Cathlab below 
0.95. The CFD process developed by Morris [92] based on the quadratic equation between 
pressure gradient and flow (Eq.6.1) provides reliable characteristics, and therefore distal 
resistances, for severe stenosis, although it is not reliable for mild stenosis, due to the 
movement of wires or imperfect calibration during the angiogram. The threshold of a baseline 
Pd/Pa of 0.95 was arbitrarily chosen. An additional criterion for the selection of the lesions, was 
the pressure gradient measured at baseline above 4 mmHg. In some cases, the pressure gradient 
across the stenosis resulted very small (below 1 mmHg or even negative). 
Figure 6.4 shows the distribution of the coefficients Z1 and Z2, which have respectively an 
average value of 1.53*109 (SD 2.58*109) Pa s m-3 and 1.64*1015 (SD 2.94*1015) Pa2 s2 m-6. As 
a preliminary indicator, and to give context, it is noted that the linear and nonlinear coefficients 
based on Poiseuille and Bernoulli drops for a ‘typical’ coronary are of the order of 108                  
Pa s m-3 and of the order of 1014 Pa2 s2 m-6 respectively for a 75% reduction area between the 
inlet and the minimum radius. 
 
Figure 6.4: Distribution of coefficients Z1 and Z2.  
 
Figure 6.5 shows the relationship between the coefficients and the FFRs both measured in 
Cathlab (FFRCL) and the stable FFR defined with the algorithm in Chapter 4 (FFRHY). An 
increase of both Z1 and Z2 was observed as the degree of stenosis is increased, indicating higher 
pressure drops across the lesion, with a R2 coefficient of 0.21 with regards of the FFRCL and 
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slightly higher with regards of the FFRST (0.27). While the Z1 and Z2 coefficients are directly 
related with the lesion severity, the FFR is also determined by the myocardial resistance and 
this might generate the low correlation between them. 
Figure 6.6 shows the relationship between the myocardial resistance at baseline and stable 
hyperaemia and the outlet radius of the vessel considered. As expected, for smaller vessel the 
resistance results are higher in both baseline and hyperaemia. 
 
Figure 6.5: Correlation between the FFR and the stenosis coefficients. 
FFRCL (in red), FFRHY (in black) and the coefficients Z1 (left) and Z2 (right). 
 
 
Figure 6.6: Relationship between the outlet radius, rout, of the vessel and the myocardial resistance at baseline, 
Rmyo,BL, and stable hyperaemia, Rmyo,HY.  
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6.4.1.2 Average hyperaemic response: myocardial resistance and blood flow 
The average myocardial resistances at baseline, peak and stable hyperaemia were respectively 
136.35 (SD 86.5) mmHg s/ml, 63.4 (SD 31.1) mmHg s/ml and 72.1 (SD 44.9) mmHg s/ml. 
The average blood flows at baseline, peak and stable hyperaemia were respectively 1.10 (SD 
0.69) ml/s, 1.76 (SD 0.92) ml/s and 1.63 (SD 0.90) ml/s. 
Overall the expected behaviour for both resistance and blood flow was observed, although the 
high standard deviations indicated high variability of these values (Figure 6.7). Nevertheless, 
the average value of baseline myocardial resistance for the analysed cases results were higher 
than what expected on average data of pressure and flow in the coronaries (Chapter 2 Paragraph 
2.1.1.3 Coronaries modelling). It needs to be considered that resistances and flow results in 
this paragraphs are related with termination of individual branches, while in Chapter 2 the 
whole myocardium compartment was considered.  
 
Figure 6.7: Average and distribution of Rmyo (left) and Q (right) obtained with coefficients from CFD.  
The values are averaged for each phase of the adenosine response: baseline, peak and stable.  
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6.4.1.3 Classification based on myocardial resistances during baseline and stable 
hyperaemia: absolute values and change 
In this section results of Rmyo during baseline (Rmyo,BL), hyperaemia (R myo,HY), the absolute 
change (ΔR myo) and the % of change (%ΔR myo) between baseline and hyperaemia are reported. 
In particular, the hyperaemic resistance results, reported already by Morris [92], are shown 
separated from the others, which this project is focused on. 
First of all, the objective was to identify correlation between Rmyo,BL, ΔR myo and %ΔR myo. 
Figure 6.8 shows the Rmyo,BL against ΔR myo and %ΔR myo. In the first relationship the linear 
coefficient is 0.66 and the correlation coefficient is 0.83, indicating a high correlation between 
the two variables. This is what is physiologically expected in the myocardium. The second 
relationship shows that for low resistances a small change in percentage during hyperaemia is 
associated, while for the higher resistances the percentage of change is close to 0.61, consistent 
with the first relationship. 
 
Figure 6.8: Correlation between the myocardial resistance at baseline (Rmyo BL) and (left) the absolute change 
of myocardial resistance (ΔRmyo) and (right) the percentage change of myocardial resistance (% ΔRmyo). 
 
This study supports the idea that the hyperaemic resistance might reasonably be estimated from 
the baseline resistance if the latter is known, especially when it is in the upper range. 
Measurement at baseline only is possible with an adjustment of the current clinical protocol, 
but this is already invasive and, although the extrapolation to hyperaemia would negate the 
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requirement for adenosine infusion and this might be preferable for patient comfort, the 
potential errors in the extrapolation, in combination with the fact that relatively few FFR 
measurements are actually made, strongly limits the value of this process. 
A weak correlation is expected between the myocardial resistance and the lesion severity, 
represented by the Pd/Pa. This is because the ratio between proximal and distal pressure has 
implicitly taken in account the myocardial resistance, from which the distal pressure is 
dependent. However, in case of severe stenosis it is supported the idea of physiological 
compensation of the myocardium to reduce the overall resistance of the coronary circulation 
and maintain an adequate coronary blood flow [200, 201]. 
Figure 6.9 shows the relationship between Pd/Pa at baseline and the Rmyo,BL, between the FFRHY 
and R myo,HY and between FFRHY and ΔR myo and %ΔR myo. Data suggest that for higher Pd/Pa at 
baseline, the myocardial resistance tends to be higher for mild stenoses, although the 
correlation coefficient is very small (Figure 6.9 – top right and bottom left). Observing the 
relationships between FFRHY and Rmyo,HY and then ΔRmyo no particular trend that allows to 
identify how the myocardial resistance influence the FFR was identified (Figure 6.9 – bottom 
left and right). Regarding the relationship between FFRHY and %ΔRmyo, a higher vasodilation 
in mild stenosis compared to the more severe ones is observed, because naturally, starting from 
a higher value of resistance it is possible to observe a high vasodilation (Figure 6.9 – bottom 
right). 
The main challenge remains the ability to predict the baseline myocardial resistance. To make 
this prediction it is necessary to understand why patients have different values of myocardial 
resistance at baseline, including identification of the data that is available for the patient 
(demographics, comorbidities) that most strongly influence this parameter. 
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Figure 6.9: Relationship between Pd/Pa and Rmyo. 
Top left Pd/Pa at baseline and Rmyo,BL on the right; Top right) FFRHY and R myo,HY ; Bottom left) FFRHY and ΔR myo; 
FFRHY and %ΔR myo 
 
Lesions were divided into 4 groups: 1st group with 54 lesions in LAD, DX, 2nd groups with 16 
lesions for the RCA, 3rd group with 9 lesions for the LCX and 4th group with 2 lesions in the 
LMS. Values of Rmyo,HY, Rmyo,BL, ΔRmyo and % ΔRmyo are summarised in table 6.2 and shown 
in figure 6.10 in terms of mean and standard mean error. 
At stable hyperaemia the average values of Rmyo were 63.8 (SD 41.8) mmHg s/ ml, 91.9 (SD 
72.8) mmHg s/ ml, 85.6 (SD 44.2) mmHg s/ ml and 34.8 (SD 7.13) mmHg s/ ml respectively 
for each group. 
The average values of RmyoBL are 124.4 (SD 103.2) mmHg s/ ml, 157.6 (SD 99.0) mmHg s/ ml, 
154.6 (SD 107.4) mmHg s/ ml and 79.9 (SD 8.3) mmHg s/ ml respectively for the 1st, 2nd, 3rd 
and 4th group.  
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The average ΔRmyo from baseline to stable hyperaemia are 60.5 (SD 71.3) mmHg s/ ml, 65.6 
(SD 62.1) mmHg s/ ml, 69.0 (SD 79.4) mmHg s/ ml and 45.1 (SD 15.5) mmHg s/ ml 
respectively for each group. 
The average % ΔRmyo from baseline to stable hyperaemia are -42.6% (SD 19.3%), -39.6% (SD 
21.8%), -35.9% (SD 26.2%) and -56.4% (SD 14.3%) respectively for each group. This is 
consistent with results reported in the literature [115]. 
As can be observed the standard deviations are high compared to the average values and this 
does not support the identification of a pattern of distinction between the myocardial resistances 
in each cardiac area supplied by the different vessels. 
Table 6.2: Average and standard deviation results for Rmyo,HY , RmyoBL, ΔRmyo and %ΔRmyo for each group of 
vessel. 
 RBL mmHg s/ ml RHY mmHg s/ ml ΔRmyo mmHg s/ ml % ΔRmyo 
1st group 
LAD, DX 
124.4 
(SD 103.2) 
63.8 
(SD 41.8) 
60.5 
(SD 71.3) 
-42.6 % 
(SD 19.3 %) 
2nd group 
RCA 
157.6 
(SD 99.0) 
91.9 
(SD 72.8) 
65.6 
(SD 62.1) 
-39.6 % 
(SD 21.8 %) 
3rd group 
LCX 
154.6 
(SD 107.4) 
85.6 
(SD 44.2) 
69.0 
(SD 79.4) 
-35.9 % 
(SD 26.2 %) 
4th group 
LMS 
79.9 
(SD 8.3) 
34.8 
(SD 7.13) 
45.1 
(SD 15.5) 
-56.4 % 
(SD 14.3 %) 
 
Figure 6.10: Histograms representing the distribution of Rmyo,HY, RmyoBL, ΔRmyo and %ΔRmyo for each group of 
vessels. 
Rmyo,BL, Rmyo,HY and ΔR are in mmHg s/ml, %ΔRmyo is in percentage. Results are reported with means and SEM. 
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In figure 6.10 it can be observed that LMS has a smaller distal resistance both at baseline and 
hyperaemia, if compared to the other group of vessels. This is expected because LMS is a larger 
vessel and its downstream resistance is represented by the parallel of LAD, DX and LCX.  
RCA and LCX show higher distal resistances compared to the LAD and DX group. The ΔRmyo 
follows the same trend, while the %ΔRmyo shows a higher percentage for the LMS compared to 
the other groups.  
In the following figures, histograms are used to represent the patients’ profile and compare 
them, to seek to identify correlation with patient pathologies/conditions. The patients’ profiles 
in terms of age, gender, BMI, smoking status, other comorbidities and myocardial infarction 
location are summarised into a number of graphs to identify any possible influence of any of 
these characteristics on the value of RmyoBL, Rmyo,HY,  ΔRmyo and %ΔRmyo. Each case is reported 
in one column and they are arranged in ascending order of the reported parameter. Figure 6.11 
shows the profiles considering Rmyo,BL; figure 6.12 shows the profiles considering Rmyo,HY; 
figure 6.13 shows the profiles considering ΔRmyo; figure 6.14 shows the profiles considering 
%ΔRmyo. On visual inspection of the histograms, none of the represented comorbidities appears 
to correlate with the value of the myocardial resistance and/or its change during adenosine 
vasodilation, with the exception of the COPD. In figure 6.11 it can be seen that patients with 
COPD have a small Rmyo,BL. Some conditions, such as hyperlipidaemia and hypertension, are 
common in this cohort, but no correlation with myocardial resistance is observed. Some of the 
pathologies, such as COPD, PDV and asthma, are uncommon in this cohort and so no firm 
conclusion can be drawn.  
Focusing on the relevant variables that are expected to determine the myocardial condition, 
such as age, BMI, smoking status and previous myocardial infarction event and location, an 
attempt was made to identify any possible correlation with Rmyo,BL, Rmyo,HY, ΔRmyo and % ΔRmyo 
(Figure 6.15). Statistic between the different groups was calculated with non-parametric T-test 
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and One-way ANOVA considering a Gaussian distribution. Data are presented with mean and 
standard error of the mean (SEM). 
 
Figure 6.11: Patients’ profiles arranged in ascending order of Rmyo,BL. 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
 
 
Figure 6.12: Patients’ profiles arranged in ascending order of Rmyo,HY. 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
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Figure 6.13: Patients’ profiles arranged in ascending order of change of Rmyo. 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
 
 
Figure 6.14: Patients’ profiles with crescent order of %ΔRmyo. 
Each column represents a single lesion. Each raw represents a specific characteristic of the patient, starting 
from the bottom: gender (male-female), BMI (normal-overweight-obese), age (35 to 45, 45 to 60, 60 to 70, 
over 70), smoking status (never-given up-current), comorbidities (type II diabetes, hyperlipidaemia, 
peripheral vascular disease, atrial fibrillation, hypertension, asthma, COPD, myocardial infarction and 
location.  
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Figure 6.15-A represents the distribution of the Rmyo,BL, Rmyo,HY, ΔRmyo and % ΔRmyo in smokers 
(current and ex-smokers) and non-smokers, (57 vs 23 samples). A slight difference between 
the two groups of patients can be observed, although it is not statistically significant: smokers 
tend to have a stiffer myocardial microcirculation at baseline, although during hyperaemia the 
difference is less pronounced.  
Figure 6.15-B represents the distribution of the Rmyo,BL, Rmyo,HY, ΔRmyo and % ΔRmyo according 
to the BMI: 11 normal BMI (BMI<25), 46 overweight (25<BMI<30), 25 obese (BMI>30). At 
baseline obese and overweight patients show a similar value of myocardial resistance, higher 
than patients with normal BMI. A similar trend is also observed for the hyperaemic resistance 
and a similar absolute change in resistance, although the percentage change results similar for 
all the groups. P - values were above 0.05, conferring non significance to the results. 
Figure 15-C shows the comparison between 3 groups of patients classified by age. Patients of 
60-70 years of age (34 samples) show the highest value of resistance for both baseline and 
hyperaemic, followed by the 45-60 years old patients (32 samples) and then by the patients 
over 70 years old (16 samples). Again, P - values were above 0.05, therefore there is lack of 
significance. An increase of myocardium stiffness is expected in old patients, but our data is 
contradictory.  
Finally, the aim was to investigate the influence of any previous event of myocardial infarction 
(MI) and its location, if known, in relation with the coronary vessel with the studied lesion. 
Considering then the MI event and its location in the three cardiac regions (anterior, posterior 
and inferior), any influence on the myocardial resistance was attempt to be identified. The 
groups are: patients who did not have MI (42 samples) and patients who did have a previous 
MI. Among the latter, then there is a group where the MI occurred in the region of the heart 
supplied by the vessel with the lesion (9 samples), a group where the region of the heart 
supplied by the vessel with lesion is different from that one where the MI occurred  (17 
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samples) and finally a group the it is not known if the MI region and the region supplied by 
stenotic vessel  are the same (14 samples) , because it is not reported where the MI occurred or 
because the stenotic vessel is an RCA or LCX and these vessel can supply both posterior and 
inferior based on the specific anatomy of the coronary circulation in each patient, for which 
there are no data.  
 
Figure 6.15: Histograms representing Rmyo,BL, Rmyo,HY, ΔRmyo and %ΔRmyo for the relevant variables for the 
myocardial condition.  
Rmyo,BL, Rmyo,HY and ΔRmyo are in mmHg s/ml, is in percentage. Results are presented with means and SEM.A) 
Smoking condition: Smokers vs Non-smokers. B) BMI: Normal vs Overweight vs Obese. C) Age: 45-60 years of 
age vs 60-70 years of age vs >70 years of age. D) Previous MI: no MI vs MI in the region supplied by the 
coronary artery with the lesion vs MI in a different region supplied by the coronary artery with the lesion vs 
MI and region unknown relative to the supplied lesion region. 
 
Figure 15-D shows the comparison between the Rmyo,BL, Rmyo,HY, ΔRmyo and % ΔRmyo in each 
group. It is observed that patients with MI in the same region of the stenotic vessel show the 
lower value of Rmyo,BL,  ΔRmyo and % ΔRmyo. There is not a clear distinction between the values 
Chapter 6 – Local tuning of coronary branches 
213 
 
of the parameters in patients with no MI and patients with MI overall. Once again P-values 
were above 0.05. 
In none of these graphs it is possible to identify any cluster of data related with the specific 
characteristic presented: smoking status, age, BMI and previous MI, suggesting that a larger 
cohort of patients might be necessary to produce statistical significance. 
 
 Classification of adenosine response based on myocardial 
adenosine concentration 
6.4.2.1 Patients demographic and lesions’ characteristics 
In the previous sections the analysis was focused on the interpretation of the measured 
responses, independently of any underpinning model of the system (except that the coronary 
flows and stenosis characterisations were computed from a CFD model). In this the focus is 
switched to the investigation of whether there is any correlation of the response with computed, 
model-based, adenosine concentration. A total number of 43 lesions in 27 patients were 
considered for this study. Patients were selected based on the availability of the clinical 
demographic and image data described in chapter 5, based on which a personalised global 
cardiovascular model was constructed, and from which the aortic concentration of adenosine 
was calculated. The demographic description of the patients is reported in Table 6.3. 
The lesions were located in different coronary arteries: 18 in the LAD, 13 in the RCA, 7 in the 
LCX, 3 in the LMS and 2 in the DX.  
The average FFR for these 43 lesion was 0.76 (SD 0.14) considering the FFR reported in the 
Cathlab (FFRCL) and 0.79 (SD 0.12) considering the FFRHY, obtained with the algorithm 
described in Chapter 4 (FFRST,0.04Hz). The average values of Z1 and Z2 were respectively 1.6∙109 
(SD 2.6∙109) Pa∙s∙m-3 and 1.7 ∙1015 (SD 2.9∙1015) Pa2∙s2∙m-6 (Figure 6.16). Figure 6.17 shows 
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their distribution associated with the lesion’s severity (FFRCL, FFRHY) and, in particular, Z1 
and Z2 increased as the FFR decreased, consistent with expectation. 
Table 6.3: Demographic data and comorbidities of the sub-cohort (27 patients) used for the local tuning 
optimisation. 
Peripheral Vascular Disease (PVD), Chronic Obstructive Pulmonary Disease (COPD), previous myocardial 
infarction (MI). 
Patient demographic Num% - mean (SD) 
Male 81% 
Age (years) 66.3 (SD 11.7) 
BMI 27.5 (SD 4.9) 
Hypertension 66.7 % 
PVD 11.1 % 
Previous MI 59.3 % 
Type II diabetes 7.4 % 
Hyperlipidaemia 70.4 % 
COPD 7.41 % 
Smoking status:  Never 29.6% 
 Ex-smoker 70.4 % 
Current 11.1 % 
 
Figure 6.16: Distribution of the coefficient Z1 (Pa∙s∙m-3) (left) and Z2 (Pa2∙s2∙m-6) (right) characteristic of the 51 
lesions. 
 
Figure 6.17: Z1 and Z2 relationship with FFR (FFRCL and FFRHY). 
43 stenoses’ quadratic and linear coefficients (Z1 and Z2) are reported in relation to the relative severity 
represented by the FFR (FFRCL and FFRHY).  
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6.4.2.2 Optimisation results 
The parameters of the branching tree structures for each patient were computed using the 
optimisation process described in paragraph 6.2.2.2. The average fitness value was equal to 
0.32. The simulation time for each optimisation is between 1 and 2 s. 
6.4.2.2.1 Patient-specific α, β and γ and errors between targets and model results 
The myocardial coefficients α, β and γ were calculated using the stable hyperaemia resistance, 
Rmyo,HY. In some cases the residuals remained relatively high with the parameters constrained 
to lie within physically plausible ranges. The average and standard deviation of the 3 
coefficients are: for α 0.78 (SD 0.02), for β 47.1 (SD 11.1) and for γ 1.68 (SD 0.23).  Results 
are shown in Figure 6.18. The average number of vessel in the capillary generation (the last 
one) was 6.76∙107. 
 
Figure 6.18: Distribution of α, β and γ results obtained with the optimisation. 
Figure 6.19 shows the comparison the target Rmyo,BL (Panel A), VB (Panel B) and  Rmyo,HY  
(Panel C) against the optimised results in terms of simple linear relationship, Bland-Altman 
and % error distribution. The correlation is high for Rmyo,BL and Rmyo,HY  with values above 0.8, 
while for VB the correlation is lower. 
For Rmyo,BL and Rmyo,HY a better correlation for the smaller values of resistances was observed, 
while for higher values the error was higher. This suggest that the model does not represent all 
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range of myocardial resistances, but could represent the myocardium resistance within 10 and 
200 mmHg s/ml. 
Considering the results of the optimisation, in our cases there are some cases where the 
resistances presented high values and in order to represent these values, obtained with the Z1 
and Z2 coefficients at baseline and hyperaemia, the selected approach was to assume a linear 
relationship between the resistances and the blood volume of myocardium using the coefficient 
CBL-HY as explained in Eq.6.12 and 6.13. 
 
Figure 6.19: Comparison between targets and model results. 
Panel A) Rmyo,B. Panel B) VB. Panel C) Rmyo,HY . Units of resistance are mmHg s/ml, units of volume are ml. 
 
6.4.2.2.2 Patient-specific baseline and hyperaemic myocardial blood volume 
The average VBL estimated with Eq.6.8 and Eq.6.9 based on BSA, left ventricular mass and 
density of blood in the cardiac tissue, was equal to 13.03 ml (SD 1.99), while the model 
produces a value of 13.6 ml (SD 3.0).  
Chapter 6 – Local tuning of coronary branches 
217 
 
The average VHY was equal to 16.2 ml (SD 4.6) using as reference the generic model with 
coefficient CBL-HY equal to 1.66 and an average of 17.07 ml (SD 4.16) calculating CBL-HY with 
the results of the optimisation considering the relationship at Eq.6.13.  
6.4.2.3 Adenosine concentration and time plateau values in the myocardium 
The personalised branching tree model enabled the estimation of the volume change of the 
myocardium in the hyperaemic state. Figure 6.20 illustrates the computed concentration 
profiles for two cases, comparing the profile including the computed volume change with that 
in which the volume is assumed constant at its baseline value. The figure indicates that the 
concentration profile is slightly affected by the inclusion of this term. And in both cases the 
myocardium concentration is higher than what was obtained with the generic model 
simulations in Chapter 3 (~1∙10-4 mg/ml). 
 
Figure 6.20: Two examples of results of blood volume, V, and adenosine concentration, C, in patient-specific 
myocardium without (blue) and with (red) vasodilation phenomena. 
The average plateau value for the concentration was 1.51∙10-4 mg/ml (SD 5.81∙10-5mg/ml), 
while the average time necessary to reach the plateau following commencement of the 
adenosine infusion was 60.64 s (SD 10.61 s). Both the plateau value and the time to reach it 
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showed a high SD compared to the value of the means, indicating the high inter-patient 
variability of the adenosine concentration. The reason of the variability of the maximum 
adenosine concentration in the myocardium and of the time to reach plateau is principally 
caused by the aortic concentration of adenosine as discussed in Chapter 3. The average time to 
reach maximal hyperaemia in the myocardium, from when the maximum in aortic 
concentration occurs (average of 47 s for the personalised model in Chapter 5), was about 13 
seconds. The different values of maximal concentration and time necessary to reach the 
maximum in the myocardium are highly influenced by the aortic profile of concentration, but 
also the myocardium resistance and the severity of stenosis influences the myocardial 
concentration profile.  
Figure 6.21 shows the relationships between the lesion severity, expressed by the FFRHY, and 
the plateau adenosine concentrations in the aorta and in the myocardium (A), the difference in 
time between the aortic maximal concentration and the myocardial maximal concentration (B), 
the difference between the aortic and myocardial maximum concentration as absolute value 
(C) and percentage (D) respectively.  
On average it is observed that, independently of the lesion severity, the myocardium 
concentration reached about half of the concentration in the aorta and that for mild stenoses 
there was an increase of the absolute difference of the concentrations, less pronounced in the 
results reported as percentage. In addition, the difference in time to reach plateau in the aorta 
and in the myocardium appears to be higher for less severe stenoses. 
In all the cases the correlation was very weak, indicating that the lesion severity does not 
influence the distribution of the adenosine concentration and therefore the vasodilation 
response. 
 
Chapter 6 – Local tuning of coronary branches 
219 
 
 
Figure 6.21: Relationships between lesion severity (FFRHY) and the plateau concentration and time values in 
the aorta and in the myocardium. 
A) FFRHY vs maximal aortic concentration, CAO (in red), and maximal myocardial concentration, Cmyo (in black). 
B) FFRHY vs the difference between the time to reach concentration plateau in the aortic concentration and 
the one in the myocardial concentration. C) FFRHY vs the difference between maximal aortic concentration, 
CAO and maximal myocardial concentration, Cmyo. D) FFRHY vs the difference between maximal aortic 
concentration, CAO and maximal myocardial concentration, Cmyo, expressed in %. 
The influence of the myocardial distal resistance at baseline and hyperaemia in the maximal 
myocardium concentration was then investigated, as shown in Figure 6.22. 
With regards of the RmyoBL (Figure 6.22 - left) it is observed that for higher myocardial 
resistances the maximal myocardial concentration is lower (Figure 6.22-A) and takes a longer 
time (Figure 6.22-B), due to the reduced myocardial blood flow. When the Cmyo is compared 
with the maximal aortic concentration, CAO, both as absolute (Figure 6.22-C) and the 
percentage (Figure 6.22-D) differences, for high myocardial resistances the maximal 
myocardial concentration increases. This highlights the high influence of the aortic 
concentration defined by the systemic characteristics of the individual.  
Same considerations can be done for the results in figure 6.22 - right with regards to the Rmyo,HY 
(Figure 6.22-E,F,G,H) . 
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Figure 6.22: Relationships between Rmyo and the plateau concentration and time values in the aorta and in the 
myocardium. 
Panels on the left show results for the Rmyo,BL and panel on the left for the Rmyo,HY. Panels A, E) Rmyo vs maximal 
aortic concentration, CAO (in red), and maximal myocardial concentration, Cmyo (in black). Panels B, F) Rmyo vs 
the difference between the time to reach concentration plateau in the aortic concentration and the one in the 
myocardial concentration. Panels C, G) Rmyo vs the difference between maximal aortic concentration, CAO and 
maximal myocardial concentration, Cmyo. Panels D, H) Rmyo vs the difference between maximal aortic 
concentration, CAO and maximal myocardial concentration, Cmyo, expressed in %. 
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A comparison between the time delays between the time to reach plateau concentration in the 
aorta in the myocardium obtained with the model and the time to reach peak response in the 
myocardial resistance obtained from the data (and the CFD model) allowed to investigate if the 
model provided reliable results in terms of the time delays. Table 6.4 reports the mean, SD and 
range of each of these time. As expected, the Tmyo was higher than Tao on average about 13 
seconds, indicating that the delay given by the system highly influences the response in the 
myocardium. Comparing these results with the time to reach minimum resistance (equivalent 
to the peak response), the results were as expected, with about 53 s to reach peak and about 60 
s to reach maximum concentration.  
Table 6.4: Comparison of time delay to reach plateau concentration obtained with the model and the time 
delay to peak response in the Rmyo. Tao and Tmyo are the time to reach respectively aortic and myocardial 
maximal concentration in the aorta, ΔT is the difference between them, Tpeak is the time necessary to the Rmyo 
to reach its minimum value. Results are reported in mean, SD and range. Units are in seconds. 
 Mean SD Range 
Tao 47.64 5.67 43.13 - 65.5 
Tmyo 60.67 10.58 46.47 - 90.41 
ΔT 12.81 10.82 0.19 - 44.35 
Tpeak 53.25 17.20 24.83 – 92.83 
The range of the peak response time includes also lower values suggesting that there is a 
saturation concentration and, therefore, the myocardium reached its maximal vasodilation.  
No conclusions can be drawn with regards to the concentration values in terms of the saturation 
values and the minimum value to trigger the vasodilation, because there is no measured data 
available in this specific study and the literature does not provide information. 
In addition, with regards to the myocardial time response the delay in the actual vasodilation 
for a certain adenosine concentration should be taken in account and our data do not allow this 
type of analysis where it is necessary to separate and analyse the different phenomena. 
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 Limitations 
The main limitations encountered in this part of the project related to the coronary patient-
specific personalisation were essentially associated with the limited amount of patient specific 
data in relationship with the number of parameters of the model. 
The lack of patient specific data on the myocardial blood volume has led the development of a 
tree-structured model and the use of some generic patient data and the literature data to make 
a prediction of it, but the main problem lies on the validation on patient data. 
The tree-structure model is very simple in order to run an optimisation with few targets. More 
complex models, which try to investigate the different mechanisms of vasodilation, are 
published in the literature. 
The problem of the validation process is applicable for the myocardial blood volume, as well 
as the concentration of adenosine in the coronary during invasive angiography. Measurements 
ensure a validation process of the model against them. Having more patient data, it would be 
potentially possible to improve the optimisation process and consider to optimize also the range 
of reactive vessel to adenosine for each patient. 
Moreover, they could be used in the whole cardiovascular model as a target and therefore get 
better optimisation results for the whole system. 
To understand the effect of the patients’ characteristic a study with a high number of patients 
should be planned considering a comparison between groups of patients with a specific 
pathology with other groups without it. It is also worth to mention and remember though that 
it is common to have a number of comorbidities in patient with CAD which might have a 
different level of severity or a different diagnostic time. Therefore, the combination of these 
can be very different in each patient. 
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 CONCLUSIONS 
In conclusion, the available patients’ data can be used to build a patient specific model of the 
coronary branch, with the help of CFD simulation and 3D reconstruction of the artery. 
It is challenging the definition of patient-specific boundaries conditions in terms of the 
myocardial resistance.  
This chapter attempted to identify any correlation between the patient physiological condition 
and its response to adenosine from the myocardial point of view. 
In a first analysis, the FFRs and the stenosis and myocardial microvasculature properties 
defined with the segmentation and the CFD model described in the PhD thesis of Dr. Morris 
[92] were investigated.  
The relationship between the FFRs and the stenosis coefficient Z1 and Z2 showed a trend as 
expected, indicating that severe stenoses have higher values for the two coefficients. The 
relationship between the outlet radius of the considered vessel and the distal resistance at 
baseline and stable hyperaemia indicated that for smaller vessels the resistance resulted higher 
in both baseline and hyperaemia. 
The average behaviours of the myocardial resistance and the blood flow showed an expected 
trend. Myocardial resistance during hyperaemia appeared to be 61% of the myocardial 
resistance at baseline, although if the baseline resistance was already low during baseline the 
vasodilation was not so effective.  
Classification of myocardial resistance at baseline and hyperaemia and the absolute and relative 
change according to the region of the myocardium did not show any difference and, therefore, 
the location cannot be used as parameter to predict the values of myocardial resistance.  
Unfortunately, no particular relationship between the myocardial adenosine response and the 
patient profile, considering gender, age, BMI, smoking status and myocardial infarction event, 
could be identified. 
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Other pathologies, such as hypertension and hyperlipidaemia were present in the majority of 
patients, making almost impossible to identify a distinction between the two categories. 
On the other hand, other pathologies, such as asthma, PVD, COPD, diabetes II, were too rare 
and again this makes difficult to define any particular difference between patients with and 
without pathologies. 
Another additional complexity is related with the lack of information of the severity and the 
duration of the pathologies. In the majority of the cases there were more than one in the same 
patient, and it was difficult to separate their single influence on the adenosine response. These 
features are challenging from the point of view of the modelling implementation. 
The challenge to predict the value of the myocardial resistance based on the patient profile is 
still open. 
A second analysis then was performed on the adenosine response in terms of time and 
adenosine concentration plateau. A tree model structure was personalised for the specific-
patient myocardium with a number of assumptions to define the change in myocardial volume 
during hyperaemia and calculate the myocardial adenosine concentration profile. This type of 
model in the end showed that it is a better representation of the phenomena, although it is 
difficult to validate against measurements. Results suggest that the myocardial response is 
strongly influenced by the aortic concentration profile and by the myocardial microvasculature 
resistance with regards to the plateau concentration and time. 
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7 CHAPTER 7          
CONCLUSIONS AND FUTURE 
WORK 
 
 
There is increasing interest in personalised medicine; developing the best treatments and 
interventions for each individual based on their own unique characteristics, including co-
morbidities and life-style. The work described in this PhD thesis is in line with this new 
healthcare philosophy, where patient-specific data are integrated into computational tools to 
represent the patient’s physiology and the impact of disease and potential treatments.  
The specific focus of this thesis is to provide an estimate of myocardial resistance and its 
hyperaemic response to adenosine based on the individual characteristics of the patient. The 
myocardial resistance is crucial for an accurate computation of vFFR. 
Through all the chapters limitations and conclusions have been presented and this final chapter 
aims to summarise them. 
 THESIS LIMITATIONS 
1. The major limitation of the model is related to the incomplete representation of the real 
physiology in the cardiovascular system limiting therefore the possibility of an accurate 
prediction and personalisation of the model itself. This has been furthermore increased by 
the de-coupling approach between systemic and coronary circulations in order to simplify 
the personalisation process in relation with the available clinical data. No model can 
represent the full complexity of the human system, but in this work the emphasis has been 
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2. on the development of a minimal systems model in order to maximise the stability of the 
personalisation process. 
3. The lumped-parameter models represent a significant simplification of reality and are 
intrinsically incapable of capturing some of the real physiology of the cardiovascular 
system, compared to other type of more sophisticated modelling such as 1D or 3D models, 
where more features can be represented with more realistic results, at the cost of increasing 
the level of details and inputs necessary to personalise them.  
4. In the model developed in this thesis all reported elements of the adenosine response are 
not represented: only the vasodilation effect was taken into account with the relative 
barocontrol response, ignoring other mechanisms involved. 
5. Simplifying hypotheses have been assumed in the different processes: 
- the distribution of blood volume, taken from the literature data; 
- a Poiseuille’s resistance for the coronary tree-structure model, ignoring effects of wave 
propagation and compliance of the vasculature;  
- instantaneous distribution of the species within each compartment; 
- a null physiological concentration of adenosine; 
- the myocardial volume variation during adenosine response, considered to be linear and 
not varying according to the stiffness of myocardium and its consequently reduced 
compliance;  
- the arbitrary adenosine concentration threshold to trigger the vasodilation effect and its 
immediate effects without delays associated with the control mechanism. 
6.  Some input and output model results were impossible to validate against measurements. 
This is valid for: 
- blood volume distribution in all compartments; 
- the adenosine concentration profile in the different compartments during the infusion; 
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- adenosine concentration threshold to trigger vasodilation and to saturation; 
- the physiological delay associated with the control mechanisms; 
- myocardial blood volume and its variation during hyperaemia. 
7. The personalisation of the systemic cardiovascular system suffered from inconsistent 
clinical data due to non-simultaneous measurements and different techniques. A strategy 
consisting of several approximations was considered to bring consistency within the 
clinical data for each patient. 
8. The personalisation of the local coronary circulation found its main limitation in the 
limited amount of patient specific data compared with the number of the model parameters 
and a simple representation with tree-structure model has been considered to evaluate the 
variation of the myocardial volume during adenosine response. 
9. Overall simulations were expensive in computational time and this is not compatible with 
clinical timescale, reducing therefore the applicability of these methods. 
 
 THESIS CONCLUSIONS 
The conclusions of this PhD project, already reported at end of each of the previous chapters, 
are now summarised in this final paragraph. 
1. A 0-D cardiovascular model including the major compartments (systemic, pulmonary and 
coronary circulations and a 4-chambered heart) and regulatory mechanisms (short-term 
regulatory pathways related to barocontrol) was developed based on data obtained from the 
published literature and it can represent the distribution of blood pressure, flow and volume 
in all the compartments. 
2. Based on a number of assumptions, the developed model is able to represent the adenosine 
response as a function of the concentration of the drug in the target vessels for vasodilation. 
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The results for a generic, non-patient-specific model, were consistent with the average 
response in terms of variation of aortic pressure and heart rate reported in the literature. The 
results obtained from the generic model also justified simplification of the parameter 
personalisation, decoupling the systemic and coronary models to study them separately. 
3. The systemic cardiovascular model was personalised at baseline using clinical data available 
for each patient (heart rate, cardiac output, ejection fraction and the invasive aortic pressure 
cycle-averaged signal) and results showed good reproduction of clinical data. The main 
outcome from this part of the project was the demonstration and quantification of the 
significant influence of the systemic cardiovascular system on the adenosine concentration 
profile in the aorta in terms of its maximum value and the time taken to reach this peak. 
Results suggest that the aortic concentration of adenosine is dependent on cardiac output, as 
would be expected intuitively. Values obtained for the maximum concentration are of the 
order of those described in the literature.  
4. The invasive pressure data recorded during FFR assessment and the Pd/Pa traces were 
analysed to describe typical phenotypes of adenosine response and to identify association 
and correlations with patient profile (gender, age, BMI smoking status and comorbidities).  
Here no definite conclusions could be drawn as the results indicate that any links were weak. 
5. An algorithm to post-process the raw pressure data and identify the minimum Pd/Pa and the 
Pd/Pa during stable hyperaemia was developed. This is a step towards standardisation of the 
process of FFR assessment which might be applied in clinical practice to improve the current 
high level of subjectivity when operators assess stenoses severity. Different schools of 
thought exist to arrive at the decision to treat or not treat; one suggests that the minimum 
Pd/Pa should be used, whilst the other suggests that the stable Pd/Pa is more appropriate for 
this purpose and the potential clinical impact of this type of choice was investigated. The 
algorithm does not solve the problem of identifying the correct FFR in terms of the minimum 
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or the stable Pd/Pa, but underlines that the lack of standardisation needs to be resolved. From 
the analysis of the Pd/Pa, it also emerged that, for some patients, it is not possible to identify 
a stable period. This supports the selection of the minimum Pd/Pa as the FFR.  
6. The invasive pressure data and patient-specific aortic concentrations obtained from the 
global model were employed in the coronary tuning, together with characterisations of the 
stenoses from CFD analysis carried out by Dr. Morris.  The coronary model also included 
the effect of vasodilation, assuming an increase of myocardial volume proportional to its 
resistance variation. Average results of myocardial resistance and blood flow at baseline, 
peak and hyperaemia results in physiological ranges and, moreover, showed the expected 
trends. The results for myocardial resistance at baseline were linearly correlated with the 
hyperaemic resistance with a 60% coefficient. This is also consistent with the literature. 
7. Investigation of the correlation between the myocardial resistance at baseline, the 
myocardial resistance at hyperaemia, its change between the two phases as an absolute and 
percentage value and the characteristics of the patient has been carried out, but this did not 
produce strong correlations which could allow a prediction of the myocardial resistance in 
any states. 
8. It is interesting to note that coronary modelling can provide an estimation of coronary flow. 
This is perhaps clinically more relevant than FFR. FFR represents a ratio of the coronary 
reserve, while flow gives an indication of whether the myocardium is adequately perfused 
which is independent of the stenosis severity.  
9. The coronary model was able to produce the myocardial adenosine concentration profile for 
each lesion considered. As defined in the global model, the delay in the myocardial response 
to adenosine is mainly determined by the systemic cardiovascular system. The results 
showed that the delay between the maximum concentration in the aorta and the maximum 
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concentration in the myocardium was less dependent on the lesion severity but rather, was 
dependent in the myocardial resistance at both baseline and hyperaemia. 
 FUTURE WORK 
Using in silico models to inform personalised medicine shows great promise to advance the 
future of healthcare. This thesis considers an example of this approach describing the 
development, and use, of a patient-specific cardiovascular model to describe the adenosine 
response. The limitations and assumptions made throughout the development of the project 
need to be addressed if further progress is to be made. 
A number of challenges were encountered in the process of optimisation. The first was related 
to the number of parameters in the model and the uncertainty of these in relation to the data 
available. Simplistically, it could be argued that the more complex the model the better it might 
be expected to represent a system but, equally, as the number of parameters increases tuning 
becomes more challenging or, indeed, impossible if the number of variables which can be 
measured clinically are limited. In addition, an uncertainty analysis using physiological ranges 
of the model parameters is necessary to increase the confidence in the model. 
Another issue was related to inconsistencies in the clinical data collected using different 
techniques and at different time points, and a strategy was needed to create a set of consistent 
input data for the optimisation process of the global system. The optimisation process also 
suffered from the lack of a more comprehensive set of parameters during hyperaemia.  For 
example, continuous measurement of cardiac output or stroke volume could be used to optimise 
the model under both baseline and hyperaemic conditions. Unfortunately, there is currently no 
simple non-invasive clinical method to collect such data which could be used in the Cathlab. 
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Improvement of the code and additional computational power are also required to make the 
simulations quicker and being acceptable for clinical timescale, exploiting for example a 
machine learning approach. 
A larger size of the cohort would also help perhaps in finding associations between the 
myocardial hyperaemic response in terms of the myocardial resistance and patient 
characteristics, providing a more homogenous distribution of comorbidities. Pathologies such 
as hypertension or hyperlipidaemia were very common in our cohort whilst others, such as 
asthma, peripheral vascular disease, COPD and diabetes II, were relatively rare and therefore, 
in both extremes, it is difficult to determine the effect of pathology on the adenosine response. 
Another challenge that needs to be addressed is concerning the relationship between Rmyo(t) 
and Cmyo(t) to identify patient-specific values of adenosine concentrations which initialise the 
vasodilatory myocardial response or saturate the vasodilation process.  
For these, it is necessary to have confidence in the coronary model and measurement of 
coronary blood flow and myocardial and aortic concentrations of adenosine should be 
performed during the adenosine infusion to validate the model. 
The relationship between Rmyo and Cmyo could add information on the patient-specific response 
allowing these to be classified based on the minimum adenosine concentration that stimulates 
vasodilation. An important effect that needs to be considered is the delay in myocardial 
response when control mechanisms are involved.  
Another important aspect to take into account in the decision-making process for coronary 
lesion treatment is to consider the life-style of the specific patient in order to personalise the 
model and study the effect of the coronary stenosis under the average workload of the specific 
individual.  
In the context of FFR measurement and personalisation of the assessment of CAD whilst 
maintaining objectivity, “FFR for Life” (FFR4L) involves activity monitoring during the 
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patient’s daily routine. This together with information about frailty, comorbidities, cardiac 
function and aerobic capacity in patients with CAD contextualises the specific stenosis.  
Non-invasive data for pressure, heart rate and number of steps can be monitored with 
ambulatory devices and an agenda of the daily activities should be reported.  
Monitoring activity should be performed for a number of consecutive days before and after the 
procedure. These data can provide information about the heart workload during daily routine. 
This information, together with the invasive pressure collected during angiogram, could be 
used to personalise the systemic and the coronary model and gain an understanding of the 
impact of a specific coronary lesion under different physiological conditions.  
 
 233 
 
APPENDIX  
The steady-state pressure gradient across the stenosis is determined by a quadratic equation 
which includes Poiseuille’s equation for the viscous losses (𝑍1 ∙ 𝑄), and by Bernoulli’s equation 
for the inertial losses (𝑍2 ∙ (𝑄)
2) as reported in Eq.A1.1. 
∆𝑃 = 𝑍1 ∙ 𝑄 + 𝑍2 ∙ (𝑄)
2 
(Eq.A.1) 
Segmentation and 3D reconstruction from angiographic images were obtained for each vessel 
with Philips software (Philips Healthcare, Best, NL). ANSYS ICEM and ANSYS CFX 
(ANSYS, Inc. PA, USA) and subsequently used in order to respectively build the volumetric 
meshes and run the Computational Fluid Dynamic (CFD) simulations. As boundaries 
conditions, flows of 1 ml/s (Q1) and 3 ml/s (Q3) were set to obtain the respective pressure 
gradients (ΔP1, ΔP3) across the lesion. The two lesion-specific parameters Z1 and Z2 were then 
calculated solving the system of equation in Eq.A1.2: 
{
∆𝑃1 = 𝑍1 ∙ 𝑄1 + 𝑍2 ∙ (𝑄1)
2
∆𝑃3 = 𝑍1 ∙ 𝑄3 + 𝑍2 ∙ (𝑄3)
2 (Eq.A.2) 
where Q1 and Q3  are known, and  ΔP1, ΔP3 are the solutions of the CFD. 
The workflow of this project is briefly represented in the diagram in figure A1.1. 
 
Figure A.1: Workflow to define the stenosis characteristics Z1 and Z2 starting from the angiogram. 
Coronary arteries were segmented from the angiographic images and 3D reconstructed with Philips tools. CFD 
simulation in ANSYS were run for each volume mesh setting as boundaries two values of flow to solve the 
quadratic relationship between pressure gradient and flow. 
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